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279.0, 292.9 and 294.9 (blue trace) and new gaburedin 165 m/z = 219.0 (green trace) in
metabolites extracted at pH 3 from the Streptomyces venezuelae gbnR strain after being grown
on SMMS + 20 mM L-alanine for 3 days. The mass spectrum of new gaburedin 165 is also
shown
Figure 4.4 – Extracted ion chromatograms for gaburedins A-F (80-85) m/z = 247.0, 261.0,
279.0, 292.9 and 294.9 (blue traces) and new gaburedins (green traces) of metabolites extracted
at pH 3 from the Streptomyces venezuelae gbnR strain after being grown on SMMS + 20 mM
L-proline, glycine, L-serine and L-threonine for 3 days
Figure 4.5 – Extracted ion chromatograms for gaburedins A-F (80-85) m/z = 247.0, 261.0,
279.0, 292.9 and 294.9 (blue traces) and m/z = 251.0 for the expected new gaburedin 170 that
would be expected from incorporation of L-cysteine (green traces) in metabolites extracted at
pH 3 from the Streptomyces venezuelae gbnR strain after being grown on SMMS and SMMS
supplemented with L-cysteine
Figure 4.6 – Extracted ion chromatograms for m/z = 262.0 of gaburedin 171 (green trace) and
m/z = 277.0 of the gaburedin 106 from incorporation of L-glutamate (orange trace) in
metabolites extracted at pH 3 from the Streptomyces venezuelae gbnR strain after being grown
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on SMMS containing 20 mM L-asparagine and SMMS + 20 mM L-glutamate (top panels), and
mass spectra of gaburedins 171 and 106
Figure 4.7 – Extracted ion chromatograms for gaburedins A-F (80-85) m/z = 247.0, 261.0,
279.0, 292.9 and 294.9 (blue traces) and new gaburedin 173 with m/z = 311.0 (red trace)
expected for incorporation of L-tyrosine, and UHR mass spectrum of this new gaburedin 173
Figure 4.8 – Mass spectra new gaburedins 156, 175, 176 and 103 containing n-butylamine,
isobutylamine, isopentylamine and cyclohexylamine displaying fragments ions at m/z = 104.0 –
corresponding to GABA – that are common to all four amine-derived gaburedins
Figure 4.9 – Mass spectra of new gaburedins containing isobutylamine, isopentylamine and
cyclohexylamine (panels a, c and e) and the species corresponding to [M+14]+ ions for
additional metabolites present in the extracts upon feeding with these precursor molecules
(panels b, d and f)
Figure 4.10 – Structures of amino acid analogues fed to the gbnR::apra mutant to probe
diversity of aminoacyl compounds with different C-terminal groups which can be incorporated
into gaburedins
Figure 4.11 – Extracted ion chromatograms for m/z = 281.0 (top panel) and 233.0 (bottom
panel) and mass spectra of the new gaburedins 183 and 184 that are produced by the gbnR
mutant when grown on SMMS + 1 mM L-phenylalaninol (top panel) and 1 mM L-valinol
(bottom panel)
Figure 4.12 – Extracted ion chromatograms for gaburedin A m/z = 294.9 (red trace) and m/z =
309.0 (black trace) expected for incorporation of L-phenylalanine-O-Me ester in the
metabolites extracted after growing the gbnR mutant on SMMS + 10 mM L-phenylalanine-O-
methyl ester. Mass spectra of gaburedins 80, 185 and 186 are also shown
Figure 4.13 – Extracted ion chromatograms gaburedins A-F (80-85) m/z = 247.0, 261.0, 279.0,
292.9 and 294.9 (blue traces) and m/z = 289.9 (red traces) for L-ala-ala incorporation into a
new gaburedin 187 and m/z = 218.8 (black traces) for gaburedin 165 arising from incorporation
of L-alanine. Mass spectra of 165 and 187 also shown, with the molecular and fragment ions
for 187 highlighted in red
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Figure 4.14 – Library of gaburedins produced during this study
Figure 4.15 – Schematic to illustrate the substrate tolerance of GbnAB leading to conserved
GABA moiety (blue) and diversity of different amino acids and amino acid analogues that can
be incorporated into gaburedins in vivo (orange, red and green)
Figure 4.16 – Schematic to show incorporation of N-acetyl-L-cysteine into the proposed
structure for gaburedin F (85) either directly or via the cysteine derived gaburedin 170. Both
routes would require very poor nucleophiles attacking either the intermediate 109, or
acetylation occurring at the poorly nucleophilic ureido nitrogen of 170. The possible structure
of gaburedin F if derived from S-acetylcysteine is highlighted
Figure 5.1 – gbnABC clusters from Streptomyces venezuelae, Salmonella enterica and
Streptococcus mutans GS-5. Only the metabolic products of the gbnABC system in S.
venezuelae have been reported so far
Figure 5.2 – Schematic to show the steps in creating pET151-derived plasmids using the gbnA
and gbnB genes from S. venezuelae. Primers were designed to include a 5’-CACC overhang to
allow topoisomerase-directed cloning of gbnA and gbnB into pET151
Figure 5.3 – 1% agarose gel of PCR products obtained for DNA regions amplified using
control screening primers F/F’ specific for gbnR, and TOPO cloning primers C/C’ specific for
gbnA. The bands for the PCR products obtained with primers C/C’ were shorter than expected.
Colours have been inverted for clarity
Figure 5.4 – Diagram to illustrate TOPO cloning of synthetic S. venezuelae gbnB, Salmonella
enterica seag_b2133 and Streptococcus mutans GS-5 smugs5_01685 into pET151. Restriction
digests using the enzymes NdeI and PstI were used to confirm the nature of plasmids pJDS06
and pJDS02 and pJDS04, respectively. These plasmids were also analysed by PCR using
primer pairs J/J’, K/K’ and L/L’ and the inserted genes were sequenced using the T7 primer
pair
Figure 5.5 – Metabolites extracted from culture supernatants of E. coli/pJDS02, pJDS04 and
pJDS06 grown in LB supplemented with 10 mM GABA. Base peak chromatograms (red
traces) and xtracted ion chromatograms for gaburedins A-F (80-85) (m/z = 247.0, 261.0, 279.0,
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292.9 and 294.9) are also shown (black traces). The large peak at t = 14.0 min has m/z = 261.0,
but is unrelated to gaburedins
Figure 5.6 – 10% SDS-PAGE gels to show comparison of soluble and insoluble proteins
extracted from E. coli/pJDS02 carrying synthetic seag_gbnB. The only lane with an intense
band for a protein of the expected mass of 60.2 kDa is the lane loaded with the insoluble
protein fraction
Figure 5.7 – Schematic of the strategy used to sub-clone synthetic gbnA into pJDS06 carrying
synthetic gbnB and sub-cloning of synthetic gbnB into pJDS05 carrying synthetic gbnA
Figure 5.8 – Agarose gel of NdeI restriction digests of plasmids after ligations to introduce
gbnB into pJDS05. Lanes giving examples of the different outcomes of the ligations are
annotated
Figure 5.9 – Vectors pET-Duet and pACYC-Duet used for cloning of synthetic S. venezuelae
gbnA, gbnB and gbnC
Figure 5.10 – Cloning strategy used to generate plasmids pJDS09-pJDS11 containing synthetic
S. venezuelae gbnA, gbnB and gbnC. Step (i) – amplification of each gene of interest by PCR;
step (ii) – digestion using specifically selected restriction enzymes to leave appropriate
overhangs; step (iii) – ligation of DNA fragments with complementary overhangs
Figure 5.11 – Base peak chromatograms (pink traces) and extracted ion chromatograms for
gaburedins A-F (80-85) m/z = 247.0, 261.0, 279.0, 292.9, 294.9 (blue traces) of metabolites
extracted from culture supernatants of E. coli BL21star/pJDS10 grown without IPTG and with
1 mM IPTG in LB with and without addition of 1 mM L-glutamic acid
Figure 6.1 – Schematic to demonstrate phenotype of S. coelicolor mmyR deletion mutant and
proposed phenotype of S. venezuelae gbnR deletion mutant. Repressor binding sites (AREs)
shown in pink. Sizes of genes not to scale
Figure 6.2 – UHR-MS data for SCB1 (36, top panel) and AHFCA5 (53, bottom panel)
illustrating the typical mass spectra of 6-hydroxy GBLs and AHFCAs observed in electrospray
MS in positive ion mode
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Figure 6.3 – Extracted ion chromatograms for [M+Na]+ ions of 6-hydroxy type GBLs m/z =
239.0, 253.0, 267.0 and 281.0 observed in metabolites extracted from S. venezuelae gbnR
mutants. Mass spectra of these GBL-like molecules are also shown with the molecular
formulae generated for the [M+Na]+, [M+H]+ and [M-H2O+H]+ ions
Figure 6.4 – Top: genetic organisation of the scb-cpk gene cluster as modified in S. coelicolor
M1152. The gene encoding for the transcriptional repressor protein scbR2 has been removed.
Bottom: Extracted ion chromatograms for [M+Na]+ ions m/z = 239.0, 253.0, 267.0 and 281.0 of
6-hydroxy type butyrolactones in the metabolites extracted from S. coelicolor M1152 and S.
venezuelae gbnB/R. Compound denoted by * has m/z = 267.0 but is not related to GBLs
Figure 6.5 – UHR-MS of 197-199 extracted from S. coelicolor M1152 grown on different
AlaMM media. From top to bottom: 197 without any labelling, 197 labelled upon feeding with
d8-DL-valine, 198 without any labelling, 198 labelled upon feeding with d7-butyric acid, 199
without any labelling, and 199 labelled upon feeding with d10-isoleucine
Figure 6.6 – UHR-MS of metabolites 193, 194, 195, 196 and 200 extracted from S. coelicolor
M1152 grown on different AlaMM media. 193 was labelled with 7 deuteriums from
incorporation of d7-butyric acid; 194 was labelled with 9 deuteriums from incorporation of d10-
isoleucine; 195 was labelled with 9 labels from incorporation of d10-leucine; 196 was labelled
with 5 labels from incorporation of d5-propionic acid; and 200 was labelled with 7 deuterium
labels from incorporation of d7-butyric acid
Figure 6.7 – Extracted ion chromatograms for [M-H2O+H]+ ions of AHFCA species present in
the metabolites extracted from the S. venezuelae gbnB/gbnR, gbnR, sgnL and wild type.
Chromatograms correspond to m/z = 195.0 (blue traces), 209.0 (black traces) and 223.0 (red
traces). Peaks denoted by * are unrelated to AHFCA compounds. EICs for m/z = 167.0, 181.0
and 237.0 have been omitted for clarity
Figure 6.8 – Mass spectra of the AHFCAs 5-8 (201-204) identified in the S. venezuelae gbnR
deletion mutants when grown on modified SMMS. AHFCA5 is labelled with 7 deuteriums
from d7-butyric acid; AHFCA6 is labelled with 9 deuteriums from d10-leucine; AHFCA7 is
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labelled with 5 labels from d5-propionic acid; and AHFCA8 is labelled with 7 deuteriums from
d8-valine. [M+Na]+ ions are highlighted in red
Figure 6.9 – AHFCAs produced by S. venezuelae gbnR deletion mutants as demonstrated by
incorporation of the specific precursor molecules shown, and UHR-MS spectra of AHFCA8
(204) unlabelled (top panel) and AHFCA8 labelled with 7 deuteriums from incorporation of d8-
valine (bottom panel) and molecular formulae generated for the [M-H2O+H]+ and [M+Na]+ and
ions are shown
Figure 6.10 – Mass spectra and proposed structures of 205 produced upon feeding the gbnB/R
strain with d10-isoleucine (top panel) and 206 produced upon feeding the gbnB/R strain with
d10-leucine (bottom panel)
Figure 6.11 – Extracted ion chromatograms for [M-H2O+H]+ ions of AHFCA species present
in the metabolites extracted from the S. venezuelae gbnB/gbnR with no AHFCA added and with
AHFCAs 5, 6 and 7 co-injected. Chromatograms correspond to m/z = 195.0 (blue traces), 209.0
(black traces) and 223.0 (red traces)
Figure 6.12 – Extracted ion chromatograms m/z = 167.0, 195.0 and 223.0 for [M-H2O+H]+
ions of 212-214 present in the metabolites extracted from the E. coli BL21star/pJDS8 strain and
E. coli BL21star/pJDS8 strain induced with IPTG. A synthetic standard of AHFCA2 (32) was
run in parallel. Mass spectra of AHFCA 212-214 are also shown
Figure 6.13 – Clustal Omega alignments of SgnR (SVEN_4182), MmfR and homologues in
other Streptomyces species. The amino acid residues identified as interacting with the AHFCA
ligand are highlighted in yellow. The key tyrosine residues identified are highlighted in cyan
Figure 6.14 – a) Active site residues of MmfR interacting with AHFCA2 from solved crystal
structure b) Active site residues of SgnR proposed to interact with AHFCA2 from SgnR
structure generated using Phyre2 c) overlaid active sites residues of MmfR (orange) and SgnR
(cyan) showing that the active site residues are predicted to be conserved between MmfR and
SgnR. Images generated using PyMOL with views restricted to 6Å around the AHFCA2 ligand
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Figure 6.15 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for
gaburedins A-F (80-85) in metabolites extracted from S. venezuelae sgnL-P::apra strain upon
addition of 10 μM, 100 μM and 400 μM AHFCA5 
Figure 6.16 – Extracted ion chromatograms m/z = 239.0, 253.0, 267.0, 281.0 for SCBs in
metabolites extracted from S. venezuelae sgnL-P::apra strain upon addition of 10 μM, 100 μM 
and 400 μM AHFCA5, with a positive control experiment adding 400 μM AHFCA5 to the 
gbnR mutant. The compound denoted by the * has m/z = 267 and is unrelated to SCBs
Figure 6.17 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for
gaburedins A-F (80-85) in metabolites extracted from S. venezuelae gbnR::apra strain upon
addition of different AHFCAs to the growth media
Figure 6.18 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for
gaburedins A-F (80-85) in metabolites extracted from S. venezuelae sgnL-P::apra strain upon
addition of different AHFCAs to the growth media
Figure 6.19 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for
gaburedins A-F (80-85) in metabolites extracted from S. venezuelae wild-type strain upon
addition of different AHFCAs to the growth media
Figure 6.20 – Proposed signalling cascade involved in gaburedin biosynthesis. AREs are
shown in pink. Inhibitory events are denoted by circular arrowheads
Figure 6.21 – Gel shift assay with SgnR protein (200 nM) and 28-bp sequence which includes
the gbnA ARE sequence. Concentrations of AHFCA6 added to each sample shown above each
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Figure 7.1 – mmfR-mmfLHP-mmyR gene clusters in other Streptomyces species shown with 10
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Abstract
Streptomyces bacteria are prolific producers of secondary metabolites. These natural
products find uses ranging from antibiotics and antifungals to immunomodulatory
agents and pesticides. Biosynthesis of secondary metabolites is often tightly controlled;
therefore novel strategies for activation of cryptic secondary metabolites are required.
The metabolites of the Streptomyces venezuelae wild type and a mutant strain lacking
the ArpA-like transcriptional repressor GbnR have been compared, leading to the
identification of the gaburedins – novel, ureido-linked dipeptides – in the gbnR mutant.
A combination of in vivo precursor-directed studies has led to a proposed biosynthetic
route to gaburedins. Metabolic profiling of a range of other mutant strains has
identified gbnB as an essential gene in the gbnABC gene cluster that is responsible for
gaburedin biosynthesis. Synthesis of an authentic standard of gaburedin A combined
with chiral HPLC analysis of culture extracts has allowed the proposed structure of
gaburedins to be confirmed. Bioinformatic analyses of the gbnABC cluster responsible
for gaburedin biosynthesis have revealed orthologous systems in a range of other
bacterial genera and efforts to reconstitute the S. venezuelae gbnABC pathway in E. coli
have begun.
The regulatory mechanism controlling gaburedin biosynthesis in S. venezuelae has also
been investigated, leading to the discovery of new AHFCA signalling molecules which
have been shown to induce gaburedin biosynthesis in a mutant strain unable to produce
AHFCAs. This work demonstrates for the first time that AHFCA signalling is involved
in regulation of other natural products as well as the methylenomycin cluster from
which AHFCAs were first identified.
Gaburedins represent the first example by which deletion of an arpA-like regulatory
gene has been used as a strategy for de-repression of a biosynthetic pathway for cryptic
natural product biosynthesis. The current project demonstrates that rational deletion of
proposed regulatory genes is a powerful approach to natural product discovery.
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“From so simple a beginning, endless forms most beautiful and most wonderful have
been – and are being – evolved.”
– Charles Darwin
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1. Introduction
1.1 Streptomyces – the natural product makers
Streptomyces are Gram-positive, soil-dwelling bacteria and belong to the large phylum
of Actinobacteria, characterised by the high G+C content in their DNA.1 Streptomyces
undergo a complex life cycle in which a single spore germinates, growing into a
branched, vegetative mycelium. Nutrient depletion is accompanied by development of
aerial hyphae, leading ultimately to sporulation (Figure 1.1).2-4 It has been widely
reported that sporulation coincides with biosynthesis of antibiotics such as actinorhodin
and streptorubin B in Streptomyces coelicolor A3(2) and production of ‘spore
pigments’ for example the green pigment in the case of Streptomyces venezuelae
(Figure 1.1).5-6
Streptomyces bacteria produce a vast array of compounds useful in medicine. Indeed,
over 70% of clinically useful antibiotics derive from compounds first isolated from
Figure 1.1 – A: Streptomyces life cycle schematic (Flärdh and Buttner)4 and B: Streptomyces
venezuelae ISP5230 grown on mannitol/yeast extract medium, MYM (image obtained during the
present study)
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Streptomyces species.7,8 Since Alexander Fleming’s discovery of the Penicillium
rubens antibiotic natural product penicillin in 1928, the capability of microorganisms
to inhibit the growth of other microbes has been rigorously explored.9 The potential of
Streptomyces to produce antibiotics was first realised as early as the 1940s, when
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Figure 1.2 – Streptomyces metabolites of historical and industrial significance
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Streptomyces were first cultivated for this purpose. Discovered in the laboratory of
Selman Waksman in 1943, the first natural product isolated from a Streptomyces
species was the aminoglycoside antibiotic streptomycin, produced by Streptomyces
griseus. Streptomycin quickly found industrial use as an agent to treat tuberculosis.10-12
Since the isolation of streptomycin, many other antimicrobial natural products have
been isolated from Streptomyces species, including tetracyclines, chloramphenicol and
daptomycin (Figure 1.2).13-15 It is estimated approximately two thirds of clinically
useful antibiotics can be attributed to Streptomyces.7,8,16
Many of these natural products produced by Streptomyces are only produced by a small
range of bacterial species and are typically not essential for growth. These so called
‘secondary’ metabolites have garnered Streptomyces bacteria a great deal of industrial
importance. Examples include S. avermitilis (producer of the anthelmintic agent
avermectin) and S. hygroscopicus (producer of the herbicide bialaphos and the
immunosuppressant rapamycin), which have been in use for decades.17-19
Despite the success of strategies for natural product discovery that will be discussed
over the following sections, there is still a great need for natural product discovery.
Indeed, resistance to every single class of clinically used antibiotic has been reported
within years of being introduced.20,21 Methicillin-resistant Staphylococcus aureus,
vancomycin-resistant Enterococci and extremely drug resistant (XDR) strains of
Mycobacterium tuberculosis are particularly well-known examples. It is estimated that
there are as many as 360,000 cases of XDR tuberculosis every year and approximately
53% of clinical strains of Escherichia coli (E. coli) are resistant to the first-line
treatment ampicillin.22,23
Chapter One | Introduction
4
This rise in antibiotic resistance has been contrasted by a dramatic shift in the
investment of big pharmaceutical companies away from antimicrobial research. Indeed,
during the 1990s, many companies scaled back development of new antibiotic
compounds, citing rediscovery of previously known natural products, flouting of
intellectual property laws and the immense cost of clinical trials compared to the return
on investment.24,25 Furthermore, there has been increased focus on more profitable
drugs to treat ailments such as cancer, depression and cardiovascular diseases. These
types of drugs are generally prescribed for periods of months or years (compared with
the relatively short-term timescales of most antibiotic regimens), therefore are more
profitable.
One example of antibiotic screening programs giving rise to low numbers of drug leads
are the in vitro target-based assays employed by GlaxoSmithKline in the late
1990s/early 2000s, which involved genetic manipulation and screening of culture
extracts of over 300 mutated strains. This generated only five new leads after seven
years of research20,26. In the last few years however, antimicrobial development has
begun to return to development of narrow-spectrum antimicrobial agents and in vivo
assays, with the ultimate aim of keeping our most effective, broad-spectrum
antimicrobials reserved for only the most life-threatening cases.26,27
Natural products are an invaluable source of compounds in the whole field of medicine,
and medicinal chemists are always in search of new compounds which are more
efficacious and exhibit fewer side effects.16,28,29 These characteristics are required for
development of all classes of medicines and are not limited to antibiotics. Indeed,
Streptomyces bacteria have made significant contributions to our arsenal of available
medicines, as discussed in the next section.2,3,28,29
Chapter One | Introduction
5
1.2 Strategies for natural product discovery
1.2.1 Phenotype-guided discovery
Many Streptomyces secondary metabolites have been discovered as a result of
phenotypic-directed assays, such as the aforementioned antimicrobials streptomycin,
chloramphenicol and daptomycin. Indeed, the biosynthetic potential of Streptomycetes
has been exploited in screening programs for discovery of other medicinal natural
products. Examples include anticancer agents such as the anthracycline doxorubicin
isolated from Streptomyces peucetius and the glycopeptide bleomycin isolated from
Streptomyces verticillus.30,31 Immunomodulatory agents such as rapamycin, isolated
from S. hygroscopicus and antifungal compounds such as the polyene amphotericin B,
isolated from S. nodosus, provide further examples of Streptomyces natural products
discovered by phenotypic screens.32-34 Example of the diversity of such structures are
shown in Figures 1.2 and 1.3.
Figure 1.3 – Anticancer (doxorubicin and bleomycin) and immunosuppressant (rapamycin) drugs
derived from Streptomyces discovered by screening programs
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The natural product(s) responsible for the desired phenotype can then be isolated by
bioassay-guided fractionation in which the compounds produced by the organism(s) of
interest are separated by chromatography.35,36 Fractions which maintain activity of the
culture extract are separated further to purify and identify the compound of interest.
Analytical chemistry techniques such as liquid chromatography-mass spectrometry
(LC-MS) offer an efficient way of comparing the metabolites produced by different
bacterial strains.35,36
This provides information on the different chemical phenotype – or ‘chemotype’ of
bacterial strains to identify natural products before establishing their physiological
function.35-38 If the natural products identified appear to be novel, then culture
conditions can be scaled up for isolation and more rigorous characterisation of the
natural product of interest, followed by activity-based assays. LC-MS analysis is an
extremely powerful technique as it allows the metabolites of different strains to be
observed either by UV detection or by mass spectrometry detection.
1.2.2 Pleiotropic regulation of secondary metabolism
Traditional approaches of growing strains on media containing different carbon and
nitrogen sources may simply alter the metabolic flux in primary metabolism, therefore
affect the intracellular availability of different precursors which may be siphoned off
for incorporation into secondary metabolites. Indeed, S. venezuelae ISP5230 is known
to produce chloramphenicol when grown at 28 °C in a glucose-isoleucine medium and
to produce jadomycin B when grown at 37 °C in media that contains galactose as the
primary carbon source (Figure 1.4).13,39 Furthermore, the reduced yield of actinorhodin
produced by S. coelicolor A3(2) when grown in high phosphate concentrations is also
well characterised.40,41
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The idea that a single bacterial strain is able to produce a host of different secondary
metabolites when grown in different conditions has been exploited for decades and has
relatively recently been referred to as ‘one strain, many compounds’ – OSMAC.42-44
This principle has been applied to Streptomyces, leading to the observation that over
50% of metabolites extracted from Streptomyces sp. Gö 40/10 grown in different
conditions proved to be novel compounds. These new metabolites have structures
varying from butyrolactones, to glycosylated macrolides and naphthalene
ansamycins.45 More recently, a similar approach has been applied to the extremophile
Streptomyces sp. C34, resulting in the discovery of a series of new polyene
macrolactones, chaxalactins A-C.46
Figure 1.4 – Some examples of Streptomyces metabolites produced in response to altered culture
conditions. For example, jadomycin B and validamycin A are each produced by their host organisms
under conditions of heat and ethanol stress. Methylenomycin is produced in acidic pH. Naphthomycin
K and chaxalactin were discovered by application of the OSMAC approach
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Stress responses to environmental factors such as temperature and pH often result in
changes in secondary metabolism. Examples include production of the antifungal
pesticide validamycin A by S. hygroscopicus, which is dramatically increased by
heat/ethanol shock and methylenomycin production by S. coelicolor when grown in
acidic conditions.44,47,48 However, the mechanisms involved in responses to heat shock
and pH are poorly understood.34,47
The ability of Streptomyces to produce different metabolites in response to stress can
also be exploited by addition of antimicrobial compounds at sub-lethal
concentrations.49 Nodwell and co-workers screened a library of over 100 compounds
for enhanced secondary metabolite production profiles in S. coelicolor, leading to the
observation that Triclosan (which is a known inhibitor of FabI in fatty acid
biosynthesis, Figure 1.5) could change the metabolic profile of S. coelicolor when
added to cultures at concentrations lower than their minimum inhibitory concentrations
(MICs). This led to the identification of antibiotic remodelling compounds (ARCs)
Figure 1.5 – Examples of known elicitors of secondary metabolism in Streptomyces. The siderophore
desferrioxamine has been implicated in interspecies signalling.52 The role of A-factor in antibiotic
biosynthesis has been extensively studied and will be discussed later. Lincomycin, triclosan and ARC2
are proposed to affect secondary metabolism by exerting stress upon the target bacteria49
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which consistently increased actinorhodin production in S. coelicolor. One such
compound, ARC2, has been shown to alter the metabolite profiles of sixty strains of
Streptomyces when added to the culture medium.49,50 Imai and co-workers have also
very recently reported that addition of sub-lethal concentrations of lincomycin to S.
coelicolor results in overproduction of actinorhodin. Furthermore, addition of
lincomycin to Streptomyces lividans at approximately one third of its MIC led to
overproduction of novel derivatives of the calcium dependent antibiotics.51
Co-culturing of Streptomyces species has also been used to alter the metabolic profiles
of some strains. For example, Ueda and co-workers have recently shown when
Streptomyces griseus and Streptomyces tanashiensis are co-cultured, antibiotic
production in S. tanashiensis is increased. This was attributed to secretion of
desferrioxamine E by S. griseus.52 This method of co-culturing had previously been
used to establish a precedent for interspecies signalling being involved in antibiotic
biosynthesis and it was suggested that this is a widespread phenomenon.53
Furthermore, Marmann and co-workers have recently reported from a study of co-
cultivating several soil and marine fungi with Streptomyces species, that the soil
bacterium Tsukamurella pulmonis can induce production of a red pigment in S. lividans
and can also induce production of the novel antibiotic alchivemycin A in Streptomyces
endus.54 Interestingly, there were also several compounds reported in this study that
were produced by fungi belonging to the genera Aspergillus and Fusarium only when
co-cultivated with S. lividans or S. peucetius, but not by exenic cultures. Therefore,
Streptomyces can both alter the secondary metabolism of other organisms, as well as
having their own secondary metabolism altered when co-cultured.
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Co-cultivation is therefore a valuable method for natural product discovery. However,
in many cases it may not be clear whether the induction of natural product biosynthesis
in heterologous strains is due to a stress response (due to change in pH of culture media
or nutrient starvation) or whether the response is caused by secretion of a specific
elicitor molecule by a particular strain.52,53 For example, some Streptomyces species are
known produce signalling molecules such as autoregulatory factor (A-factor, Figure
1.5)55, which will be discussed in Section 1.4. Therefore, the molecular mechanisms
involved in interspecies induction of natural product biosynthesis can be complex. Co-
cultivation has also resulted in the observation that many previously characterised
natural products were also overproduced by some of the test strains.52-54
Figure 1.6 – Strategies for phenotype-based natural product discovery
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In summary, the methods for natural product discovery discussed thus far all involve
‘black box’ approaches. Whilst some are phenotypically-guided in order to search for
novel compounds with antibiotic activity, for example, other strategies exploit bacterial
responses to particular extracellular conditions such as nutrient availability, stress or
chemical signals (Figure 1.6). More rational strategies are therefore required to unlock
the biosynthetic potential of Streptomyces (and other bacteria) in order to discover
novel natural products. Secondary metabolite biosynthesis is tightly regulated and poor
yields of natural products are often observed regardless of the nature of the culture
medium.16,34,56,57
One caveat of these phenotype-based methods discussed is the large amount of
chemical redundancy inherent in this approach; the same classes of compounds (or the
exact same compounds) are rediscovered time and again. This has in part been
attributed to cultivation conditions in the laboratory being far removed from the
environment in which bacteria exist in nature – Streptomyces for example inhabit soil
and marine ecosystems, with complex biotic and abiotic factors that are difficult to
reproduce in the laboratory.28,29,56,58
In order to address this problem – and therefore gain access to previously
uncultivatable bacteria, Ling and co-workers have recently reported how emerging
technologies such as the iChip can be utilised to culture new strains of bacteria. This is
achieved by inoculating a chip with a suspension of cells and growing them in their
native environment, separated by a semi-permeable membrane.58 Their report of the
new antimicrobial NRPS teixobactin earlier this year received a significant amount of
media attention.58 Whilst the iChip represents a significant advance in the biochemical
arsenal available to researchers (it is estimated that only 1 % of microorganisms can be
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grown in a laboratory environment)58,59 this still represents a ‘black box’ approach to
natural product discovery.
1.3 Genome mining approaches to natural product discovery
1.3.1 Sequencing projects have revealed the biosynthetic potential of Streptomyces
One of the primary reasons for Streptomyces – and indeed other microorganisms –
being unable to synthesise the full range of secondary metabolites they have the genetic
capability to produce in a laboratory environment, is that secondary metabolite
pathways are very tightly regulated.56,57 In an evolutionary context, this represents a
way in which bacteria can preserve energy by only producing proteins that they need in
response to specific extracellular stimuli.16,56,59
The genes encoding for biosynthetic enzymes involved in the synthesis of a specific
natural product are often clustered together in bacteria. Regulatory elements and genes
encoding for self-resistance mechanisms are also often located within the same cluster
as the biosynthetic (structural) genes.60,61 Upon sequencing of the S. coelicolor A3(2)
genome in 2002, it was revealed that the S. coelicolor chromosome is 8.7 Mbp in size
and contains 25 gene clusters involved in secondary metabolite biosynthesis. As S.
coelicolor had been extensively studied for decades, this large number of secondary
Table 1.1 – Examples of biosynthetic potential of some sequenced Streptomyces
Organism Size /
Mbp
Number of
genes
Number of secondary
metabolite clusters
Ref
Streptomyces coelicolor A3(2) 8.7 7825 25 61
Streptomyces avermitilis 9.0 7583 34 62
Streptomyces scabies 87-22 10.1 8530 28 20
Streptomyces venezuelae 8.2 7238 31 63
Streptomyces griseus IFO 13350 8.5 7138 34 64
Chapter One | Introduction
13
metabolite gene clusters was very surprising.3,61 Since then, dozens of other
Streptomyces genomes have also been sequenced (Table 1.1 includes examples from
some industrially important microbes). It would appear that 20-30 secondary metabolite
gene clusters per Streptomycete is the norm, demonstrating that the Streptomyces genus
is still a largely untapped reservoir of natural products.61-64
Sequencing projects have identified many gene clusters in Streptomyces species that
might not be expressed in laboratory conditions.20,61-64 Indeed, many of these silent
pathways are also ‘cryptic’; they encode enzymes for biosynthesis of unknown natural
products. Exploiting the vast quantity of new genomic data has reinvigorated natural
product discovery by development of a new paradigm – ‘genome mining’.59,65-69
Bioinformatics tools such as BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) can be
used to find homologous gene and protein sequences in vast depositories of genomic
information. Newer tools such as multi-gene BLAST and antiSMASH 3.0
(http://antismash.secondarymetabolites.org/) can now be used to identify whole
biosynthetic gene clusters for a natural product of interest.70,71 Whilst in most cases
nucleotide or protein sequences alone cannot be used as a predictive tool to reveal the
structure of the natural product encoded for by a whole gene cluster, these
bioinformatics tools are invaluable to infer the function of individual biosynthetic
enzymes and regulatory proteins.
In order to determine the nature of cryptic natural products, it is important to first
establish that the cluster is expressed. This may be achieved by reverse transcription-
polymerase chain reaction (RT-PCR), DNA microarrays or RNA-Seq analyses.67,68
Assigning functions to a specific biosynthetic gene cluster based on bioinformatics
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analyses alone is still extremely challenging in most cases. Therefore, genetic
manipulation is required in order to link a specific pathway to a particular natural
product.65,66 Some genome mining methods for overproduction of natural products are
detailed in the next section.
Figure 1.7 – Genome mining strategies for natural product discovery. Bioinformatics can be used to
predict natural product structures assembled by gene clusters, or by specific enzymes (A and B). Genes
may be expressed in a heterologous host (C) or knocked out (D) in order to deduce their roles in natural
product biosynthesis. Alternatively, if activators/repressors can be identified, they may also be
overexpressed/deleted to increase expression of the biosynthetic cluster of interest (E and F)
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1.3.2 Bioinformatics can be used to predict natural product scaffolds
Highly conserved multienzyme complexes such as polyketide synthases (PKSs) and
non-ribosomal peptide synthetases (NRPSs) have distinctive amino acid sequences.
Indeed, the sequences of acetyl transferase (AT) domains within PKSs and adenylation
(A) domains in NPRSs are conserved to the extent that substrate specificity can often
be predicted from the amino acid/nucleotide sequence alone. Indeed, there are now
tools such as NRPSpredictor (nrps.informatik.uni-tuebingen.de/) available to help with
predicting substrate specificity of A domains.72,73 Predictions of the substrate
specificity of the A domains of the NRPS involved in biosynthesis siderophore
coelichelin 22 allowed the structure to be predicted with a high level of accuracy; this
information was used to guide the purification of this cryptic metabolite.74 A similar
approach (panel A in Figure 1.7) was used recently to identify a new siderophore
natural product 23 produced by S. peucetius (Figure 1.8).75
Furthermore, sequencing data can also provide information on what tailoring reactions
may occur during the synthesis of natural products synthesised by these enzyme
complexes. Similarly, reactions involved in the synthesis of ribosomally synthesised,
post-translationally-modified peptides (RiPPs) can be predicted. One recent example of
a RiPP structure predicted using bioinformatic analysis is grisemycin 24 (Figure 1.8),
produced by the grn gene cluster in S. griseus IFO 13350.76
The grn cluster was compared to the cypemycin gene cluster in Streptomyces sp. OH-
4156 (each gene in the S. griseus cluster was >60% identical to its homologue in the
OH-4156 cluster).76 However, such bioinformatic comparisons were only possible
because a very similar biosynthetic system had been studied previously. If the gene
cluster of interest has little or no homology to characterised metabolic pathways, then
Chapter One | Introduction
16
other approaches may be necessary to link the specific genes involved to a natural
product structure.
Bioinformatics tools such as the conserved domain search on NCBI
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) may also be used to determine
the specific function of a particular enzyme, therefore allowing the substrate to be
predicted.77 When bioinformatic analyses allow partial structural predictions to be
made, stable-isotope precursor molecules can be used to guide the purification of the
compound of interest. This ‘genomisotopic’ methodology (panel B in Figure 1.7) has
been applied by Gross and co-workers to discover orfamides A-C produced by
Pseudomonas fluorescens Pf-5.78
Figure 1.8 – Examples of Streptomyces metabolites, the structures of which were predicted by
bioinformatics comparisons of their biosynthetic gene clusters with previously characterised ones74,75
Chapter One | Introduction
17
1.3.3 Heterologous expression
In order to identify and solve the structure of a cryptic natural product, it may be
advantageous to express the gene cluster of interest in a heterologous host. It may be
particularly difficult to detect the metabolic product of a particular pathway if there are
many other metabolites produced by the host strain or if the gene cluster is poorly
expressed.
Upon introduction of the gene cluster of interest into a heterologous host, metabolites
produced by the wild type and mutant strains may then be compared to discover new
natural products and link their biosynthesis to the gene cluster introduced into the host
organism (panel C in Figure 1.7). The 2-alkyl-4-hydroxymethylfuran-3-carboxylic
acids (AHFCA) compounds such as 25 from S. coelicolor A3(2) provide an example of
novel natural products discovered by this approach and will be discussed in more detail
later.79 A novel sesquiterpene, epi-isozizaene 26, was shown to be the product of the
cryptic Streptomyces coelicolor gene sco_5222 when it was heterologously expressed
in E. coli.80 However, epi-isozizaene is not produced by wild-type S. coelicolor, which
converts it into albaflavenol and albaflavenones.
Indeed, there are now several ‘superhost’ strains of S. coelicolor available, such as
M1146 and M1152. These hosts were constructed by the removal of large gene clusters
Figure 1.9 – Examples of S. coelicolor metabolites discovered by heterologous expression of genes
(AHFCAs and epi-isozizaene) and by gene knockouts (germicidin B)79,83
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encoding for known metabolites such as actinorhodin (act), streptorubin B (red),
calcium-dependant antibiotic (cda) and coelimycin (cpk) clusters.7,81 These gene
deletions were made in order to increase metabolic flux by removing the sink for many
secondary metabolite precursor molecules from primary metabolism and to provide a
cleaner background in LC-MS analyses of natural products. Streptomyces M1152 also
carries a mutation in the RNA polymerase B gene rpoB that favours biosynthesis of
secondary metabolites.81
Heterologous expression of the aforementioned S. griseus grm gene cluster in the
Streptomyces coelicolor host strain M1146 allowed the new peptide metabolite product
grisemycin (Figure 1.8) to be characterised by comparison of the metabolite profiles of
the parent and daughter strains.7,76 However, if the biosynthetic gene cluster of interest
is very large (for example, polyketide biosynthetic genes can exceed 100 kb in size),
then heterologous expression is more difficult. One complementary approach is to
target specific structural or regulatory genes in a particular cluster to identify a novel
natural product.66-68
1.3.4 Gene knockouts
In order to assign functionality to a specific biosynthetic gene, the gene can be knocked
out by replacement with a resistance marker (panel D in Figure 1.7).82 For example,
three new germicidins (as well as the two originally isolated from Streptomyces
viridochromogenes) were identified as being present in the metabolite profile of S.
coelicolor M145 but absent in a sco_7221 deletion strain (Figure 1.9).83
To provide further evidence for a specific function of a given gene, the deletion
mutants can be complemented either genetically (by re-introducing the deleted gene
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into the genome) or by supplementing culture media with a putative or known
biosynthetic intermediate. In the case of germicidins, the sco_7221 gene was re-
introduced into the sco_7221 deletion mutants, restoring germicidin production in S
coelicolor. The sco_7221 gene was also heterologously expressed in S. venezuelae
ISP5230, thus leading to production of germicidins by S. venezuelae.83
1.3.5 Genetic inactivation of repressors/overexpression of activators
As mentioned above, secondary metabolite gene clusters often include regulatory genes
controlling the production of that metabolite.56,57 For example, genes actII-orf4, redD
and mmyB all encode for transcriptional activators are found within in the gene clusters
for biosynthesis of actinorhodin, streptorubin B and methylenomycin, respectively, in
S. coelicolor.84,85 Therefore, specific regulatory elements in the biosynthetic pathway of
interest may be targeted in order to turn on potentially silent pathways and to determine
the nature of the corresponding cryptic natural product. This may be achieved by
overexpression of transcriptional activators, or by deletion of transcriptional repressors
(Figure 1.7 – panels E and F).84,86
The first example of this approach being used to discover novel metabolites in
Streptomyces was overexpression of the samR0484 gene encoding for a transcriptional
activator in Streptomyces ambofaciens. Overexpression of samR0484 was achieved by
construction of a vector in which samR0484 was placed under the control of the strong
ermE* promoter and subsequent transformation of S. ambofaciens using this vector.
This led to the discovery of a series of new 51-membered macrolactones – the
stambomycins (for example 28 in Figure 1.10).86
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Furthermore, derepression of a biosynthetic pathway may be achieved by deletion of a
gene encoding for a transcriptional repressor. For example, deletion of the mmyR gene
leads to overproduction of methylenomycin in S. coelicolor.85 MmyR is proposed to be
a transcriptional repressor protein; when the mmyR gene was deleted, there was
constitutive production of methylenomycin. However, there are very few examples of
this approach being used to specifically ‘wake up’ silent pathways.84
One example from Aroonsri and co-workers demonstrates that deletion of the ksbC
transcriptional regulator in the Actinomyctete Kitasatospora setae led to
overproduction of the novel alkaloid ketasetaline 29 (Figure 1.10). The ksbC gene was
identified as a pseudo γ-butyrolactone (GBL) receptor and subsequently deleted, 
leading to the discovery of kitasetaline. Even though it was initially predicted that
KsbC would act as a repressor, it was found that KsbC also acts as an activator in the
Figure 1.10 – Examples of Actinomycete metabolites discovered by overexpression of a gene encoding
for an activator (stambomycin B 28) and by deletion of a genes encoding for a transcriptional
repressors (kitasetaline 29 and coelimycin P1 30)87-89
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biosynthesis of bafilomycin.87 A further example is the yellow S. coelicolor pigment
coelimycin 30, which is overproduced by a strain in which the scbR2 transcriptional
repressor gene has been deleted (Figure 1.10).88,89
These examples provide precedent for overexpression of activators or deletion of
transcriptional repressors as powerful strategies for natural product discovery, if the
activators/repressors in a silent biosynthetic gene cluster can be identified and their
potential functions predicted. Transcriptional activators and repressors may be
pleiotropic (for example AdpA in S. griseus) or pathway specific (for example, MmyR
in S. coelicolor) and may involve indirect regulatory effects.85,90,91 In the case of
pleiotropic regulators such as adpA or ksbC, the gene clusters regulated by a specific
activator/repressor may be situated hundreds of kb away in the chromosome. Therefore,
it is necessary to understand the molecular mechanisms by which particular
transcriptional activators/repressors function in order to determine exactly which genes
to overexpress/delete within a specific cluster to elicit overproduction of the cryptic
metabolite.
1.4 TetR transcriptional regulators
1.4.1 Functions of TetR family regulators
There are many distinct classes of transcriptional regulator proteins in prokaryotes.
Most are one-component systems (in which sensory and DNA-binding domains exist in
a single polypeptide), for example, LysR, ArsR and TetR family transcriptional
regulators.92,93 Over twenty classes of one-component systems have been discovered in
prokaryotes, as defined by the primary amino acid sequence of their DNA-binding
domains. Members of each class typically act as either activators (such as the LuxR
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family regulators), or as repressors (for example, the LacI and TetR families) or indeed
act as both.92 For example, the LysR family of transcriptional regulators can either
promote or repress transcription.92,93 In many cases, several classes of regulatory
protein may exist in one biosynthetic gene cluster; hence deciphering regulatory
mechanisms directing biosynthesis of a given natural product can be a very difficult
task.94,95
For example, if a transcriptional regulator represses transcription of another repressor,
which in turn represses expression of structural genes, then deletion of the first
repressor will result in expression of the structural genes. In Jadomycin biosynthesis for
example, JadR3 has been shown to repress transcription of the regulatory gene jadR2,
which is also proposed to act as a repressor of jadomycin biosynthesis.95 Hence,
understanding of the regulatory mechanisms involved with specific pathways is
necessary to deduce exactly which regulatory genes to delete in a given system.
Named after the tetracycline resistance protein TetR first discovered in E. coli, this
family of transcriptional regulators mainly act as repressors and generally function as
homodimers, with each subunit consisting of a ligand-binding domain and an N-
terminal DNA-binding domain.92,96 TetR family proteins are widespread in
prokaryotes. For example, analysis of the S. coelicolor genome revealed it to contain
genes encoding for 965 regulatory proteins, many of which are located in or adjacent to
biosynthetic gene clusters.61 Over 150 of these regulatory proteins belong to the TetR
family.92 As well as a clear role in controlling metabolite export, therefore contributing
significantly to antibiotic self-resistance mechanisms, TetRs have been implicated in a
number of other functions including regulation of amino acid, lipid and nitrogen
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metabolism. Other functions of TetRs include roles as effector proteins in quorum
sensing and regulators of secondary metabolism.92
TetR binds to the region in which its promoter and the promoter of the divergently
adjacent tetA gene overlap (Figure 1.11). Upon binding tetracycline, TetR undergoes a
conformational change, reducing the affinity of the DNA binding domain for its target
sequence in the tetA-tetR intergenic region.14,97 Therefore TetR dissociates from the
DNA, allowing RNA polymerase to bind to the tetA-tetR promoter and therefore
transcribe tetA. The translated TetA protein acts as export protein for tetracycline, thus
conferring self-resistance to tetracycline when it reaches a high enough intracellular
concentration to induce tetA expression (Figure 1.11).98 This mechanism is important
for self-resistance, as tetracycline will trigger transcription of tetA at sub-inhibitory
concentrations, therefore allowing tetracycline to start being exported before it damages
the host cell.92
Figure 1.11 – Mode of action of TetR. TetR binds to the tetA-tetR promoter, repressing transcription of
tetA (A). When tetracycline is present inside the cell, it binds to the ligand binding domain of TetR (B).
This leads to dissociation of TetR from its DNA target (C) allowing tetA to be transcribed (D); TetA
then exports tetracycline out of the cell97,98
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1.4.2 Ligands for TetRs
Of the TetRs for which the structures have been solved, there are approximately 200
apo structures, 21 with ligands bound and 7 with DNA bound (as reported in 2013 by
Cuthbertson and Nodwell).92,99 The crystal structure of the S. coelicolor MmfR protein
with its ligand AHFCA2 32 was solved in our group in 2013 and will be discussed in
Section 1.6.100 Indeed, the known ligands for TetRs vary in structure from large
amphipathic molecules such as stearoyl-CoA 33, to spirotetronates such as kijanimicin,
porphyrins such as heme 34 and small signalling molecules such as AHFCA2 (Figure
1.12).92,99,101
Of particular interest to secondary metabolite pathways are those TetRs which bind to
diffusible, low molecular weight signalling molecules – ‘bacterial hormones’ – such as
AHFCAs or γ-butyrolactones (GBLs). Repressors which recognise these types of 
molecules all belong to the TetR subfamily of ArpA-like transcriptional repressors and
are often involved in regulation of antibiotic biosynthesis.102-105
Figure 1.12 – Examples of structural diversity of ligands known to interact with TetR proteins92,100
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1.4.3 ArpA family transcriptional repressors
The archetypal ArpA protein from S. griseus has been studied in detail.90,102,106 ArpA
acts as a negative regulator of expression of the adpA gene, binding to a specific DNA
sequence – an autoregulatory response element (ARE) – situated in the adpA operator
region. ArpA is responsive to autoregulatory factor (A-factor).91,92 When the
intracellular concentration of A-factor reaches a critical point, it binds to ArpA, causing
a conformational change, therefore reducing the affinity of ArpA for the ARE sequence
in the adpA operator. Therefore, RNA polymerase is able to bind the adpA promoter,
Figure 1.13 – Mode of action of ArpA and the regulatory cascade activating streptomycin biosynthesis
upon A-factor binding to ArpA.91 ArpA prevents transcription of the activator adpA (pathway A), until
A-factor is detected, allowing for transcription of adpA and subsequent activation of streptomycin
biosynthesis (pathway B)
Chapter One | Introduction
26
allowing transcription and translation to occur.91,106
AdpA is a pleiotropic transcriptional activator implicated in the regulation of secondary
metabolite production and morphological differentiation. It is believed to regulate
transcription of as many as 80 different genes.57,106 One of the targets of AdpA is the
operator region of strR, a gene which encodes for the transcriptional activator StrR,
which activates streptomycin biosynthesis (Figure 1.13).90,91 AdpA also indirectly
regulates expression of griR, a pathway-specific activator in biosynthesis of the yellow
pigment grixazone.103,107
Interestingly, ArpA is distinct from other ArpA-like transcriptional regulators in the
context of both its gene location and its function; it does not appear adjacent to a
Table 1.2 – Examples of ArpA-like proteins and their cognate ligands and antibiotic biosynthetic
pathways they regulate
Strain Ligand
biosynthetic
enzyme
Ligand Ligand
acceptor(s)
Natural product
biosynthesis
regulated
Refs
6-keto type GBLs:
S. griseus AfsA A-factor ArpA streptomycin 55,102
6-hydroxy-type
GBLs:
S. coelicolor ScbA SCB 1-3 ScbR act, red, coelimycin 88,110
S. venezuelae JadW1 SCB3 JadR3 jadomycin B 95
S. lavendulae FarX IM-2 FarA showdomycin 113,114
S. virginiae BarX VB A-E BarA virginiamycin 115,116
butenolides:
S. avermitilis Aco avenolide AvaR1 avermectin 117
S. rochei SrrX SRB1/2 SrrA lankamycin 118
furans:
S. coelicolor MmfL AHFCA 1-5 MmfR methylenomycin 79,85
ligands unknown:
S. ambofaciens unknown unknown AlpZ alpomycin 119
S.aureofaciens SagA unknown SagR auricin 120
S. acidiscabies SabA unknown SabR angucyclinone 121
S. fradiae unknown unknown TylP tylosin 122
S. pristinaespiralus unknown A-factor-like SpbR pristinamycim 94
K. setae KsbS4 unknown KsbA bafilomycin 87
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biosynthetic gene cluster which it regulates, and it appears to be an indirect pleiotropic
regulator as it negatively affects transcription of the pleiotropic activator adpA. Whilst
some other ArpA-like proteins are pathway-specific regulators of secondary metabolite
biosynthesis, ArpA is also involved in morphological differentiation.90,105 Some
examples of ArpA-like transcriptional repressors and the antibiotic biosynthetic gene
clusters they regulate are shown in Table 1.2. As mentioned in the previous section,
targeted gene deletions of transcriptional regulators such as ArpA family regulators
represent a valuable tool to access new natural product scaffolds from cryptic, silent
gene clusters.
1.4.4 Ligands for ArpA-like repressors
Discovered in 1967, autoregulatory factor (A-factor 19) was the first example of a γ-
butyrolactone (GBL) to be isolated from Streptomyces species.55 AfsA has been
identified as the key biosynthetic enzyme required for A-factor production and is
encoded for by the afsA gene.108,109 Biosynthesis of A-factor is discussed in Section 1.5.
Concurrent research over the last 40 years has led to the isolation and characterisation
of other γ-butyrolactones and GBL signalling systems in a range of Streptomyces
species; factor I from S. viridochromogenes, three Gräfe factors isolated from S.
bikiniensis, virginiae butanolides VB-A to E isolated from S. virginiae, factor IM-2
from S. lavendulae FRI-5 and Streptomyces coelicolor butyrolactones (SCBs) 1-3 from
S. coelicolor.112,113,115,123,124 Structures of known γ-butyrolactone and other inducer 
molecules proposed to interact with ArpA-like proteins are shown in Figure 1.14.
The functions of these GBLs and other Streptomyces signalling pathways have been the
subject of several recent reviews16,104,105 and the systems in which the functions of the
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AfsA and ArpA homologues have been investigated are shown in Table 1.2. GBLs can
be classified as ‘6-keto-type’ – in which there is a keto group at carbon 6 (A factor is
still the only example of this type of GBL) and ‘6-hydroxy-type’ – in which the keto
group has been converted to a hydroxyl group (Figure 1.15). The natural 6-hydroxy-
type GBLs can be sub-divided into other classes based on the stereochemistry at
carbons 2, 3 and 6 (Figure 1.15).
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Figure 1.14 – Structures of known Streptomyces signalling molecules.79,112-124 The absolute
stereochemistry of Gräfe factors and factor I have not been reported
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It has been shown that the absolute stereochemistry of carbons 2, 3 and 6 confers the
specificity of each GBL receptor for its cognate ligand(s).112,125,126 A-factor is the only
natural example of the 6-keto type of GBL reported and readily undergoes
epimerisation due to the relative acidity of the proton at carbon 2. The butyrolactones
from the most studied systems, SCBs and VBs systems, all share 2R, 3R
stereochemistry. In addition, the length of the alkyl chain also affects the ligand binding
affinity of ligand receptor protein. For example IM-2 and SCBs 1-3 have the same (2R,
3R, 6R) configuration and vary only in the length of their alkyl chains. Their cognate
receptor proteins, FarA for IM-2 and ScbR for SCBs, have different specificities – in
vitro assays have shown FarA is most responsive to IM-2 type GBLs with alkyl chain
lengths containing four or five carbons, and ScbR has been show in vivo to be most
responsive to IM-2 type GBLs with eight or nine carbons in the alkyl chain.112,125
Other GBLs for example the aforementioned factor I and Gräfe factors have not been
fully characterised. There are also examples of other γ-butyrolactones which have 
Figure 1.15 – Stereochemistry of γ-butyrolactones varies at carbons 2, 3 and 6. The stereochemistry is 
2R, 3R for all the examples discussed in the text (A-factor, SCBs and VBs)
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different stereochemistry (54 has 2S, 3R, 6R stereochemistry) and derivatised
hydroxymethyl or alkyl groups, such as the butyrolactones 54-57 isolated from
Streptomyces sp. W5 and Streptomyces sp. Gö 40/10 (Figure 1.16).45,126 The
biosynthetic origin and functions of these GBLs have not been investigated, however.
Comparative genomic analysis has more recently led to the identification of many
AfsA-like biosynthetic enzymes. ArpA-like putative GBL receptors and their proposed
roles in the regulation of antibiotic biosynthesis and morphological differentiation have
also been reviewed.104,105,128,129 Some AfsA homologues and the ligands that they
biosynthesise are shown in Table 1.2.
Furthermore, the ArpA-like repressor homologues are referred to in the literature as
‘GBL receptors’ and ‘pseudo-GBL receptors’, as defined by phylogenetic
analyses.92,128 This nomenclature is misleading, as the ligands for ArpA-like repressors
are more structurally diverse than just different GBL structures (Figure 1.14 and Table
1.2).
Figure 1.16 – Examples of other butyrolactones isolated from Streptomyces species45,126
Stereochemistry at position 3 is R in all cases where the structure have been elucidated fully, and others
have derivatised alkyl chain substituents
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Indeed, investigation of the role of the aco gene in regulation of avermectin
biosynthesis in S. avermitilis has resulted in the discovery of avenolide (Figure 1.14) as
a signalling molecule regulating that system. The butenolides SRB1 and SRB2 have
also recently been reported to regulate lankamycin biosynthesis in S. rochei.117,118
Investigation of another afsA-like signalling pathway involved in regulation of
methylenomycin biosynthesis has led to the identification and structural
characterisation the AHFCAs – as exemplified by the methylenomycin furans (MMFs),
the structures of which are shown in Figure 1.14.79,85
If the nature of the signalling molecules interacting with specific ArpA-like repressors
could be predicted, then adding that specific signalling molecule to the host strain
might induce expression of biosynthetic pathways for cryptic natural products. This
principle has been tested using an indirect kanamycin-activity reporter assay in the case
of the SCBs, in which the ability of SCB analogues were used to de-repress ScbR
protein from the cpkO promoter upstream of a kanamycin resistance gene.112 AHFCAs
have also been used to induce methylenomycin production in strains unable to produce
them (as the mmfLHP genes had been deleted).79,85
Many of the GBL or GBL-like signalling molecules proposed to be involved in
regulation of antibiotic biosynthetic pathways remain unidentified due to poor
production levels (see Table 1.2 for examples).87,94,122 Indeed, the inductive effect of
these signalling molecules is only observed at very low – and very narrow ranges – of
concentrations (A-factor induces streptomycin biosynthesis in S. griseus at 0.5-250 nM
concentrations and avenolide was also shown to induce avermectin production in an
aco mutant of S. avermitilis at an extracellular concentration of 4-150 nM).117,130 In
order to understand the biochemical determinants linking a particular inducer molecule
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to biosynthesis of a specific natural product, it is necessary to consider the substrate
tolerance of the AfsA-like enzyme, the ligand binding properties of the ArpA-like
receptor protein(s) and the DNA sequences to which the ArpA protein binds.
1.5 Biosynthesis of Streptomyces signalling molecules
1.5.1 The key step in GBL biosynthesis
Before the afsA-like enzyme BarX was identified, a biosynthetic route to virginiae
butenolide A (VB-A) 39 was first proposed by Sakuda and co-workers and was verified
by incorporation experiments using stable isotope precursors (58, 61 and 62 in Scheme
Scheme 1.1 – Specific incorporation of 13C labels from acetate (filled circles), isovalerate (grey square)
and glycerol (grey circles) precursor molecules into virginiae butenolide-A (VB-A)131
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1.1).131 Over the last decade, investigations into the biosynthesis of several GBLs and
GBL-like molecules have revealed more details of the specific functions of AfsA and
AfsA-like enzymes. In particular, AfsA has been shown to be the key enzyme required
for A-factor biosynthesis by Kato and co-workers, ScbA has been shown to be required
for SCB biosynthesis and MmfL was described as the key enzyme for MMF
biosynthesis by Corre and co-workers.79,109,132 The only published in vitro work on
AfsA-type enzyme thus far is for AfsA itself.
Following from the initial observation that A-factor production is restored by insertion
of the afsA gene into a S. griseus mutant lacking a DNA fragment that includes afsA, it
has been shown that AfsA is required for A-factor biosynthesis.133 More recent in silico
modelling studies suggested AfsA contains a tunnel capable of accepting an acyl-ACP
acyl chain, implying AfsA may be involved in catalysing the condensation of a β-
ketoacyl chain and 3-carbon containing compound to produce an A-factor precursor.109
Kato and co-workers confirmed in vitro that AfsA is the key enzyme for A-factor
biosynthesis, as it catalyses the condensation of an intermediate from fatty acid
metabolism – 8-methyl-3-oxononanoyl-acyl carrier protein (ACP) 65 – and
dihydroxyacetone phosphate (DHAP) 60 to form an 8-methyl-3-oxnonanoyl-DHAP
ester intermediate 66, shown in Scheme 1.2.
Regarding the downstream steps from the phosphorylated ester intermediate 66, three
further reactions are required for A-factor biosynthesis – an intramolecular aldol
reaction that results in the butenolide, a dephosphorylation step and a step involving
reduction of the C2-C3 double bond in the butenolide intermediate. Two initial
pathways for these three steps were proposed by Sakuda and co-workers in which: i)
dephosphorylation of the ester intermediate is followed by the aldol reaction and final
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reduction of the butenolide to A-factor and ii) intramolecular aldol reaction occurs
before the reduction step, which is followed by the dephosphorylation (Scheme 1.2).134
Indeed, Kato and co-workers presented evidence for both of these pathways occurring
during their investigations of AfsA and A-factor biosynthesis in vitro (Scheme 1.2).109
An enzymatic assay utilising His-tagged AfsA, 32P-labelled DHAP and the synthetic 8-
methyl-3-oxononanoyl-acyl ACP analogue, 8-methyl-3-oxononanoyl-N-
Scheme 1.2 – Biosynthetic route to A-factor as proposed by Kato and co-workers109.134
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acetylcysteamine (NAC) led to the detection of a radioactive ester intermediate on thin
layer chromatography (TLC). This product was compared with an authentic synthetic
standard of the ester intermediate 66. After dephosphorylation of the ester, analysis by
LC-MS confirmed the presence of the butenolide expected to be formed by a non-
enzymatically catalysed intramolecular aldol reaction of the dephosphorylated ester
intermediate 67 to yield 68 (Scheme 1.2).
This synthetic ester 66 was also added to a lysate of a S. griseus ΔafsA mutant, and
resulted in production of A-factor thus confirming that AfsA is required for A-factor
biosynthesis and that this ester intermediate could be converted into A-factor by other
enzymes present in the ΔafsA mutant lysate. Additionally, when testing other 3-carbon
substrates in the AfsA assay, only upon addition of DHAP did the initial concentration
of 8-methyl-3-oxononanoyl-N-acetylcysteamine (NAC) decrease with time, implying
that the enzyme is specific for condensation of DHAP with the fatty acid derivatives to
yield A-factor 19.
This result was complemented by introduction of afsA into E. coli, which resulted in
production of A-factor like molecules 71 and 72 (one of these molecules 71 exhibited
the same m/z = 241 for its [M-H]- ion as does A-factor, the other 72 had m/z = 213 for
its [M-H]- ion), shown in Figure 1.17. Both A-factor-like GBLs fragmented with the
O
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Figure 1.17 – A-factor and A-factor analogues produced by E. coli when expressing afsA as proposed
by Kato and co-workers109
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same patterns as does A-factor when analysed by tandem mass spectrometry. The
structural difference between A-factor and 71 and 72 was attributed to the differences
in fatty acid metabolism between Streptomyces species and E. coli. Streptomyces
species can produce branched fatty acids from starter units such as isobutyryl-CoA, 2-
methylbutyryl-CoA and 3-methylbutyryl-CoA, whereas E. coli predominantly uses
acetyl CoA.135,136 Only afsA was expressed in the E. coli strain that produced these A-
factor-like molecules. This observation implied that downstream steps in A-factor
biosynthesis (the reduction of the butenolide and the dephosphorylation steps) are
catalysed by enzymes that are non-specific to the A-factor biosynthetic pathway and
such promiscuous phosphatases and reductases may be present across a wider range of
bacteria than just Streptomyces.
Furthermore in the region close to afsA, an NADPH-dependent specific reductase –
butenolide phosphate reductase, BprA – was identified, encoded by bprA. Recombinant
BprA was shown to catalyse the reduction of the butenolide phosphate 69 to a
butanolide phosphate 70 in vitro, but was also shown not to be able to catalyse the
reduction of the dephosphorylated butenolide 68, suggesting that there is a non-specific
reductase in E. coli that can catalyse the reduction of the butenolide 68 to butanolide
69. In both cases, it was suggested that there were other enzymes to catalyse the
dephosphorylation step present in the asfA mutant lysate. This series of experiments
therefore provided additional evidence for the biosynthetic pathway initially proposed
by Sakuda and co-workers for VB biosynthesis.131,134
Biosynthesis of SCBs has been attributed to the ScbA protein in S. coelicolor (64%
identity and 73% similarity to AfsA).132,137 In silico analysis of ScbA and its homology
to FabA and FabZ from fatty acid biosynthesis were used as a predictive tool for
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identification of key glutamate and arginine residues in the proposed active site.132
Indeed, when these mutations were made, ScbA was no longer able to synthesise SCBs
in vivo. These observations were accompanied by RT-PCR experiments to verify that
the scbA mutant genes were being expressed. Attempts to reconstitute this pathway in
vitro with recombinant ScbA were hindered by the poor solubility and expression
levels of ScbA in heterologous hosts.132
1.5.2 Reduction of 6-keto-type GBLs to 6-hydroxy-type GBLs
All characterised 6-keto and 6-hydroxy-type GBLs have R stereochemistry at position 3
(Scheme 1.3). It was suggested by Kato and co-workers that BprA and its orthologue
ScbB (SC06267), which has 76% identity and 84% similarity to BprA, convert the
butenolide phosphate 69 into a butanolide phosphate 70 in a conserved stereospecific
fashion, generating the 3R configuration in A–factor and SCB type GBLs,
respectively.109
The reduction of the keto groups at position 6 and the resulting stereochemistry have
been suggested to arise due to action of additional, NADPH-dependent reductases. One
such enzyme has been characterised, BarS1, in S. virginiae.138,139 The barS1 gene is
essential for VB biosynthesis and BarS1 has been shown to be specific for 6-keto-like
butanolides with 3R stereochemistry, yielding only 6-hydroxy-type butyrolactones with
2R, 6S stereochemistry as in the natural metabolites VB-A-E (Scheme 1.3).
BarS1 orthologues are encoded for by sco6264 in S. coelicolor (31% identity and 46%
similarity at amino acid level) and jadW3 in S. venezuelae (29% identity and 42%
similarity at amino acid level).95,139 jadW3 has been shown to play a role in
butyrolactone biosynthesis in the regulatory cascade controlling jadomycin production
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in S. venezuelae, however deletion of jadW3 did not completely abolish jadomycin
production.95 SCO6264 has also been implicated in SCB biosynthesis in S. coelicolor
but has not been investigated thoroughly.132
Scheme 1.3 – General scheme of proposed steps in GBL biosynthesis, showing a conserved pathway to
6-keto type GBLs, where the stereochemistry of carbon 3 is determined by BprA (or homologous
proteins), then the absolute configuration of carbons 2 and 6 are determined by either SCO6264/JadW3
or BarS1 enzymes109,132,138
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Therefore, it is possible that the reductases SCO6264, JadW3, BarS1 are stereoselective
for keto-type butanolides with specific absolute configurations at carbons 2 and 3.
Hence, the substrate specificity of these reductases may determine the stereochemistry
at carbon 2 in GBL; they also determine the stereochemistry of carbon 6 by their
catalytic activity. More work is needed in order to ascertain the precise function of
SCO6264 or JadW3, however.132,139
1.5.3 AHFCA biosynthesis
The afsA homologue on the SCP1 plasmid of S. coelicolor, mmfL, has been shown to
be essential for biosynthesis of methylenomycin.79,85 Indeed, an mmfL deficient strain
was created that no longer produced methylenomycin. However, production of
methylenomycin was restored upon addition of ethyl acetate extract from a strain in
which mmfL was present.79 Upon introducing the mmfLHP genes from S. coelicolor
A3(2) into a heterologous host which lacks the SCP1 plasmid, it was reported that the
new strain constructed produced a series of novel inducer molecules, the 2-alkyl-4-
hydroxymethylfuran-3-carboxylic acids (AHFCAs), the structures of which are shown
in Figure 1.14.
After the discovery of AHFCAs, Corre and co-workers proposed that the function of
MmfL was to catalyse an analogous reaction to that of AfsA, by which the hydroxyl
group of dihydroxyacetone phosphate (DHAP) undergoes a condensation reaction with
β-ketothioester intermediates from fatty acid metabolism, yielding an ester intermediate 
78. Intermediate 78 then undergoes intramolecular aldol condensation to form a
butenolide phosphate intermediate 79 (Scheme 1.4).79,140 It was also hypothesised that
subsequent dephosphorylation and reduction steps, catalysed by MmfP and MmfH
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respectively, yield the AHFCA molecules from the butenolide intermediate. MmfH is a
flavin-dependent putative dehydrogenase and MmfP is a phosphatase.140
Evidence for this hypothesis was provided by the initial structure elucidation studies of
the AHFCA compounds, during which deuterium-labelled precursors for starter units of
fatty acid biosynthesis were added to the culture medium of the S. coelicolor W74.
Mass spectrometry analyses revealed that seven of the deuterium labels from d8-valine
73 were incorporated into AHFCA3 51 (Scheme 1.4).79 Analogous experiments were
Scheme 1.4 – Proposed biosynthetic route to AHFCAs isolated from Streptomyces coelicolor W74,
showing the proposed origin of the isobutyryl-CoA incorporated into AHFCA379,100,140
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performed with each of the proposed precursors that yield the different alkyl chains
found in the other AHFCA compounds. Therefore it was deduced that the AHFCAs
incorporate intermediates in fatty acid metabolism that are derived from with 3-
methylbutyryl-CoA for AHFCA1, butyryl-CoA for AHFCA2 and AHFCA5 and
propionyl-CoA for AHFCA4.
Expression of mmfL in the heterologous host E. coli also provided further evidence for
AHFCAs being derived from intermediates in fatty acid metabolism, as only AHFCA2
and AHFCA5 with linear alkyl chains were produced by E. coli carrying mmfL,
consistent with the previously established preference of E. coli to utilise acetyl-CoA as
the starter unit for fatty acid biosynthesis.136 This is also consistent with the deduction
made by Kato and co-workers made about the A-factor analogues 71 and 72 produced
when afsA was heterologously expressed in E. coli (Figure 1.17).109 The reactions
catalysed by MmfL, MmfH and MmfP have also been studied in vitro (N. Malet).100
It was suggested by Davis and co-workers that the divergence between GBL and
AHFCA biosynthesis may arise due to the orientation of DHAP relative to the β-
ketothioester precursors in the reactions catalysed by different AfsA-like enzymes.141
This hypothesis implied that AHFCA biosynthesis would not proceed via a butenolide
intermediate. However, subsequent incorporation experiments performed by Corre and
co-workers confirmed the orientation of DHAP with respect to the β-ketothioester, thus 
providing evidence for AHFCA biosynthesis proceeding via a butenolide
intermediate.140
Because in vivo DHAP is derived from glycerol, as is acetyl CoA (the precursor from
which β-ketothioesters in fatty acid biosynthesis are derived), the incorporation of 
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carbon atoms (13C) into the AHFCAs using 13C-labelled glycerols labelled at the pro-R
and pro-S carbon atoms – and subsequent analysis of which fragments the 13C were
retained in – was used to confirm the orientation of DHAP with respect to the β-
ketothioesters.140
Therefore, the formation of GBLs and AHFCAs are proposed to proceed via a shared
intermediate butenolide phosphate intermediate.140 Scheme 1.5 summarises the
biosynthetic routes to GBLs and AHFCAs from DHAP and β-ketothioesters from fatty 
Scheme 1.5 – General structures of Streptomyces signalling molecules which are proposed to share an
intermediate butenolide phosphate.138,140 Labels of enzymes catalysing each step are shown; the
specificity of each type (AfsA, MmfL, ScbA, for example) is presumably determined by the length of
the alkyl chain in the β-ketothioester precursors 
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acid metabolism. The genetic arrangement of several clusters involved in GBL-like
signalling molecule biosynthesis are shown in Figure 1.18.
1.6.Ligand-protein and protein-DNA interactions of ArpA-like repressors
1.6.1 Determination of ligand-repressor specificity
As discussed in Section 1.4, genes required for signalling molecule biosynthesis are
located adjacent to genes encoding for specific ArpA-like repressors. In most cases,
there are multiple arpA-like genes, one of which is situated divergently adjacent to the
afsA homologue.114 Figure 1.18 illustrates examples of the relative arrangement of
genes proposed to be involved with signalling molecule biosynthesis and the structures
of the signalling molecule(s) they produce.
Figure 1.18 – Examples of genetic arrangement arpA-afsA like homologues in different Streptomyces
signalling molecule systems.79,89,95,117,139 The diversity of structures produced by each system arise from
the action of the biosynthetic enzymes shown in yellow/blue
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Ligand-repressor interactions have been investigated in several ArpA-like systems, and
have been shown to be highly selective. For example, ScbR from S. coelicolor has been
shown to have a much greater affinity for 6-hydroxy-type GBLs with (2R, 3R, 6R)
stereochemistry compared to 6-hydroxy-type GBLs with (2R, 3R, 6S)
stereochemistry.132 Furthermore, SCB1 with native stereochemistry (2R, 3R, 6R) was
shown to be much more effective at releasing ScbR from its target sequence in the
cpkO promoter than SCB1 with (2S, 3S, 6R) stereochemistry.132 Furthermore, of the
SCB analogues tested with the preferred (2R, 3R, 6R) stereochemistry, there was also a
preference for alkyl chains containing between 7 and 9 carbons in the chain, and this
correlated well with the structures of the characterised SCBs 1-3 from this system,
which all contain 8 or 9 carbons in their alkyl substituents.
In addition to these in vivo methods, ligand binding of ArpA-like regulators has been
studied in vitro. For example, radioisotope-labelled ligands have been used in
competition assays to determine the ligand specificity of the S. lavendulae ArpA
homologue, FarA. These experiments demonstrated that FarA is highly selective for
IM-2 35 (a 6-hydroxy-type GBL with (2R, 3R, 6R) stereochemistry) compared to GBLs
with (2R, 3R, 6S) stereochemistry or 6-keto type GBLs.142 One more widely used
method for assaying ligand-repressor interactions is electrophoretic mobility shift
assays (EMSAs). The binding of a specific ArpA protein to a particular DNA sequence
can be observed by gel electrophoresis by DNA staining in a native polyacrylamide gel.
DNA fragments to which a protein binds can be identified by running parallel samples
with and without protein. If the protein binds to the DNA, there will be retardation of
the DNA migration through the gel, therefore a band shift will be observed (Figure
1.19).87,125,126 Upon addition of the cognate ligand, the DNA binding affinity of the
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protein will be reduced. Therefore, the DNA will be released from the protein and its
migration through the gel will no longer be retarded.
EMSAs have been used to demonstrate specificity of S. virginiae BarA for 6-hydroxy-
type GBLs with (2R, 3R, 6S) stereochemistry over 6-hydroxy-type GBLs with (2R, 3R,
6R) stereochemistry or 6-keto type GBLs.126 Furthermore, EMSAs have been used in
our group to probe the ligand specificity of MmfR for different AHFCA ligands,
illustrating that AHFCAs with alkyl chains between 3 and 5 carbons long were most
effective at attenuating the ability of MmfR to bind its DNA target in the mmfR-mmfL
intergenic region.100 The specificity of each ArpA-like repressor shown by EMSAs
correlated well with the structures of the ligands extracted from these organisms in both
these cases.
The MmfR structure with AHFCA2 bound is the first example of an ArpA-like
repressor structure being solved with its ligand bound, and allowed for the AFHCA
binding pocket in MmfR to be identified.100 Key residues involved with interactions
with AHFCA ligand were identified, in particular tyrosines at positions 85 and 144, and
Figure 1.19 –Example of electrophoretic mobility shift assay (EMSA)100
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the effect of mutation of these amino acids is ongoing (C. Corre and G. L. Challis
groups).
1.6.2 A potential role for ArpA ligands in interspecies signalling
If several different ArpA-like repressors can respond to the same ligand, there is
precedent for the GBL or GBL-like signalling molecules to be involved in interspecies
signalling.143 Indeed, SCB3 38 has recently been shown to be the elicitor of jadomycin
biosynthesis.95 The role of SCB3 in jadomycin biosynthesis was confirmed by
chemically complementing a jadW123 deletion mutant unable to produce SCB3 and
jadomycin, upon addition of purified SCB3. In the presence of SCB3, jadomycin
production was restored in this strain. Indeed, when growing the jadW123 deletion
mutant adjacent to S. coelicolor M145 (a known producer of SCB3), production of
jadomycin was also restored.95
A complementary experiment was also performed in which the S. venezuelae wild type
was grown in the presence of a S. coelicolor M145 strain in which scbA (required for
SCB biosynthesis) had been deleted. However, enhanced antibiotic production was not
shown in this strain. This was attributed to the concentration of SCB3 produced by the
different strains; however, as it was shown that 1 nM SCB3 was sufficient to induce
jadomycin biosynthesis in S. venezuelae, compared to 128-256 nM required for
induction of antibiotic biosynthesis in S. coelicolor M145.95
These experiments demonstrate that GBL-mediated interspecies signalling may occur
between different Streptomyces species in nature. Indeed, Sakuda and co-workers
previously reported that VB-A 39 can be produced by S. antibioticus.131 A-factor has
also been implicated in an indirect mechanism of activation of pimaricin biosynthesis
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in S. natalensis, even though there is no evidence that S. natalensis can itself produce
A-factor.143 Furthermore, A-factor, or an A-factor-like GBL has been implicated in
regulation of pristinamycin by S. pristinaespiralis.94,144
The addition of the A-factor analogue 1,4-butyrolactone has recently been shown to
increase validamycin A production in S. hygroscopicus and an ArpA-like receptor
ShbR3 was identified as a potential target for 1,4-butyrolactone.145 However, 1,4-
butyrolactone was shown to be a very poor ligand for ShbR3 when analysed in EMSAs.
Furthermore, the concentration of 1,4-butyrolactone used (10 mM) is unlikely to be
biologically relevant.145 Despite the growing amount of evidence for interspecies
signalling, addition of an ArpA ligand to induce production of cryptic metabolite
biosynthesis has yet to be demonstrated.
1.6.3 Repressor-DNA interactions
As described in Section 1.4, ArpA binds to a specific DNA sequence in the adpA
operator region in S. griseus. By comparison of the DNA sequences upstream of genes
to which ArpA is proposed to bind, a general consensus was proposed by Folcher and
co-workers and is shown in Figure 1.20.144 Collectively, these specific DNA sequences
are known as autoregulatory response elements (AREs), due to these being the DNA
elements to which the repressor proteins bind, regulating their own expression as well
as that of other biosynthetic genes. For example the mmfL-mmfR intergenic region is
the target for MmfR. AREs are often situated in the operator regions upstream of genes
encoding for transcriptional activators, for example mmyB in the methylenomycin
cluster, and cpkO in the coelimcyin cluster.85,88
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The presence of AREs in gene clusters regulated by ArpA-like repressors also
demonstrates a further level of complexity within these signalling pathways. For
example, the jadomycin biosynthetic (jad) cluster in S. venezuelae contains four AREs
to which the repressor JadR3 binds with different affinities. Indeed, the far cluster in S.
lavendulae also contains five AREs. Furthermore, multiple repressors may also bind
the same AREs. In the scb cluster for example, ScbR and ScbR2 both bind to one of the
AREs in the scbA-scbR intergenic region, yet only ScbR has been shown to bind to the
other.149
The regulatory mechanisms involved can also be complicated by the presence of
multiple regulatory proteins. For example in the jad cluster, there are four regulators,
JadR1, JadR2, JadR3 and JadR*. JadR1 is an OmpR-type transcriptional activator and
is negatively regulated by JadR2, but positively regulated by JadR3. JadR2 and JadR3
are both ArpA-like repressors, and JadR2 has been proposed to respond to antibiotics
such as jadomycin and chloramphenicol at 500 μM concentrations, whereas JadR3 has 
been shown to bind a GBL with the same structure as SCB3.95,146
Intergenic region Sequence Gene cluster
ARE consensus AWACNNACYNNNCGGTTT consensus from Folcher144
mmyB-mmyT AAACCTTCGGGAAGGTTT mmy (methylenomycin)
gbnA ATACCTTCGTGAAGGTTT gbn (sven_4179-sven_4181)
jadR1 AAACCGGCGCAGCGGTTT jad (jadomycin)
vmsR AAACCGTATAGTCTGTTT vms (virginiamycin)
tylS AAACCGTCCGCTCCGTTT tyl (tylosin)
alpV ACAAACCGACTGTGCTGT alp (alpomycin)
Figure 1.20 – Examples of ARE consensus sequences from operator regions of transcriptional
activators in gene clusters from different Streptomyces species.85,95,114,122,126,144 Conserved nucleotides
are highlighted in yellow
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Due to the high degree of conservation between the AREs in different systems, AREs
can be identified by using bioinformatics tools such as MEME (multiple Em for motif
elucidation, http://meme.nbcr.net/meme/).147 The likelihood of highly similar DNA
sequences to occur in specific regions is determined, compared to their likelihood of
appearing randomly in nature. Some examples of ARE consensus sequences for GBL
systems are shown in Figure 1.20. Experimentally, these elements can be identified by
DNaseI footprinting (although this technique shows which DNA regions are protected
from being digested by DNaseI, the individual proteins protecting each DNA region
must be determined later).87,95,119
Therefore, identification of AREs that ArpA-like repressors bind to represents a
powerful tool for predicting which genes are controlled by these regulators. Specific
inactivation of an ArpA-like repressor may result in de-repression of gene expression
and can constitute a strategy to activate silent biosynthetic pathways. However,
identifying which specific ArpA-like repressor to delete in order to get overproduction
of the specific compound of interest may be very challenging. Indeed, systematic
deletion of genes encoding for ArpA-like repressors may have unexpected effects.150
1.6.4 Phenotypes of arpA deletion mutants
Deletion of arpA-like repressors has been shown to regulate antibiotic activity in a
variety of Streptomyces species.120,121,144,148 For example, in S. venezuelae, deletion of
jadR3 decreases jadomycin production, whereas deletion of jadR2 increases jadomycin
production.95,149 In S. coelicolor, deletion of scbR2 increases coelimycin production by
de-repression of transcription of the cpkO gene. It has been shown that several different
repressors may bind the same operators, as in the case of the scb cluster, in which scbR
and scbR2 both bind to the scbA operator.88,149 The ability of JadR2 and JadR3 to bind
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to the jadR1 operator in the jad cluster has also been demonstrated.95,149 Due to the
complexity of these regulatory networks, there is no general ‘rule’ for predicting the
phenotype of the arpA-deletion mutant by simply choosing to inactivate the ‘GBL-
receptor’ or the ‘pseudo-GBL-receptor’ (Table 1.3).
In the methylenomycin gene cluster in S. coelicolor, there are genes encoding for two
repressors, mmfR and mmyR. Deletion of these two repressors gives distinct
phenotypes: a deletion mutant of mmfR was shown to be deficient in methylenomycin
production, whereas a deletion mutant of mmyR overproduced methylenomycin.79,85
1.6.5 Regulatory cascade controlling methylenomycin biosynthesis
Methylenomycin production was also abolished in a strain in which mmfLHP had been
deleted. Furthermore, when mmfR and mmyR were each introduced into this mmfLHP
deletion mutant, it was found that methylenomycin production was only restored in the
Table 1.3 – Effect of deletion of genes encoding for ArpA-like repressors on antibiotic production in
host strains
Streptomyces
strain
gene
cluster
Ligand
acceptor
Natural product
biosynthesis
regulated
Effect of
deletion
on production
Refs
S. griseus N/A ArpA streptomycin increased 102
GBL receptor
S. coelicolor cpk/scb ScbR coelimycin no production 88
S. venezuelae jad JadR3 jadomycin B decreased 95
S. lavendulae far FarA showdomycin increased 125
S. virginiae vms/bar BarA virginiamycin increased 126
S. coelicolor mmy/mmf MmfR methylenomycin decreased 85
pseudo receptors
S. coelicolor cpk/scb ScbR2 coelimycin increased 88
S. venezuelae jad JadR2 jadomycin B increased 146
S. lavendulae far FarR2 showdomycin unknown 125
S. virginiae vsm/bar BarB virginiamycin increased 148
S. coelicolor mmy/mmf MmyR methylenomycin increased 85
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mmfR-containing strain when grown in close proximity to an AHFCA-secreting strain.
The same inductive effect of AHFCAs was not observed in the mmfLHP strain to
which mmyR had been introduced, implying that MmfR is the effector protein which
binds AHFCAs, not MmyR.85
As in other afsA-arpA-like repressor gene clusters, the afsA homologue mmfL is
divergent to one of the arpA homologues, mmfR. The AREs identified in the mmy-mmf
gene cluster are situated in intergenic regions of mmfR-mmfL, mmyB-mmyY and the
region upstream of mmyR (Figures 1.20 and 1.21). MmyB is a transcriptional activator
belonging to the unusual MltR (MmyB-like transcriptional regulator) family of
regulators.151 It was hypothesised that the ArpA homologues MmfR and/or MmyR
repress biosynthesis of the mmyB, mmfL, mmfR and mmyR, regulating methylenomycin
biosynthesis.85
Figure 1.21 – Signalling cascade involved in methylenomycin biosynthesis.85 ARE sequences are
shown in pink. Stimulatory events are denoted by blocked arrowheads, inhibitory events are denoted by
circular arrowheads
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Additional transcriptional analyses revealed that there was a small amount of mmfL,
mmyR and mmfR transcription between 12 and 36 hours, with mmyB beginning to
increase between 36 and 48 hours, before mmy biosynthetic genes were transcribed.
The presence of TTA codons in the mmyB and mmfL genes was also noted, implying
that translation of MmfL and MmyB may be delayed until the late stages of growth, as
the leucinyl-tRNA corresponding to a TTA codon is not produced until a later stage in
the developmental cycle.85
Based upon these observations, a sequence of regulatory events in methylenomycin
biosynthesis was proposed. Initially, there is a small amount of mmfL, mmfR and mmyR
transcription. This leads to a low concentration of AHFCA molecules being synthesised
by MmfLHP. A small amount of MmfR and MmyR protein is also being produced,
which is enough to repress transcription of mmyB. Eventually, a critical AHFCA
concentration is reached, where there is a sufficiently high concentration to cause de-
repression of MmfR binding to the mmfL-mmfR intergenic region. This leads to a rapid
increase in the amount of mmfLHP transcription, therefore the intracellular
concentration of AHFCAs increases. AHFCAs are then exported into the extracellular
milieu, thus synchronising the de-repression of the mmfL-mmfR promoter between
neighbouring cells. The intracellular concentration of AHFCAs is now great enough to
cause de-repression of the mmyB promoter, therefore MmyB can be produced. MmyB
is proposed to bind to the operator regions of mmyB-mmyY (in pseudo-palindromic
regions known as a ‘B-boxes’, which are distinct from the ARE) and mmyT, therefore
activating transcription of the structural genes in the mmy cluster, leading to
methylenomycin production.85 This regulatory cascade is summarised in Figure 1.21.
Chapter One | Introduction
53
It has recently been shown (in our group and G. L. Challis group) that MmfR is
responsive to AHFCAs in vitro. Addition of the AHFCAs 1-5 isolated from S.
coelicolor to MmfR and a DNA fragment containing the mmfL-mmfR intergenic region
caused disassembly of the MmfR protein-DNA complex, confirming that MmfR is a
furan-responsive regulator.100 Furthermore, the crystal structure of MmfR with
AHFCA2 bound has also been solved, allowing key residues involved in AHFCA
binding to be proposed. These residues are not conserved between MmfR and MmyR,
which is consistent with the hypothesis that MmyR is unresponsive to AHFCAs.
1.7 mmfLHP-like biosynthetic gene clusters
1.7.1 Identification of other mmfLHP clusters
During the initial study in which AHFCAs were established as being the products of
the mmfLHP genes, it was noted that an analogous set of genes, sav_2269, sav_2267
and sav_2266 is present in Streptomyces avermitilis MA-4680 (Figure 1.22). This mini-
cluster of genes also contains genes encoding for two putative transcriptional
regulators, sav_2270 and sav_2268.79 BLAST analyses revealed the presence of a
similar cluster of genes in S. venezuelae, named sgnL (sven_4183), sgnP (sven_4185)
and sgnH (sven_4188), after their homologues in S. coelicolor (Figure 1.22).152 These
genes are located in a mini-cluster which also contains genes encoding for homologues
of MmfR and MmyR, named SgnR (SVEN_4182) and GbnR (SVEN_4187)
respectively (Figure 1.22). The mmfLHP-like system in S. venezuelae is situated
adjacent to the sven_4179-sven_4181 gene cluster, which had not been previously
investigated. It was hypothesised that if the key repressor was deleted, this would lead
to overexpression of the sven_4179-sven_4181 gene cluster, revealing new natural
products.152
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The genome of S. venezuelae was recently sequenced, revealing it to contain 31 gene
clusters encoding for secondary metabolite gene clusters (Figure 1.23).63 Interestingly,
the sven_4179-sven_4181 gene cluster was not identified by antiSMASH, as these
genes are atypical in secondary metabolite pathways.
S. venezuelae is known to produce chloramphenicol, jadomycin and the macrolides
pikromycin, narbomycin and methymycin.13,39,153 Recently, a series of phenoxazine
alkaloids and aminophenols, venezuelines A-G, have also been shown to be produced
by S. venezuelae.154 This relatively short list of natural products produced by S.
venezuelae illustrates that the biosynthetic potential for S. venezuelae is still largely
unexplored.
Figure 1.22 – Analogous mmfLHP systems identified in S. avermitilis and S. venezuelae. The mmfLHP
system in S. venezuelae is located adjacent to the cryptic gbnABC cluster.79,152 AREs are highlighted in
pink, and S. coelicolor and S. venezuelae AREs compared with the general consensus proposed by
Folcher and co-workers144 are shown are shown. W = A/T, Y = C/T
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1.7.2 Previous work on gbnABC system in S. venezuelae
By comparing the promoter sequences of the gbnABC genes to those in the sgnR-
sgnLPH-gbnR mini-cluster in S. venezuelae, AREs were identified in the operator
regions of gbnA, sgnR-sgnL and gbnR-sgnH (Figure 1.22). These AREs identified in S.
venezuelae are almost identical in sequence to the ARE consensus from the mmf-mmy
cluster proposed by O’Rourke and co-workers (Figure 1.21). The presence of an ARE
in the gbnA promoter implied that transcription of gbnA is regulated by SgnR/GbnR, as
in the case of MmfR/MmyR-mediated regulation of mmyB in the methylenomycin
cluster.
Therefore, it was hypothesised that sgnLPH are transcribed, leading to an increase in
the intracellular concentration of AHFCAs. At a critical concentration, AHFCAs bind
to SgnR, causing it to dissociate from its DNA targets (the AREs located in the gbnA,
sgnR-sgnL and gbnR-sgnH operators). As a result, transcription of gbnABC can occur,
leading to biosynthesis of new natural product(s). It is proposed that GbnR would bind
to the ARE located in the gbnA promoter and switch off transcription of gbnABC
(Figure 1.24).
Figure 1.23 –Secondary metabolite gene clusters identified in S. venezuelae by antiSMASH (October
2014)
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As reported previously, deletion of the transcriptional repressor protein mmyR in S.
coelicolor leads to overproduction of AHFCAs by de-repression of the mmfR/mmfL
promoter, in addition to triggering overproduction of methylenomycin via de-
repression of transcription of mmyB. As the S. venezuelae sgnR-sgnL and gbnA
promoters both contain AREs, it seemed likely that deletion of the mmyR homologue
gbnR in S. venezuelae could therefore lead to overproduction of AHFCA-like signalling
molecules and also to overproduction of the natural products encoded for by the
gbnABC cluster, as the ‘off switch’ GbnR protein would no longer be produced.
If this hypothesis proved to be true, then deletion of mmyR-like transcriptional
repressors from gene clusters which contain the mmfR-mmfLHP-mmyR-like mini-
cluster represents a powerful new strategy for natural product discovery in a range of
Streptomyces species. Therefore, as a proof-of-concept study, a S. venezuelae gbnR
deletion mutant was constructed and the metabolites produced by the gbnR deletion
mutant were compared with the wild type.152
Figure 1.24 – Proposed regulatory mechanism involved in regulation of the cryptic gbn cluster
Chapter One | Introduction
57
LC-MS analyses of the metabolites extracted from these cultures revealed that new
metabolites 80-85 were produced by the gbnR mutant. A common neutral loss of 129
Da corresponding to a C5H7NO3 fragment was observed, and tandem mass
spectrometry revealed each [M–C5H7NO3+H]+ ion to correspond to a different amino
acid. Partial NMR structures elucidated for the metabolites 80, 81/82, 83 and 85 were
found to contain a conserved CH2CH2CH2CO moiety.152
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1.8 Aims of project
• Complete structure elucidation of gaburedins A-F (80-85) by MS, NMR and
HPLC analyses and by synthesis of an authentic standard.
• Link the production of gaburedins to the gbn gene cluster by comparing
metabolites produced by S. venezuelae wild type, gbnR mutant and a double-
deletion gbnB/gbnR strain.
• Propose a biosynthetic route to gaburedin biosynthesis based upon
bioinformatics and experimental analysis including incorporation of proposed
precursor molecules and analogues.
• Reconstitute the GbnA, GbnB, GbnC biosynthetic pathway by heterologous
expression of proposed biosynthetic genes gbnA and gbnB in E. coli.
• Determine the nature of any signalling molecules overproduced by the S.
venezuelae gbnR mutant and develop an assay to investigate their role in
regulation of gaburedin biosynthesis.
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1.9 Outline of thesis
Chapter 2 focuses on the structure elucidation of the gaburedins – synthesis of an
authentic standard of gaburedin A is discussed, along with feeding experiments to
verify the structure of each of the gaburedins A-F. Chiral HPLC analysis of culture
extracts is also discussed, to verify the stereochemistry of the cognate amino acids.
Chapter 3 includes bioinformatic analyses of each of the GbnA, GbnB and GbnC
proteins. The identification of a key gene for gaburedin biosynthesis is discussed and a
biosynthetic route to gaburedins is presented. Incorporation experiments with stable
isotope precursor molecules are used to probe the proposed biosynthetic route. The
substrate tolerance of enzymes GbnA and GbnB is also discussed. Chapter 4 includes
feeding experiments to produce a library of gaburedin analogues to further investigate
diversity of aminoacyl moieties which can be incorporated into gaburedin biosynthesis.
Chapter 5 details attempts to reconstitute the S. venezuelae GbnA, GbnB biosynthetic
pathway in vitro by heterologous expression of gbnA and gbnB in E. coli and
overproduction of recombinant proteins. The construction of a series of vectors for
heterologous expression of the complete gbnABC gene cluster is also reported.
Chapter 6 deals with the characterisation of the signalling molecules produced by the S.
venezuelae gbnR deletion mutant. The development of an assay to demonstrate the
ability of some of these signalling molecules to induce gaburedin biosynthesis is also
discussed. Finally, Chapter 7 summarises the findings of this PhD project and discusses
the context of the results herein. Some analogous mmfLHP-like systems in other
Streptomyces species identified during the course of this project are also discussed.
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2. Identification and characterisation of the novel natural
products gaburedins A-F from Streptomyces venezuelae
Preliminary work comparing the metabolites produced by the Streptomyces venezuelae
wild type and gbnR::apra strain revealed that there is a series of metabolites
overproduced by the gbnR::apra strain (Section 1.7). These metabolites were shown to
have m/z values corresponding to [M+H]+ of 294.9 (compound 80), 261.0 (compounds
81 and 82), 247.0 (compound 83), 279.0 (compound 84) and 292.9 (compound 85).
These compounds all exhibited a common fragmentation pattern in electrospray
ionisation mass spectrometry, with loss of a neutral 129 Da fragment corresponding to
a C5H7NO3 moiety.152
Fully elucidating the structures of these new metabolites would provide the first
example of new natural products to be discovered by deletion of an ArpA-like
transcriptional regulator. The diverse structures of this family of metabolites are
discussed in Chapters 3 and 4.
Figure 2.1 – Panel A: genetic arrangement of the gbn/sgn cluster in S. venezuelae. Panel B: Base peak
chromatograms of metabolites extracted at pH 3 from the Streptomyces venezuelae wild-type (red trace)
and gbnR mutant (blue trace) after being grown on SMMS for 3 days152
A
B
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A series of additional metabolites unrelated in structure to those mentioned above were
also were overproduced in the gbnR strain, eluting between 14 and 18 minutes (Figure
2.1). The nature of these additional molecules will be discussed in Chapter 6.
2.1 Growth conditions
2.1.1 Production of metabolites 80-85 in S. venezuelae gbnR::apra mutant
In order to confirm the presence of compounds 80-85, the S. venezuelae gbnR mutant
was grown on both mannitol-yeast medium (MYM) and supplemented minimal
medium (SMM). MYM is a rich medium typically used for spore production, with
mannitol being the primary carbon source and SMM is a simple production medium for
secondary metabolites, with glucose as the primary carbon source.155 Richer media
contain more sources of carbon and nitrogen, therefore are favoured for activating the
biosynthesis of secondary metabolites. Compounds 80-85 were produced on both
media, however, there were fewer different metabolites produced by S. venezuelae
when grown on SMMS. Therefore, the gbnR::apra strain was grown on SMMS in
future experiments.
To confirm that the overproduction of these new metabolites 80-85 in the gbnR::apra
strain is only observed in the gbnR deletion mutant, this strain was grown for 3 days on
supplemented minimal media solid (SMMS), cultures acidified to pH 3, and the
metabolites extracted. The metabolites produced were compared to those produced by
the S. venezuelae wild-type and sgnL-P::apra strains when grown on SMMS for 3
days. Metabolites were analysed by liquid chromatography-mass spectrometry (LC-
MS) analyses, confirming that the metabolites 80-85 are overproduced in the
gbnR::apra strain relative to the wild type and the sgnL-P::apra strain (Figure 2.2).
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As discussed in Section 1.6.2, it was expected that the wild type would not overproduce
the metabolites of interest due to the regulatory gene gbnR being present, therefore
GbnR is still able to act as an ‘off’ switch by binding to the gbnA promoter, preventing
transcription. Therefore, transient transcription of gbnABC genes was predicted.
Similarly, the sgnL-P mutant is missing the afsA-like gene sgnL thought to be essential
for the biosynthesis of the AHFCA signalling molecules controlling the transcriptional
repressor/DNA interactions, therefore SgnR protein will stay bound to the ARE in the
gbnA promoter, and will not be dissociated to allow transcription of gbnABC. Therefore
in both the wild type and sgnL-P mutant, the natural products biosynthesised by
GbnABC are expected to be observed in much smaller quantities than in the gbnR
mutant (if they are observed at all).
It was found that after both 3 and 6 days of growth, the yield of the metabolites
extracted was greater when the culture media was acidified prior to extraction with
ethyl acetate. Furthermore, the relative abundance of the metabolites of interest after 3
and 6 days growth appeared to be largely unchanged. Hence, in future experiments on
SMMS, S. venezuelae strains were only grown for 3 days.
Figure 2.2 – Extracted ion chromatograms for m/z = 247.0, 261.0, 278.9, 292.9 and 294.9 for
metabolites 80-85 extracted from the Streptomyces venezuelae wild type (green trace), gbnR mutant
(blue trace) and sgnL-P mutant (purple trace) at pH 3 after being grown on SMMS for 3 days
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2.1.2 Culture conditions for maximising production of S. venezuelae gbnR::apra
metabolites 80-85
This experiment was extended to monitor the production of these metabolites as a
function of time; plates were inoculated with gbnR mutant spores and grown for 24, 48
or 72 days before the metabolites were extracted.
Upon extraction, it was found that the yield of these metabolites was almost unchanged
after 1 day of growth compared with 3 days of growth (Figure 2.3). However, there
were notable changes in the base peak chromatograms and sporulation phenotypes
between days 1 and 3 of growth (data not shown). It was therefore decided to grow
future cultures for 3 days.
S. venezuelae is known to grow well in liquid culture compared to other Streptomyces
Figure 2.3 – Extracted ion chromatograms m/z = 247.0, 261.0, 278.9, 292.9 and 294.9 for metabolites
80-85 extracted from the Streptomyces venezuelae gbnR at pH 3 after being grown on SMMS for 24, 48
and 72 h
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species, which are prone to clumping or do not sporulate efficiently.5 However it was
discovered that production of the metabolites 80-85 was not consistent in liquid media,
therefore future attempts to scale up production of these metabolites were focussed on
solid SMM.
2.2 Structure elucidation
2.2.1 Liquid chromatography-mass spectrometry (LC-MS) analysis
The metabolites 80-85 overproduced by the S. venezuelae gbnR mutant were analysed
by ultra-high resolution LC-MS (UHR-LC-MS). The mass spectra of these compounds
all displayed the characteristic fragmentation pattern corresponding to the presence of
the [M+H]+ and [M+Na]+ species, in addition to a [M–129+H]+ fragment (Figure 2.4).
UHR-LC-MS analyses also allowed for molecular formulae to be obtained for each of
the species of interest. For example, compound 80 – the metabolite in this series
produced in the greatest abundance – has a molecular ion [M+H]+ corresponding to
C14H19N2O5 (calculated m/z = 295.1288, found 295.1287), a [M+Na]+ species with
formula C14H18N2O5Na (calculated m/z = 317.1108, found 317.1105), and also a [M–
C5H7NO3+H]+ fragment ion corresponding to a molecular formula C9H12NO2
(calculated m/z = 166.0863, found 166.0864), verifying the loss of a neutral C5H7NO3
fragment consistent with the mass loss of 129 Da. Compounds 81-85 exhibit similar
fragmentation patterns, confirming the loss of a neutral C5H7NO3 fragment from all six
compounds, summarised in Table 2.1. The mass spectrum fragmentation patterns
observed are consistent with previously reported MS-MS experiments by which a
parent protonated or sodiated adduct of each compound 80, 81/82, 83 and 85 were
isolated and then fragmented further and shown to lose this 129 Da fragment.
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It was noted that the fragments remaining after loss of the C5H7NO3 fragments from
compounds 80-84 corresponded to m/z values and molecular formulae of protonated
amino acids. For compound 85, C10H17N2O6S an additional fragment ion corresponding
to a molecular formula of C3H8NO2S was also observed (expected m/z = 122.0270,
found 122.0281) and was assigned as a [M–C5H7NO3–C2H2O+H]+ daughter ion (Table
2.1) corresponding to C3H8NO2S, the molecular formula of protonated cysteine. A
summary of the parent and fragment ions of 80-85 is shown in Table 2.1.
The observation that all metabolites 80-85 lose a conserved C5H7NO3 fragment
strongly implied that they belong to the same series of natural products. The difference
in the retention times on the reverse phase HPLC column also correlate with the
relative hydrophobicity of the amino acid fragments of these metabolites. Indeed, the
Figure 2.4 – UHR-LC-MS trace of metabolites extracted from S. venezuelae gbnR::apra mutant.
Extracted ion chromatogram corresponds to m/z = 295.1, 261.1, 247.1, 279.1, 293.1 for metabolites 80-
85. The mass spectrum of compound 80 is also shown, with molecular formulae for molecular and
fragment ions
Chapter Two | Gaburedin characterisation
66
more polar, hydrophilic metabolites 84 and 85 which appear to contain methionine or
an acetyl derivative of cysteine, respectively, elute sooner than the metabolites 80-83
which appear to be derived from more hydrophobic, non-polar amino acids such as
phenylalanine and leucine/isoleucine.
To acquire enough material for NMR characterisation, the gbnR mutant was grown on
800 mL SMMS (16 x 50 mL plates) for 3 days, the agar acidified and ethyl acetate
extraction performed at pH 3. The residue was analysed by LC-MS in order to confirm
the presence of the metabolites of interest, before the extract was introduced to a
Table 2.1 – UHR-MS assignments of molecular and fragment ions for metabolites 80-85
calculated
m/z value
observed
m/z value
Molecular formula Assignment
compound 80
317.1108 317.1114 C14H18N2NaO5 [M+Na]+
295.1288 295.1298 C14H19N2O5 [M+H]+
166.0863 166.0872 C9H12NO2 [M+H–C5H7NO3]+, phe
compound 81
283.1264 283.1260 C11H19N2NaO5 [M+Na]+
261.1445 261.1441 C11H20N2O5 [M+H]+
132.1019 132.1019 C6H14NO2 [M+H–C5H7NO3]+, leu/ile
compound 82
283.1264 283.1260 C11H19N2NaO5 [M+Na]+
261.1445 261.1440 C11H20N2O5 [M+H]+
132.1019 132.1018 C6H14NO2 [M+H–C5H7NO3]+, leu/ile
compound 83
269.1108 269.1114 C10H18N2NaO5 [M+Na]+
247.1288 247.1295 C10H19N2O5 [M+H]+
118.0863 118.0874 C5H12NO2 [M+H–C5H7NO3]+, val
compound 84
301.0829 301.0834 C10H18N2NaO5S [M+Na]+
279.1009 279.1015 C10H19N2O5S [M+H]+
150.0583 150.0591 C5H12NO2S [M+H–C5H7NO3]+, met
compound 85
315.0621 315.0622 C10H16N2O6SNa [M+Na]+
293.0802 293.0809 C10H17N2O6S [M+H]+
164.0376 164.0382 C5H10NO3S [M+H–C5H7NO3]+, acetyl-cys
122.0270 122.0281 C3H8NO2S [M+H–C5H7NO3-C2H2O]+, cys
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preparative high performance liquid chromatography (HPLC) system. LC-MS analyses
had previously shown the compounds of interest to absorb at 210 nm (Appendix 1),
therefore absorption at 210 nm was used to guide the HPLC purification. The closely
eluting compounds 80, 81 and 82 proved difficult to separate, so were isolated as a
mixture, re-extracted from the HPLC solvents and re-injected into the HPLC (Figure
2.5).
2.2.2 Characterisation of metabolite 80 by nuclear magnetic resonance (NMR)
spectroscopy
NMR spectra (1H, COSY, PENDANT, HSQC, HMBC) were obtained for the
compound 80 and a structure was proposed (Figure 2.6, see Section 8.1 for full
assignments). The structure proposed was consistent with previous data obtained for
crude samples of compounds 80-83 and 85 illustrating the presence of the conserved γ-
aminobutyrate (GABA)-like moiety (H-l, H-m, and H-n all representing 2 protons in a
CH2CH2CH2 chain located adjacent to an amide proton H-k). Furthermore, COSY
correlations between the aromatic protons H-d and H-c, HMBC correlations between
H-d and aromatic carbons C-e and C-f suggested the presence of a phenylalanine-like
moiety also to be present in compound 80. This observation is consistent with the
fragment ion m/z = 166.0872 observed in the mass spectrum of compound 80.
Figure 2.5 – HPLC traces from purification of compound 80 from 300 μL injection of crude S.
venezuelae gbnR::apra extract. The peak collected in red during the first round (left panel) was
collected and re-injected (right panel)
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Another interesting feature is the presence of a quaternary carbon C-j at 158 ppm
consistent with an ureido carbonyl shift, linking the GABA and phenyalaninyl
moieties.156-158 The conservation of a ureido-linked GABA-like moiety across this
series of metabolites 80-85 therefore led to them being named gaburedins.
These initial NMR data could not be used to unequivocally elucidate the structure of
gaburedin 80 due to the absence of key correlations. Cross peaks expected in the
HMBC spectrum between the proton H-c and ureido carbonyl C-j were missing,
therefore the aminoacyl moiety could not be confirmed as being attached to the ureido
carbonyl as proposed in Figure 2.6. Some HMBC correlations expected to be seen in
the GABA-like moiety between protons H-l and H-m with carbon C-n were also not
observed (Figure 2.6 shows all HMBC correlations observed). Furthermore, impurities
in the NMR spectrum (signals at 1.24 ppm, 6.45 ppm) and the overlaps of signals for
protons d and l at 2.84-3.01 ppm complicated the spectra.
Figure 2.6 – Proton NMR spectrum and assignments of gaburedin A (80) in d6-DMSO (700 MHz). 2D
correlations are also shown (COSY correlations in bold bonds, HMBC correlations denoted by red
arrows)
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It was therefore decided that an authentic standard corresponding to the proposed
structure of gaburedin 80 should be synthesised. Using well documented reactions is
also useful as it allows one to reliably predict the structure of the product from the
reagents and conditions used.159 Total synthesis also results in higher purity of the
compound of interest, as the resultant mixture contains fewer compounds compared
with the complex mixture of different compounds present in microbial culture extracts.
2.2.3 Synthesis of authentic standard of gaburedin A
Synthesis of ureido containing molecules has been widely reported in the literature.
Such ureas can be synthesised in a few steps via the corresponding isocyanate
intermediates.159,160 The required intermediate isocyanate was synthesised via a
modified Curtius rearrangement, starting from mono-methylglutaric acid 86 and
diphenylphosphoryl azide (DPPA) 87 under basic conditions to yield methyl 4-
isocyanatobutanoate 88 (Scheme 2.1).160 The consumption of mono-methyl glutarate
was monitored by TLC after which L-phenylalanine-O-methyl ester hydrochloride 89
was added in order to yield a dimethyl ester protected gaburedin 90 (Scheme 2.1).
Scheme 2.1 – Synthetic route to gaburedin 1 from mono-methyl glutaric acid
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Intermediate 90 was isolated by flash column chromatography and characterised by
LC-MS and NMR. LC-MS analysis showed that compound 90 fragmented the same
way as the gaburedins (Figure 2.7), with a molecular ion peak m/z = 323.0 as expected
for a dimethyl ester of gaburedin A, and a fragment ion m/z = 179.9 which would be
expected for L-phenylalanine-O-methyl ester remaining after cleavage of the same
ureidyl C-N bond that is observed upon fragmentation of gaburedins A to F.
Double deprotection of the diester was achieved by heating 90 overnight in the
presence of sodium hydroxide in order to furnish 12.6 mg final product 91 (Scheme
Figure 2.7 – Extracted ion chromatogram for m/z = 323.0 for the intermediate 90 and extracted ion
chromatograms m/z = 294.9, corresponding to the authentic standard 91 and proposed structure of
gaburedin A 80 in metabolites extracted from S. venezuelae gbnR mutant after 3 days (upper panel).
Mass spectra of the 90, 91 and 80 are also shown (lower panel)
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2.1). Compound 91 was purified by HPLC, solvents removed and the white solid
obtained was analysed by LC-MS alongside crude S. venezuelae gbnR::apra extract
(Figure 2.7).
Extracted ion chromatograms for m/z = 294.9 confirm the synthesised compound 91
has the same retention time and mass spectrum fragmentation pattern as gaburedin A
80 isolated from the crude microbial extract, suggesting that the compounds are
identical. The absolute stereochemistry at C-c in the natural gaburedin 80 had not yet
been confirmed, however, and will be discussed in Section 2.2.5.
Comparison of the 1H NMR spectrum of compound 91 (in d6-DMSO) shows signals
corresponding to the 1H spectrum of gaburedin A 80 purified from the culture extract
Figure 2.8 – 1H NMR spectra in d6-DMSO of 80 isolated from S. venezuelae grown for 3 days on
SMMS (upper spectrum) and authentic standard of 91 (500 MHz, lower spectrum). 2D COSY and
HMBC correlations for 91 are also shown
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(Figure 2.8). Furthermore, HMBC correlations between the ureido C-j and the protons
H-c and H-l confirm that the ureido bridge links the phenylalaninyl and GABA
moieties. The presence of HMBC correlations between C-b and H-c and H-d also
allowed unequivocal confirmation of the phenylalaninyl portion of the molecule.
As shown in Figure 2.8, the signals corresponding to H-k in the synthetic 91 and
bacterial-derived gaburedin 80 samples have slightly different chemical shifts (6.13 for
80 compared to 6.17 for 91). However this may be attributed to the precise chemical
shift of amide protons being variable dependent on the pH of the individual samples, or
intramolecular hydrogen bonding due to the difference in concentrations between the
two samples.161
2.2.4 Feeding experiments to overproduce gaburedins 80-85
As discussed in Section 2.2.1, it would appear that each gaburedin 80-85 contains a
different amino acid moiety. Therefore, it was hypothesised that the relative
abundances of gaburedins extracted from S. venezuelae gbnR::apra cultures may be
altered by growing the bacteria on media enriched with each amino acid proposed to be
incorporated into the structures of gaburedin 80-85.
To test this hypothesis, L-valine was added to SMMS to final concentrations of 1 mM,
5 mM and 20 mM and the pH altered to 7.2 as normal prior to autoclaving. Metabolites
were extracted from the acidified gbnR::apra culture extract after being grown on these
media for 3 days, and analysed by LC-MS. Extracted ion chromatograms for m/z =
247.0 (corresponding to gaburedin C 83) illustrate a marked increase in the production
of 83 as the concentration of L-valine in the media was increased (Figure 2.9).
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In order to further verify the incorporation of valine into gaburedin C, the gbnR::apra
strain was grown on SMMS enriched with 20 mM d8-DL-valine. If d8-DL-valine is
incorporated into gaburedin C, a mass shift of 8 Da should be observed. Indeed, LC-
MS analysis revealed that the m/z of the [M+H]+ species of gaburedin C increased by 8
Da from 246.9 to 254.9 upon feeding with d8-DL-valine, and that the [M–129+H]+
fragment ion m/z also increased by 8 from m/z = 118.1 to 126.1 (Figure 2.10).
The assignments of these ions were confirmed by UHR-LC-MS analysis, which
confirmed the presence of molecular ions [M+H]+ corresponding to C10H11D8N2O5
(calculated m/z = 255.1791, found 255.1802) and [M+Na]+ corresponding to
C10H10D8N2O5Na (calculated m/z = 277.1610, found 277.1617). An additional [M–
C5H7NO3+H]+ fragment ion corresponding to a molecular formula C5H4D8NO2 was
Figure 2.9 – Extracted ion chromatograms for m/z = 247.0 corresponding to gaburedin C 83 for
metabolites extracted from LC-MS analysis of the metabolites extracted at pH 3 from the S. venezuelae
gbnR::apra strain when grown on SMMS for 3 days with different concentrations of L-valine added to
the media
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also observed, representing a protonated d8-valine ion (calculated m/z = 126.1365,
found 126.1372).
As gaburedins B and C (81 and 82) both have the same fragmentation patterns and
daughter ions with the same molecular formula of C6H14NO2, the gbnR::apra strain
was grown on media enriched with L-leucine and with L-isoleucine (20 mM each). In
both cases, there was a dramatic increase in the intensity of the peaks corresponding to
m/z = 260.9 at retention time = 17.0-17.3 min. The microbial extracts were therefore
diluted 10 fold and re-analysed. After dilution, there were two resolvable peaks for m/z
= 260.9 (Figure 2.11) showing that gaburedin B (tR = 17.2 min), is overproduced upon
addition of L-leucine, and gaburedin C (tR = 17.0 min), is overproduced upon addition
of L-isoleucine into the growth media. This is consistent with previous reports of other
natural products only differing in the branching of leucine/isoleucine moieties, for
Figure 2.10 – Extracted ion chromatograms for m/z = 247.0 for metabolites extracted from the S.
venezuelae gbnR mutant when grown on SMMS enriched with 20 mM L-valine and 20 mM d8-DL-
valine (upper panels) and mass spectra of the unlabelled gaburedin C (lower panels)
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example in the case of germicidins where the isoleucine-derived compound elutes
earlier than the leucine-derived compound.83
To confirm which of the gaburedins B and C contained leucine or isoleucine, this
experiment was repeated with SMMS enriched with 10 mM each of d10-L-leucine or
d10-L-isolecucine. It was predicted that the gaburedins B and C extracted from these
cultures would each be specifically labelled in one of the samples, but not the other. In
order to determine which gaburedin was labelled with which precursor molecule,
extracted ion chromatograms (m/z = 271.0) were generated from LC-MS analysis of the
metabolites extracted from the gbnR::apra strain after feeding with 10 mM d10-L-
leucine and d10-L-isoleucine.
Figure 2.12 shows the difference in retention times for ions with m/z = 271.0,
confirming that the slightly earlier eluted compound, gaburedin C (82), contains 10
deuterium labels upon feeding with d10-L-isoleucine. Conversely, the compound that
Figure 2.11 – Extracted ion chromatograms for m/z = 260.9 for metabolites extracted from the S.
venezuelae gbnR mutant when grown on SMMS and SMMS enriched with 20 mM L-leucine and 20 mM
isoleucine. Culture extracts were diluted by factor of 10 prior to LC-MS analysis
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elutes later, gaburedin B (81), contains 10 deuterium labels from feeding with d10-L-
leucine. Furthermore, the labelling can be seen in the [M–129+H]+ fragment ions of
gaburedins B and C (their m/z values increased from 131.9 to 142.0) demonstrating that
the deuterium labels are in the amino acid moiety of the molecules. These data confirm
the structures of gaburedins B and C contain leucine and isoleucine, respectively.
Similar feeding experiments were performed with SMMS supplemented with 1 mM, 5
mM and 20 mM phenylalanine in order to demonstrate a specific increase in the yield
of gaburedin A (80). Furthermore, to demonstrate specific incorporation of L-
Figure 2.12 – Extracted ion chromatograms for m/z = 271.0, corresponding to d10-gaburedin B (81) and
d10-gaburedin C (82) extracted from the S. venezuelae gbnR::apra strain after growing on SMMS for 3
days upon addition of 10 mM d10-leucine (black trace) 10 mM d10-isoleucine (red trace). Extracted ion
chromatogram for m/z = 261.0, corresponding to unlabelled gaburedins B and C extracted from S.
venezuelae gbnR::apra strain after growing on SMMS for 3 days (blue trace). Mass spectra of the
labelled gaburedins B and C are also shown
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methionine into gaburedin E (84), LC-MS analysis of metabolites extracted upon
feeding the gbnR::apra strain with 20 mM L-methionine showed there to be
overproduction of gaburedin E.
It was unclear from NMR experiments with a crude sample of gaburedin F (85)
whether or not the structure contained N- or S-acetyl cysteine. Tandem mass
spectrometry had only previously show loss of an acetyl group from the [M–129+H]+ at
m/z = 163.9 to leave a fragment with m/z = 122.1 (Table 2.1). In order to confirm the
structure of gaburedin F, feeding experiments were performed in which the gbnR::apra
mutant was grown on media supplemented with N-acetyl cysteine at 5 mM and 10 mM
final concentrations.
If gaburedin F contained S-acetyl cysteine then it would be expected that upon feeding
with N-acetyl cysteine that there would be no increase in the amount of gaburedin F
produced. Alternatively, there would potentially be the appearance of an additional
peak with m/z of [M+H]+ = 292.9 with a retention time distinct from that of gaburedin
F due to the different regiochemistry of these two cysteine derivatives.
Analysis of metabolites extracted from the media containing different concentrations of
N-acetyl cysteine (Figure 2.13) showed that increasing the concentration of N-acetyl
cysteine in the growth medium specifically increased the production of gaburedin F,
suggesting that gaburedin F contains N-acetyl cysteine (Figure 2.13). Interestingly, the
yields of the gaburedins A-E decreased as the concentration of N-acetyl cysteine in the
media was increased. This may simply be due to a competitive effect when there is
more N-acetyl cysteine available to react with any intermediates in gaburedin
biosynthesis, and will be discussed in more detail in Chapter 3.
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2.2.5 Chiral HPLC analysis of L- and D-gaburedin A
The feeding experiments in Section 2.2.5 illustrate the incorporation of L-amino acids
into gaburedins A-F. To provide further evidence for the absolute stereochemistry of
the amino acid moieties found in the natural gaburedins, this series of feeding
experiments were extended to include amino acids with D- configuration as well as
amino acids of L- configuration.
For example, both 20 mM L- and D-valine were added separately to SMMS, and the
gbnR::apra strain grown for 3 days, the metabolites extracted and analysed by LC-MS.
Interestingly, the addition of both L- and D-valine resulted in overproduction of
gaburedins 92 and 93 with identical retention times as gaburedin C (83) (Figure 2.14).
Incorporation of both L- and D-phenylalanine into gaburedins 94 and 95 was also
Figure 2.13 – Extracted ion chromatograms for m/z = 247.0, 261.0, 279.0, 293.0 and 295.0 for
gaburedins A-F in metabolites extracted from S. venezuelae gbnR::apra grown on SMMS and SMMS
enriched with 5 mM and 10 mM N-acetyl-L-cysteine. The mass spectrum and proposed structure for
gaburedin F derived from N-acetyl-L-cysteine (85) are also shown
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observed (Figure 2.14). The amino acid source in the media (casamino acids) are
derived from casein, therefore contain L-amino acids (hence it was proposed that
gaburedin D 83 has identical stereochemistry to 92, and that gaburedin A 80 has
identical stereochemistry to 94.162 However there may be intracellular epimerisation of
the amino acids that are incorporated into the gaburedin natural products observed.
In order to determine if there was epimerisation of one amino acid enantiomer to the
other in vivo, chiral HPLC analysis of the culture extracts from feeding with both 20
mM L-phenylalanine and D-phenylalanine were performed (L. Song) using a Chiral-
PAK IA column with a chiral polysaccharide stationary phase. Both extracts were
injected separately, followed by co-injection of both extracts in order to determine
whether or not the gaburedins 94 and 95 had different configurations in the
phenylalaninyl moiety. Figure 2.15 demonstrates that there are two distinct compounds
Figure 2.14 – Extracted ion chromatograms for m/z = 247.0 corresponding to metabolites 92 and 93
extracted from the S. venezuelae gbnR mutant when grown on SMMS enriched with 20 mM L-valine
and 20 mM D-valine (blue traces) and extracted ion chromatograms for m/z = 295.0 for metabolites 94
and 95 extracted from the S. venezuelae gbnR mutant when grown on SMMS enriched with 20 mM L-
phenylalanine and 20 mM D-phenylalanine (red traces)
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with m/z = 295.0 in the co-injected sample, confirming the incorporation of both L- and
D-phenylalanine into gaburedins 94 and 95 respectively. This result has implications
for how gaburedins are biosynthesised, and will be discussed further in Section 3.2.
Furthermore, this also implies that the stereochemistry of the amino acids found in the
gaburedins 80-85 isolated from the gbnR::apra strain is L-, as the casamino acids
present in the SMMS are of L- configuration (Figure 2.16).162 The result that
modification of the media to contain D- as well as L- amino acids can lead to
incorporation of either enantiomer into gaburedins implies that there is unprecedented
substrate tolerance by one of the enzymes involved (one would expect an enzyme that
is specific for an amino acid would only be able to tolerate one enantiomer).
Alternatively, it could imply that the incorporation of amino acids into gaburedins is
not enzyme catalysed.
Figure 2.15 – Extracted ion chromatograms from chiral HPLC-MS analysis of metabolites extracted
from the S. venezuelae gbnR::apr mutant grown on 20 mM L- or D-phenylalanine for m/z = 295,
corresponding to L- and D- enantiomers of gaburedin A, (panels a and b, respectively). Coinjection of
extracts a and b (panel c) confirmed that the gaburedins 94 and 95 produced upon supplementation with
L- or D-phenylalanine are different; as gaburedin 94 (panel a) and its enantiomer 95 (panel b) have
different retention times
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2.3 Discussion
The gaburedins reported here represent one of the first examples of novel natural
products being discovered by deletion of a gene encoding for an ArpA-like
transcriptional repressor. In the previously mentioned examples, deletion of scbR2 in S.
coelicolor led to overproduction of a yellow pigment, coelimycin (30), which had been
observed previously.88,89 In the example of deletion of ksbC being deleted in K. setae,
the motivation behind deletion of ksbC was to determine the effect of that repressor on
morphological differentiation and bafilomycin production, but had the additional effect
of leading to identification of the previously uncharacterised kitasetaline.87 The strategy
employed herein contrasts these other examples, as a targeted gene deletion of gbnR
was made to specifically de-repress a cryptic natural product gene cluster, gbnABC.
Production of the gaburedins in the gbnR deletion mutant had not been directly
attributed to the gbnABC cluster, however.
Contrary to the hypothesis that translation of MmfL may only occur once the leucinyl-
tRNA responsive to the TTA codon becomes available, it would appear that sgnL
(which also has a TTA codon) is translated earlier in the gbnR mutant, as gaburedins
Figure 2.16 – Proposed structures of gaburedins A-F (80-85)
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are observed as being produced in the culture extract of the gbnR mutant after just 24 h.
Furthermore, the relative yields of gaburedins A-F extracted from the gbnR mutant
culture did not vary much between 24 and 72 hours, suggesting that there may be an
additional mechanism for switching off gaburedin biosynthesis than just the GbnR
protein itself.
The ureido bridge found in gaburedins A-F is an interesting functional group as there
are several other examples of natural products in which ureido bonds are present. For
example, the antibiotic pacidamycins 96 produced by Streptomyces coeruleorubidus,
the protease inhibitor syringolin 97 isolated from Pseudomonas syringae, and the
potential HIV-1 protease inhibitor Mer-N5075A 98 which is biosynthesised by
Streptomyces chromofuscus Mer-N5075 (Figure 2.17).163-166 Natural products such as
the potential anticancer bromophenol 99 and derivatives have also been isolated from
the red alga Rhodomela confervoides. Grateloupine 100 and lividine 101, isolated from
red algae Grateloupia filicina and Grateloupia livida, also bear striking resemblance to
gaburedins, although no potential biological role for these compounds has been
reported.156,157 Based upon some of these ureido containing compounds as having
antibacterial activity, culture extracts containing gaburedins were tested in preliminary
antibiotic assays against E. coli, B. subtilis, and S. coelicolor M145, but no antibacterial
activity was observed.
Ureido bridges have been used synthetically to produce several interesting
biomolecules, such as the glutamate carboxypeptidase inhibitor 102 synthesised by
Kozikowski and co-workers, the epoxide hydrolase inhibitor 4-(3-
cyclohexylureido)butanoic acid 103 produced by Gomez and co-workers, the series of
aminopeptidase N inhibitors 104 produced by Su and co-workers, and the first-
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generation diabetes drug tolbutamide, 105.158,167-169 Ureido bridges are an interesting
functional group, as they offer additional stability compared with amide bonds (they
will not be hydrolysed by proteases).159 The enzymes proposed to catalyse the
formation of ureido linkages have received little attention, however, with the only
mechanistic studies to date involving the enzyme SylC which has been shown to
catalyse the formation of the ureido bond in syringolin biosynthesis.165 Therefore,
investigation of the mechanism by which gaburedins are biosynthesised could provide
insight into how such functionalities arise in nature and is discussed further in Section
3.3.3.
Figure 2.17 – Examples of natural products and synthetic candidate drug molecules containing ureido
bridges
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3. Towards gaburedin biosynthesis
As demonstrated by results in Section 2.2.4, the incorporation of a variety of amino
acids the observation that both L- and D-amino acids can be incorporated into
gaburedins suggest that a diverse range of substrates can be tolerated by the
biosynthetic enzyme(s) involved. It will therefore be interesting to probe the substrate
specificity of the enzymes GbnA and GbnB, to determine the range of structures to
which a GABA moiety can be introduced.
Primarily, it will be important to establish that the genes gbnA and/or gbnB confer the
gaburedin-producing chemotype (from the results presented thus far, it could be argued
that gbnR inactivation induces various metabolic changes which indirectly result in
gaburedin biosynthesis). In addition, it would be interesting to investigate whether the
gbnABC cluster is present in any other organisms, or whether it is unique to
Streptomyces venezuelae. Therefore, Chapter 3 will focus on elucidating a biosynthetic
route to gaburedins by investigating the origin of the GABA and ureido groups (blue in
Figure 3.1); Chapter 4 will focus on the diversity of amino acids and amino acid
analogues that can be incorporated into the aminoacyl moiety (red and green in Figure
3.1).
Figure 3.1 – General structures of gaburedins 80-85 characterised in Chapter 2. Chapter 3 will focus on
the origin of the GABA-like moiety (blue) and ureido bridge. Chapter 4 will focus on the diversity of
substrates with different amino acid side chains (red) and different groups in place of the aminoacyl
carboxylic acid group (green) which can be incorporated into gaburedins
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3.1 Bioinformatic analyses of GbnA, GbnB, GbnC
3.1.1 BLAST analysis
BLAST analysis of GbnA, GbnB and GbnC individually revealed homologous gbnABC
gene clusters in other organisms (Figure 3.2 and Table 3.1). The arrangement of the
genes in several of these organisms, namely Streptococcus mutans GS-5, Salmonella
enterica subspecies serovar Agona strain SL483, Pantoea ananatis LMG 5342,
Azosporillum brasilense sp245 and Vibrio vulnificus MO6_24/O were easily
confirmed, as their entire genome sequences are available on NCBI.
Nine other systems were identified in other microorganisms by a BLAST search of the
protein sequences of GbnA, GbnB and GbnC from S. venezuelae as a single query. This
search – followed by manual annotation of the partial genome sequences from which
these proteins originated – revealed gbnABC gene clusters in three other Streptomyces
species; Streptomyces globisporus subspecies NRRL B-2293, Streptomyces Amel2xE9
B065 and Streptomyces sp. NRRL B-24482. gbnABC systems were also identified in
the Gram-positive organisms Lactobacillus paraplantarum strain L-ZS9 and
Clostridium papyrosolvens DSM 2782 as well as in the Gram-negative species
Enterobacter cloacae (from a multi-species source), Marinomonas sp. MED121,
Providencia alcalifaciens Dmel2 and Photobacterium halotolerans DSM 18316. The
different gbnABC gene clusters identified from these analyses are represented in Figure
3.2 The sequence identity and similarity to GbnA, GbnB and GbnC from S. venezuelae
are also shown in Table 3.1.
As shown in Figure 3.2, in five of the gbnABC systems present in Gram-negative
bacteria there appear to be larger proteins (approximately 800 amino acids) comprised
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of domains which are analogous to both GbnB and GbnC from S. venezuelae. As GbnC
are membrane-associated exporters of small amino acid-like molecules (see Section
3.2.1 below), this observation could also imply that GbnB and GbnC function together
as a complex for gaburedin biosynthesis/export in the organisms in which gbnB and
gbnC are encoded by distinct genes. Furthermore, the cluster in Clostridium
Figure 3.2– gbnABC clusters identified by BLAST searches. More detailed analysis of these gene
clusters is shown in Appendix 2
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papyrosolvens has an additional gene encoding for a pyruvate carboxyltransferase
situated between the gbnB and gbnC orthologues.
3.1.2 gbnA encodes for a PLP-binding putative decarboxylase
The NCBI database was used to analyse the protein sequences of GbnA, GbnB and
GbnC. Analysis of GbnA (encoded for by sven_4179 gene) revealed it to belong to the
pyridoxyl 5’-phosphate (PLP)-dependent class of transaminase/decarboxylase
enzymes.170 This analysis highlighted a conserved domain (residues 26-420,
pfam01276) including a PLP-binding pocket composed of eight conserved residues
T116, S117, N120, S197, D227, W230, S268 and the catalytic lysine residue,
K271.171,172 Alignment of GbnA and its orthologues revealed that the eight amino acid
Table 3.1 – Sequence homology of S. venezuelae GbnA, GbnB and GbnC and orthologous proteins
present in other systems as revealed by BLAST searches. Numbers denoted in each column indicate
number of amino acids, % identity, % similarity compared with S. venezuelae GbnA, GbnB and GbnC
Organism
GbnA
homologue
GbnB
homologue
GbnC
homologue
N %I %S N %I %S N %I %S
Other Streptomyces species
Streptomyces venezuelae 558 100 100 532 100 100 354 100 100
Streptomyces globisporus 579 93 95 532 96 98 345 96 98
Streptomyces amel 2xE9 530 83 87 528 79 88 345 83 91
Streptomyces NRRL B-24484 465 80 87 537 64 78 338 77 86
Gram positive species
Streptococcus mutans GS-5 324 27 48 487 27 48 311 41 60
Lactobacillus paraplantarum 460 33 54 492 27 45 308 41 62
Clostridium papyrosolvens DSM 2782 500 33 55 487 30 49 319 40 62
Gram negative species
Enterobacter cloacae complex 461 35 54 498 32 48 321 55 69
Salmonella enterica serovar Agona SL483 460 35 55 498 31 49 320 56 71
Pantoea ananatis LMG 5342 461 37 55 498 31 48 321 55 70
Gram negative species with fused gbnBC
Azosporillum brasilense sp245 494 48 61 846 37 52 846 36 52
Vibrio vulnificus MO6_24/O 465 28 49 834 31 51 834 37 54
Marinomonas sp. MED121 491 29 52 836 31 52 836 36 57
Providencia alcalifaciens Dmel2 451 26 90 812 29 50 812 37 56
Photobacterium halotolerans 467 25 51 833 31 52 833 35 56
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residues associated with PLP-binding are well conserved across all 15 GbnA proteins
(Figure 3.3). The N-terminus of the Streptococcus mutans orthologue SMUGS5_01680
is truncated, however, and it is missing several PLP-interacting residues.
The observation that all the natural products 80-85 contain a conserved GABA-like
moiety (blue in Figure 3.1) suggests that the decarboxylase GbnA might catalyse
glutamate decarboxylation rather than Orn/Lys/Arg decarboxylation. Decarboxylation
of glutamate would generate GABA, which could be then used by GbnB as a precursor
to gaburedins. However, the C-terminal domain of GbnA was identified as belonging to
A
Organism 116 117 120 197 227 230 268 271
Streptomyces venezuelae T S N S D W S K
Streptomyces globisporus T S N S D W S K
Streptomyces amel 2xE9 T S N S D W S K
Streptomyces NRRL B-24484 T S N S D W S K
Streptococcus mutans GS-5 - - - N D W S K
Lactobacillus paraplantarum T S N N D W S K
Clostridium papyrosolvens DSM 2782 T T N N D W S K
Enterobacter cloacae complex T S N T D W S K
Salmonella enterica serovar Agona SL483 T S N T D W S K
Pantoea ananatis LMG 5342 T S N T D W S K
Azosporillum brasilense sp245 T T N N D W S K
Vibrio vulnificus MO6_24/O S T N N D W S K
Marinomonas sp. MED121 S S N N D W S K
Providencia alcalifaciens Dmel2 S T N N D W S K
Photobacterium halotolerans S T N N D W S K
B
Streptomyces venezuelae SVEN_4179 IIAYPPGIPITVPGEKLCERTLSQIDTLR
Streptomyces globisporus IH67_RS0133445 IIAYPPGIPITVPGEKLCERTLSQIDTLR
Streptomyces Amel2Xe9 B065_RS0108240 IIAYPPGIPIAVPGERVCDRTLGEIDALR
Streptomyces NRRL_B24484 IE98_RS0127045 IIAYPPGIPITVPGEKLCDATRAEIRALR
Streptococcus mutans GS-5 SMUGS5_01680 IIPYPPGVPIAVPGEVMTTGLKQRIEEYR
Lactobacillus paraplatarum HR47_00315 IIPYPPGVPLIVPGEKFNSSIIAQLSVYE
Clostridium papyrosolvens CPAP_2202 VIPYPPGVPLLFKGDIINRKEAEKIKILK
Enterobacter cloacae AF39_RS01110 IIPYPPGVPLVFPGEIIDDGIRNKIDEYR
Salmonella enterica SL483 SEAG_B2134 IISYPPGVPLVFPGDVISKDVRNKINECK
Pantoea ananatis LMG 5342_3762 IIPYPPGVPLVFPGEVIDEVIKSKIEKYR
Azosporillum brasilense sp245 AZOBR_p310354 IIPYPPGVPIIVPGEEIGGDTLRRIEAIR
Vibrio vulnificus MO6_24/O VVMO6_04450 YILYPPGIPILTPGQTICNNVITKINQSI
Marinomonas MED121_03055 FILYPPGIPVLKPGQRVCENALSKIN
Providencia alcalifaciens Dmel2 OO9/006362 VIPYPPGVPIVFPGQNISSLDLEKINKHK
Photobacterium halotolerans H511_RS0105745 FILYPPGTPVLTPGQTVCKFDLDKINNSL
Figure 3.3 – A) Conservation of amino acid residues involved in PLP-binding domains in GbnA and
orthologues B) C-terminal motifs of GbnA and orthologues, illustrating the IXYPPGXP consensus
Chapter Three | Towards gaburedin biosynthesis
89
pfam03711 (ornithine/lysine/arginine substrate binding motif, amino acid residues 452-
481), and this region was found to contain a highly conserved IXYPPGXP motif that is
also present in the 1ORDA crystal structure for ornithine decarboxylase from
Lactobacillus 30a.171 Ornithine, lysine, arginine and glutamic acid are structurally
related and all share the substructure represented in Figure 3.4, which could explain the
observation that the C-terminal motif of GbnA and its orthologues share this common
OKR-binding motif.
Other, more specific, residues in the ligand binding pocket would vary to accommodate
the amine groups of ornithine, lysine or arginine, or the carboxylate group of glutamate,
therefore conferring specificity for one substrate over another. However, these residues
could not be identified.
3.1.3 gbnB encodes for a putative AMP-ligase
GbnB (encoded for by sven_4180 gene) is labelled as containing an adenylate forming
domain (positions 169-505, CD04433) and this domain contains thirteen out of
fourteen of the conserved residues involved in adenylate-monophosphate binding at
positions T170, G285, G286, L307, Y308, Y309, G310, T311, T312, D394, L406,
Figure 3.4 – Structures of L-glutamic acid, L-ornithine, L-lysine and L-arginine. Conserved structural
motif is highlight in red
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R409 and K502.77,170 A conserved motif found in acyl-activating enzymes can also be
mapped onto the GbnB sequence at the nine positions L150, T170, S171, G172, T173,
S174, G175, P177 and K178 (Figure 3.5).173,174 Furthermore, ten conserved residues
involved in coenzyme A substrate binding can also be mapped to the GbnB sequence at
positions V210, P259, V260, R262, G285, A418, G419, K420, A480 and L486. These
are distinct from the acyl-activating consensus, therefore suggesting that the specific
substrate for GbnB may only have some structural features shared with coenzyme A.173
GbnB and its orthologues were aligned using Clustal Omega, revealing highly
conserved residues at the positions identified as being associated with AMP-binding. In
addition, all fifteen proteins contain the conserved TSGTSXXPK motif involved acyl-
activation (Figure 3.5). These observations together imply that the substrate and/or
product of GbnB are structurally similar to AMP or a derivative of AMP.
The specific residues mentioned above are all part of large domains that belong to
classes of adenylate-forming enzymes that are shared between the A-domain of non-
ribosomal peptide synthetases (NRPSs) as well as enzymes involved in Coenzyme A
Figure 3.5 –Sequence alignment of GbnB and orthologues, illustrating the acyl-activating motif
TSGTSXXPK identified during conserved domain (CD) searches
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binding. Specific residues relating to a particular substrate were not identified,
however.
3.1.4 gbnC encodes for a transport protein
GbnC (encoded for by the sven_4181 gene), belongs to the EamA-like family of
membrane transport proteins (pfam00892) characterised by two 129 amino acid
repeated regions (residues 19-147 and 174-302) which are similar in sequence to other
members of this family, that includes amino acid, peptide and amine transporters.77,175
This analysis implies that GbnC does not have a catalytic role in gaburedin
biosynthesis, but would be responsible for the export of gaburedins from the cells to the
extracellular milieu.
3.2 GbnB is essential for gaburedin biosynthesis
3.2.1 Characterisation of the gbnB/gbnR double mutant strain
After characterisation of the gaburedin natural products overproduced by the gbnR
mutant strain, it was important to establish if the gbnABC gene cluster was directly
responsible for gaburedin assembly and export. Deletion of gbnR was predicted to
directly control the expression of the gbnABC operon (Section 1.7). Strains lacking the
gbnR gene (hence able to transcribe gbnABC and hence are able to produce gaburedins)
would lose the gaburedin-producing phenotype if one of the essential biosynthetic
genes in the gbnABC cluster was also deleted.
The gbnB/gbnR strain was constructed by replacing (and therefore disrupting) the gbnB
gene with an apramycin resistance gene in the SV4 F01 cosmid carrying the complete
gbn-sgn gene clusters. The gbnR gene was also removed, and replaced by an 81 bp
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‘scar’ mutation. This cosmid was then introduced into the S. venezuelae wild-type
strain and apramycin resistant clones were isolated (O. Lazos, G. L. Challis group).
To identify S. venezuelae gbnB::apra, gbnR::scar strains with the correct genotype,
genomic DNA was extracted and polymerase chain reactions (PCRs) were performed
with specific primers F/F’ and H/H’ to screen for the disruption of gbnR and of gbnB,
respectively (primer sequences can be found in Section 8.5). The SV4 F01 and SV4
F01 gbnR::scar cosmids were used as control templates with each set of primers. The
PCR products were analysed by agarose gel electrophoresis (Figure 3.6).
The PCR products obtained using the gbnR screening primer pair F/F’ were the sizes
predicted (323 bp for the gbnR::scar mutation in the gbnB/gbnR double mutant
genomic DNA and SV4 F01 gbnR::scar cosmid control, and 863 bp for the undisrupted
gbnR gene from the SV4 F01 cosmid DNA template). Figure 3.6 illustrates bands at
just above the 2000 bp marker for the PCR product using primer pair H/H’ to amplify
Template B,R B,R WT R WT
Screening primers used H/H’ F/F’ H/H’ F/F’ F/F’
Predicted size / bp 1884 323 2112 323 863
Figure 3.6 – Agarose gel of PCR products used to verify the correct construction of the S. venezuelae
gbnB/gbnR mutant strain. The templates used were genomic gbnB::apra, gbnR::scar mutant (B, R) and
cosmids SV4 F01 containing the wild-type gbn-sgn gene clusters (WT) and SV4 F01 gbnR::scar (R).
Different screening primers were used to amplify the genes shown
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the gbnB gene from the SV4 F01 cosmid (expected 2122 bp), and a band at just below
the 2000 bp marker for the gbnB::apra cassette amplified from the gbnB/gbnR double
mutant genomic DNA (1884 bp predicted), therefore confirming the genotype of this
new strain.
3.2.2 Chemotyping of the gbnB/gbnR double mutant strain by LC-MS analyses
After confirming that the gbnB/gbnR strain had the desired genetic modifications, spore
stocks were prepared and this strain was grown for 3 days on SMMS. The metabolites
produced were extracted at pH 3, and compared with metabolites produced by the wild-
type and the gbnR::apra single deletion mutant strains by LC-MS in order to determine
the effect of gbnB gene deletion on gaburedin production (Figure 3.7). As illustrated by
the extracted ion chromatograms for the gaburedins 80-85, in the
gbnB::apra,gbnR::scar mutant strain, gaburedin production was completely abolished.
This result confirmed that gbnB is essential for gaburedin biosynthesis. The potential
role of GbnB in gaburedin biosynthesis is discussed further in Section 3.4.5.
Figure 3.7 – Extracted ion chromatograms m/z = 247.0, 261.0, 279.0, 292.9 and 294.9 of gaburedins A-
F (80-85) extracted at pH 3 from the Streptomyces venezuelae wild-type (red trace), gbnR mutant (blue
trace) and gbnB/gbnR mutant (green trace) after being grown on SMMS for 3 days
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3.3 Proposed biosynthetic route to gaburedins
3.3.1 Feeding experiments with putative precursor molecules
As mentioned in Section 3.1.2, the observation that all the gaburedins produced by the
gbnR::apr mutant contain a conserved GABA moiety implies that the substrate of
GbnA could be L-glutamate, rather than L-lysine, L-ornithine or L-arginine. To test this
hypothesis, the gbnR mutant was grown on SMMS supplemented with 10 mM L-
glutamic acid. Extracellular metabolites produced after 3 days were then extracted and
submitted to LC-MS analyses. It was expected that by enriching the culture media with
L-glutamic acid that the yield of gaburedins would be increased. Instead, two additional
new gaburedin-like molecules 106 and 107 were observed (Figure 3.8).
It was observed that there was a new gaburedin 106 with m/z = 277.0, as would be
expected for a gaburedin containing L-glutamic acid (Figure 3.8). Molecular formulae
of the ions of C10H17N2O7 for the [M+H]+ ion (calculated m/z = 277.1030, found
277.1030), C10H16N2O7Na for the [M+Na]+ ion (calculated m/z = 299.0850, found
299.0858), and C5H10NO4 for the [M+H-C5H7NO3]+ fragment ion (calculated m/z =
148.0604, found 148.0602) were confirmed by UHR-LC-MS. Interestingly, an
additional gaburedin 107 with m/z = 232.9 for [M+H]+ 254.9 and [M+Na]+ and a small
fragment ion [M+H-C5H7NO3]+ m/z = 104.0 were also observed in this sample,
suggesting that a new gaburedin containing GABA was also formed (Figure 3.8 and
Scheme 3.1).
This result is consistent with the hypothesis that GbnA acts as a glutamate
decarboxylase, as providing the bacteria with a greater concentration of glutamate
would lead to an increase in the amount of available substrate for GbnA to turn over
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into GABA, hence there would be a greater intracellular concentration of GABA.
However, the observation of a new gaburedin 107 (Figure 3.8, Scheme 3.1) resulting
from from GABA being incorporated into gaburedins instead of an aminoacyl moiety,
was unexpected.
In order to determine whether this additional gaburedin 107 with m/z = 232.9 for the
[M+H]+ ion was indeed a GABA-derivative of gaburedins, SMMS containing 10 mM
(GABA) was prepared, the gbnR::apra strain grown and metabolites extracted and
Figure 3.8 – Extracted ion chromatograms for m/z = 292.9 (blue) for gaburedin F (85) , m/z = 277.0
(green) for new gaburedin 106 and m/z = 233.0 (orange) for new gaburedin 107 for metabolites extracted
from the S. venezuelae gbnR mutant when grown on SMMS enriched with 10 mM L-glutamate, 10 mM
GABA and unmodified SMMS. Mass spectra of the new gaburedin 106 containing L-glutamate and
gaburedin 107 containing GABA are shown
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analysed by LC-MS. A new compound was observed in the LC-MS trace with m/z =
232.9 and was shown to have the same retention time as the compound with m/z =
232.9 observed in the metabolites of the gbnR::apra strain when grown on media
supplemented with increasing concentrations of L-glutamate (Figure 3.8).
This sample was analysed by UHR-LC-MS which confirmed the molecular formulae of
107 to be C9H17N2O5 for the [M+H]+ ion (calculated m/z = 233.1132, found 233.1134),
C9H16N2O5Na for the [M+Na]+ ion (calculated m/z = 255.0951, found 255.0949), and
small peak corresponding to C4H10NO2 for the [M+H-C5H7NO3]+ fragment ion
corresponding to protonated GABA (calculated m/z = 104.0706, found 104.0714).
Therefore, it would appear that both L-glutamate and GABA can replace
phenylalanine, leucine, isoleucine, valine, methionine or acetylcysteine as the
aminoacyl moiety of gaburedins (Scheme 3.1).
Scheme 3.1 – Schematic to show incorporation of L-glutamate and GABA into gaburedins.
Decarboxylation of L-glutamate by GbnA produces GABA, which is incorporated into gaburedins
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3.3.2 Proposed biosynthetic scheme
The combination of bioinformatic analyses and experimental results discussed thus far
allow for a feasible biosynthetic route to gaburedins to be proposed. Primarily, the
proposed decarboxylase function for GbnA, and the presence of a conserved GABA
moiety across all of the urea natural products identified as being produced by the
gbnR::apra strain, strongly suggest that L-glutamate is the cognate GbnA substrate.
The decarboxylation product of L-glutamate would be GABA, which could react
spontaneously with CO2 to yield a carbamate intermediate 108, shown in Scheme 3.2.
As this reaction would be reversible (one would expect a carbamate intermediate would
readily be hydrolysed back to GABA in aqueous conditions) intermediate 108 could be
trapped by activation with ATP, to form one of two AMP-ester intermediates, 109 or
110.
Bioinformatic analyses suggested GbnB to be an AMP-ligase and experimental
evidence suggested GbnB to be an essential enzyme for gaburedin biosynthesis. Hence
GbnB was proposed to adenylate either the carboxyl or the carbamoyl group of
compound 108, (Scheme 3.2). Carboxyl adenylate 110 would need to undergo
cyclisation to the N-carboxyanhydride 111, which would then afford the gaburedins via
ring opening with amino acids (this would involve nucleophilic attack at the less
electrophilic carbonyl group of 111, which is chemically unlikely). On the other hand,
the carbamoyl adenylate 109 could react with the appropriate amino acids either
directly, or via anhydride 111, to form gaburedins.
Other urea-containing natural products were discussed in Section 2.3 and include
syringolins and pacidamycins.163-165 Interestingly, the adenylation domain of SylC,
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which has been shown to catalyse urea formation in syringolin biosynthesis, shares
39% similarity and 22% identity with GbnB.165 The mechanism for SylC-catalysed
urea formation has been proposed to involve a five-membered cyclic N-
carboxyanhydride 115, or a closely related species (Scheme 3.3). This anhydride is
hypothesized to be formed via an analogous mechanism to that suggested for the
formation of 111 (Scheme 3.2). Trapping of the anhydride with an isoleucyl or valinyl
acyl carrier protein thioester would lead to formation of the ureido linkage of the
syringolins. As noted above, an analogous mechanism for the formation of the
gaburedins via intermediate 111 seems unlikely.
The AMP-carbamate intermediate 109 is sufficiently reactive that it would be a short-
lived species in aqueous conditions; therefore it is likely that it would readily react with
Scheme 3.2 – Proposed biosynthetic route to gaburedins. L-glutamate is decarboxylated to give GABA,
which may proceed by one of two possible intermediates 109 or 111, to furnish gaburedins
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excess intracellular nucleophiles. Therefore, the incorporation of phenylalanine,
leucine, isoleucine, valine, methionine and N-acetyl cysteine into the gaburedins A-F
(80-85) may reflect the relative availability of amino acids in the cell at the time of
formation of the AMP-intermediate 109, rather than specific incorporation of these
amino acids by an enzyme recognising particular structural features (GbnB). In the case
of gaburedin F, this could be formed via acetylation of a cysteine-containing gaburedin,
or by N-acetyl cysteine attacking the AMP-ester intermediate. However, both of these
routes to gaburedin F would require a poorly-nucleophilic amide nitrogen lone pair (or
an ureido-nitrogen lone pair) attacking an electrophile, both of which are chemically
unlikely.
The presence of such a reactive intermediate species 109/111 is also consistent with the
observation that a vast range of different substrates are incorporated into gaburedin
Scheme 3.3 – Biosynthetic origin of ureido-linked dipeptides in syringolin biosynthesis as proposed by
Imker and co-workers165
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natural products; both L- and D- amino acids are tolerated aminoacyl moeities. The
biosynthetic scheme proposed here would also account for the additional gaburedins
106 and 107 resulting from feeding experiments with L-glutamic acid both L-glutamate
and the decarboxylation product GABA can also both act as nucleophiles to react with
109/111.
Finally, the GbnC enzyme (belonging to a large family of small amino acid / peptide
transporters) may be involved with export of the gaburedins into the extracellular
milieu. Alternatively, GbnC may be involved in export of the AMP-carbamate
intermediate 109, allowing nucleophiles in the extracellular medium to react with it to
furnish gaburedins.
3.3.3 Origin of the ureidyl carbon
To probe the biosynthetic origin of the central carbon atom and GABA moieties (blue
in Figure 3.1), incorporation experiments with 13C-labelled precursors were carried out.
If the precursor to gaburedins is glutamate, one would expect that feeding the
gbnR::apra mutant with 13C-labelled L-glutamic acid would result in 13C labelled
gaburedins.
Initially, to probe the origin of the ureidyl carbonyl carbon, the gbnR::apra strain was
grown on SMMS enriched with [1-13C]-L-glutamic acid added to a 10 mM final
concentration. If the ureidyl carbonyl is directly incorporated from the carboxylate
group lost during the decarboxylation of L-glutamate to yield GABA (Scheme 3.2),
then the 13C label from [1-13C]-L-glutamic acid added to the media would be expected
to be retained through the biosynthesis, and therefore observed in the gaburedins
extracted from this culture extract (Scheme 3.2). LC-MS analysis of the gaburedins
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extracted from the gbnR::apra strain grown on SMMS with [1-13C]-L-glutamic acid
revealed that there was no labelling of the gaburedins A-F (80-85) present in the culture
extract (Figure 3.9). The only gaburedin extracted that contained a 13C label was the
gaburedin 106 derived from attack of the carbamate intermediate by [1-13C]-L-
glutamate, confirmed by the increase in the m/z values of the [M+H]+, [M+Na]+ and
[M+H–C5H7NO3]+ ions by 1, compared with gaburedin 106 derived from unlabelled L-
glutamic acid (Figure 3.9).
Figure 3.9 – Mass spectra of gaburedins 80, 106 and 107 from metabolites extracted from the S.
venezuelae gbnR mutant when grown on SMMS and SMMS enriched with 10 mM [1-13C]-L-glutamic
acid illustrating the only labelled gaburedin is gaburedin 106, the product of the reaction of [1-13C]-L-
glutamic acid with the proposed biosynthetic intermediate 109/111
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The result of this labelling experiment therefore confirms that the ureidyl carbon is not
derived from L-glutamate. It was predicted that if the ureidyl carbon is derived from
sodium hydrogen carbonate, that specific labelling of gaburedins would be observed
when the gbnR::apra strain was grown on SMMS enriched with 10 mM NaH13CO3 as
in the case of the ureidyl carbon present in syringolins.165 LC-MS analysis of the
culture extract revealed that the mass spectra of the gaburedins observed were
unchanged compared to those extracted from unmodified SMMS (Figure 3.10),
suggesting that the ureidyl carbon is not derived from sodium hydrogen carbonate.
3.3.4 Origin of the conserved GABA moiety
The gbnR::apra strain was then grown on SMMS enriched with [U-13C]-L-glutamic
acid, as it was hypothesised four of the 13C labels would be retained throughout the
biosynthesis of the gaburedins and therefore be detected in the gaburedins extracted.
This would be consistent with the previous observation that the C-1 carbon lost in the
decarboxylation step is not retained in the final gaburedin natural products observed in
the culture extract, but the other four carbon atoms are retained in gaburedins produced.
Figure 3.10 – Mass spectra of gaburedin A (80) in metabolites extracted from the S. venezuelae gbnR
mutant when grown on SMMS (top panel) and SMMS enriched with 10 mM NaH13CO3 (bottom panel),
illustrating that the 13C label from NaH13CO3 is not retained in gaburedin biosynthesis
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Figure 3.11 – Biosynthetic route to gaburedins, showing the proposed incorporation of 13C labels upon
feeding the gbnR::apra strain with [U-13C]-L-glutamic acid (top panel). Mass spectra of gaburedins A 80,
106 and 107 from metabolites extracted from the S. venezuelae gbnR mutant when grown on SMMS and
SMMS enriched with 10 mM [U-13C]-L-glutamic acid (bottom panel), showing retention of 13C labels in
gaburedins identified in this culture extract
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Indeed, LC-MS analysis of the gaburedins 80-85 present in the culture extract of the
gbnR::apra strain on SMMS enriched with 10 mM [U-13C]-L-glutamic acid revealed
that there is specific incorporation of four 13C labels into all six gaburedins A-F (Figure
3.11 shows the mass spectra of gaburedin A upon feeding the gbnR::apra mutant with
[U-13C]-L-glutamic acid compared with feeding with 10 mM unlabelled L-glutamic
acid). Although the isotope patterns in the mass spectra are complicated, the
predominant m/z for the [M+H]+ species is shifted from 295.0 to 299.0 for gaburedin A
80, however the fragment ion [M+H-C5H7NO3]+ still has m/z = 166.0 as would be
expected if the 13C labels are in the conserved GABA moiety, and are therefore lost
upon loss of the neutral C5H7NO3 fragment.
In addition, consistent with previous data from feeding with unlabelled L-glutamic
acid, the gaburedin 107 derived from GABA was also observed, again the m/z of its
molecular ion being increased in value by 4 from m/z = 232.9 to 236.9, and the
[M+Na]+ peak increased in value from m/z = 254.9 to 258.9.
Furthermore, the mass spectrum of the gaburedin 106 derived from L-glutamate
showed an increase in its m/z = 276.9 to 281.9 and 286.0 for the [M+H]+ ion, consistent
with the incorporation of four 13C labels into the conserved ureidyl-GABA moiety, in
addition to five 13C labels consistent with the addition of [U-13C]-L-glutamic acid to
the proposed AMP-carbamate intermediate (Figure 3.11). UHR-LC-MS analysis
confirmed the molecular formulae of the ions for the unlabelled and labelled
gaburedins containing 13C-labels.
The relative abundance of the labelled vs unlabelled peaks in the mass spectra for
gaburedins A-F 80-85, gaburedin 106 and gaburedin 107 shown in Figure 3.11 may
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have been affected by the relative amounts of labelled vs unlabelled glutamate present
in the media. It would be expected that the relative intensities of unlabelled:labelled
peaks would be approximately 1:4 for each gaburedin, as there is 2.8 mM L-glutamic
acid in the media from the casaminoacids, yet the media was supplemented with 10
mM [U-13C]-L-glutamic acid, also. The complex fragmentation patterns observed may
simply reflect the complicated role of L-glutamic acid in central metabolism, and
supplementing the growth media with such a large quantity (final concentration of 12.8
mM L-glutamic acid in total compared to 2.8 mM in unmodified SMMS) may have
diverted metabolic flux to other pathways rather than into gaburedin biosynthesis.
3.4 Probing substrate diversity of GbnA and GbnB
3.4.1 Substrate specificity of GbnA
Contrary to the bioinformatic analysis of GbnA, the experimental evidence presented
thus far implies that L-glutamate, rather than L-ornithine, L-lysine or L-arginine is
utilised by GbnA as a substrate. To determine whether any gaburedin analogues could
be derived from decarboxylation of L-ornithine, L-lysine or L-arginine, the gbnR::apra
mutant was grown on SMMS supplemented with these amino acids. Extracellular
metabolites produced after 3 days were then extracted and submitted to LC-MS
analyses.
As the enzyme GbnA and its orthologues belong to the Orn/Lys/Arg decarboxylase
family, extracted ion chromatograms were generated for the m/z of species that would
be expected if the decarboxylated form of the precursor molecules were incorporated to
give gaburedin-like compounds derived from GABA analogues. For example,
decarboxylation of L-ornithine would yield putrescine, L-lysine would yield
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Scheme 3.4 – Biosynthetic route to gaburedin analogues that would be produced if GbnA decarboxylated
L-ornithine, L-lysine or L-arginine, and if the resulting carbamoyl amines are activated by GbnB
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cadaverine, decarboxylation of L-arginine would yield agmatine.171,172 It is conceivable
that each of these amines could spontaneously react with CO2 to give analogous
carbamates 112, 117 or 122 shown in Scheme 3.4.
These carbamoyl compounds could then be activated by GbnB to yield the
intermediates 113, 118 and 123, resulting from activation of carbomoyl derivatives of
putrescine, cadaverine, and agmatine, respectively. These adenylated carbamoyl
intermediates could then react with a range of nucleophiles; they could react with the
amino acids that form gaburedins A-F (compounds 114, 119, and 124 in Scheme 3.4);
they could react with the intermediate amines formed by action of GbnA to give
compounds 115, 120 and 125; or they could react with the precursor amino acids to
form 116, 121 and 126 from L-ornthine, L-lysine and L-arginine, respectively. These
potential biosynthetic processes are summarised in Scheme 3.4.
Extracted ion chromatograms were generated for the m/z of the ions expected if
cadaverine, agmatine or putrescine were incorporated instead of GABA to yield the
ureas 114-116, 119-121 and 124-126. No compounds corresponding to these m/z values
were observed, implying that no putrescine-, cadaverine- or agmatine-derived
gaburedin analogues are produced by the gbnR::apra strain on these supplemented
media.
Extracted ion chromatograms were also generated for the [M+H]+ ions of the
gaburedins 127-129 that would be observed if the amino acids L-arginine, L-lysine and
L-ornithine were incorporated into the aminoacyl moiety of gaburedins instead of the
amino acids found in gaburedins A-F by reacting with intermediate 109. Again, LC-MS
analysis of the culture extracts revealed there to be no gaburedins with the expected m/z
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values of 304.0, 276.0 and 262.0 corresponding to 127, 128 and 129 respectively.
However, the gaburedins A-F could still be observed in the metabolites extracted from
the SMMS enriched with each of these three amino acids (Figure 3.12), implying that
the increased concentrations of L-ornithine, L-lysine and L-arginine in these media had
not inhibited GbnA.
In the case of L-ornithine, there was no gaburedin found with m/z = 262.0 as would be
expected for incorporation of L-ornithine into gaburedin biosynthesis (Figure 3.12).
However, there was a gaburedin derivative 130 with m/z = 243.9 for its [M+H]+ ion, 18
Da less than expected. The feeding experiment was repeated with 20 mM L-ornithine
Figure 3.12 – Extracted ion chromatograms for m/z = 247.0, 261.0, 279.0, 292.9 and 294.9 (blue) for
gaburedins A-F (80-85) extracted from the S. venezuelae gbnR mutant when grown on SMMS enriched
with 1 mM L-arginine, 1 mM lysine and 1 mM L-ornithine. The structures and extracted ion
chromatograms for the [M+H]+ species of gaburedins 127-129 expected if these amino acids attack
intermediate 109 are also shown
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to verify the new compound 130 was present. This suggested that the L-ornithine fed to
the gbnR::apra mutant was perhaps cyclised to 3-aminopiperidine-2-one before being
incorporated into the gaburedin 130 shown in Figure 3.13.
UHR-LC-MS analysis confirmed the molecular formulae of each ion in the mass
spectrum of this compound to be C10H18N3O4 for the [M+H]+ ion (calculated m/z =
244.1292, found 244.1309), C10H17N3O4Na for the [M+Na]+ ion (calculated m/z =
266.1111, found 266.1116), consistent with a structure of 4-(3-(2-oxopiperidin-3-
yl)ureido)butanoic acid 130. The C5H11N2O for the [M+H-C5H7NO3]+ fragment ion
(calculated m/z = 115.0866, found 115.0873) was also consistent with the molecular
formula of 3-aminopiperidine-2-one. As L-ornithine was added to the SMMS before
autoclaving, it is possible that the cyclisation occurred before being imported into the
gbnR::apra cells.
Figure 3.13 – Extracted ion chromatograms for m/z = 247.0, 261.0, 279.0, 292.9 and 294.9 (blue) for
gaburedins A-F (80-85) and m/z = 244.0 (red trace) for new gaburedin-like compound 130 extracted from
the S. venezuelae gbnR mutant when grown on SMMS supplemented with 20 mM L-ornithine (top panel)
and mass spectrum and proposed structure of new gaburedin 130
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These feeding experiments were repeated with media being supplemented with 20 mM
each of L-arginine, L-lysine and L-ornithine. Indeed, as previously observed, in the
metabolites extracted from the gbnR::apra mutant after being grown on these
supplemented media, there were no new compounds observed with the expected m/z
values for incorporation of L-arginine or L-lysine into new gaburedin analogues. It was
observed however that the yield of gaburedins 80-85 was decreased in metabolites
extract from the gbnR::apra mutant grown on SMMS enriched with 20 mM L-lysine.
In the culture extract from the gbnR::apra strain grown on SMMS enriched with L-
arginine, however, there was no significant reduction in the relative amount of
gaburedins 80-85 produced compared to unmodified SMMS.
This series of feeding experiments was expanded on further by feeding L-norvaline (L-
2-amino pentanoic acid) 131, which is a potential substrate analogue for GbnA that has
a propyl-side chain instead of a propionic acid side chain of L-glutamate. Therefore it
was hypothesised that L-norvaline could be a substrate for GbnA, as the
decarboxylation is occurring at the aminoacyl carboxylate compared with the side chain
carboxylate. Decarboxylation of L-norvaline would produce n-butylamine 132, which
could be spontaneously activated by CO2 to give 133, which may be adenylated by
GbnB to give 134. Nucleophilc attack of this intermediate 134 would furnish a range of
gaburedin analogues 135-137 with an n-butylamine moiety in place of the GABA
moiety (Scheme 3.5).
Therefore, the gbnR::apra strain was grown on SMMS supplemented with 1 mM and 5
mM final concentration of L-norvaline, and the metabolites produced after 3 days were
analysed by LC-MS. None of the m/z values for the species 135-137 were observed,
implying that GbnA cannot catalyse decarboxylation of L-norvaline. However, an
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Scheme 3.5 – Biosynthetic route to gaburedin analogues that would be produced if GbnA decarboxylated
L-norvaline, L-glutamine or L-aspartate and the resulting carbamoyl amines are activated by GbnB
Chapter Three | Towards gaburedin biosynthesis
112
additional peak with m/z = 247.0 was observed, as would be expected if L-norvaline
was acting as a nucleophile to attack the intermediate 109 to give a new gaburedin
analogue 138 (Figure 3.14). This gaburedin has the same molecular formula as
gaburedin D 83, however, 138 elutes later. This is consistent with other molecules
which only differ in the branching of their alkyl chains, as in the case of the
germicidins and AHFCAs.79,83
To probe whether or not L-glutamine can be turned over by GbnA (L-glutamine has an
amide instead of a carboxylic acid group at the end of its R substituent), SMMS was
prepared with 20 mM final concentration of L-glutamine. If L-glutamine is
decarboxylated by GbnA, 4-aminobutanmide 139 would result. This could then yield a
series of gaburedin analogues 142-144 shown in Scheme 3.5. LC-MS analysis of
metabolites extracted from the gbnR::apra strain grown on SMMS supplemented with
Figure 3.14 – Extracted ion chromatogram for m/z = 247.0 corresponding to gaburedin D (83) and new
gaburedin 138 corresponding to incorporation of L-norvaline from the metabolites extracted from the
gbnR mutant after growing on SMMS + 1 mM L-norvaline for 3 days
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20 mM L-glutamine, however, revealed that no species with m/z values corresponding
to the molecules 142-144 from Scheme 3.4 were observed.
There was also no observed compound with m/z = 276.1 as would be expected from
incorporation of L-glutamine into gaburedin biosynthesis from attack of the
intermediate 109, to yield the gaburedin 145 (Figure 3.15). However, the gaburedins A-
F were still produced, therefore it would appear that L-glutamine is not inhibiting
gaburedin biosynthesis, nor is it acting as a nucleophile to produce an addition
gaburedin 145.
A similar experiment was performed with L-aspartic acid in order to determine whether
GbnA could tolerate a substrate with a shorter alkyl chain. Therefore extracted ion
chromatograms for m/z = 278.9, 264.9, 231.0, 247.0 and 281.0 were generated for
gaburedin-like ureas that would be observed if β-aminopropionate was inserted in place 
of GABA to furnish gaburedin analogues 149-151. However, no compounds with these
m/z values were identified in the culture extract of the gbnR mutant grown on SMMS
supplemented with 10 mM L-aspartic acid. If β-aminopropionate is indeed produced by 
the action of GbnA on L-aspartate, however, it is conceivable that β-aminopropionate 
or its derivative would not be turned over by GbnB. Furthermore, there is no peak in
Figure 3.15 – Extracted ion chromatograms for m/z = 276.1 of gaburedin 145 which would be derived
from L-glutamine (red trace), m/z = 247.0, 261.0, 279.0, 292.9 and 294.9 of the gaburedins A-F (80-85,
blue trace) in metabolites extracted from the Streptomyces venezuelae gbnR strain after being grown on
SMMS containing 20 mM L-glutamine for 3 days
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the extracted ion chromatogram for m/z = 263.1 as would be expected for a gaburedin
152 containing L-aspartic acid, nor is there a peak with m/z = 219.0 corresponding to
incorporation of β-aminopropionate attacking 109 to furnish 158. Gaburedins A-F are
still produced, however (Figure 3.16).
3.4.2 Probing GbnB substrate specificity
The feeding experiments in Section 3.4.1 suggest that the only substrate GbnA can
tolerate out of the compounds tested is L-glutamate. However, these results do not
confer much information regarding the substrate tolerance of GbnB. For example, it is
possible that GbnA can tolerate other substrates (for example, L-norvaline could be
decarboxylated to give n-butylamine), and the resulting amines/GABA analogues were
simply not tolerated by GbnB and would therefore accumulate inside the cell.
However, if there was an accumulation of these amines inside the cell, one might
expect them to react with 109 to give a series of gaburedin analogues 153-158 (Scheme
3.6). No such species were observed, however.
Figure 3.16 – Extracted ion chromatograms for metabolites extracted from the S. venezuelae gbnR
mutant after growing on SMMS + 10 mM L-aspartate for 3 days. Gaburedins A-F (80-85) m/z = 247.0,
261.0, 279.0, 292.9 and 294.9 (blue traces) and m/z = 263.0 (green trace) for new gaburedin 152 that
would be expected for incorporation of L-aspartate into gaburedins via attack of intermediate 109
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In order to determine whether the carboxylic acid group of GABA is required for
GABA (or a derivative of GABA) to be activated by GbnB, SMMS media
supplemented with n-butylamine 132 and methyl 4-aminobutyrate 159 were prepared.
The gbnR::apra mutant was grown on these media, metabolites extracted after 3 days,
and analysed by LC-MS. If the GABA carboxylic acid group is not required for
incorporation in gaburedin biosynthesis, it would perhaps be expected that n-
butylamine could be activated in a similar way, leading to formation of a putative
carbamoyl ester intermediate 134 as shown in Scheme 3.7. This intermediate 134 could
Scheme 3.6 – Biosynthetic route to gaburedin analogues that would be produced if GbnA decarboxylated
any of the putative precursors (left hand column) and the resulting amines attack 109 to furnish gaburedin
analogues
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then be available for attack by amino acid nucleophiles or n-butylamine itself to furnish
gaburedin analogues 135 and 136, respectively.
Scheme 3.7 – Biosynthetic route to gaburedin analogues that would be produced if carbamoylated n-
butylamine or methyl 4-aminobutyrate were activated by GbnB (top panels) and structures of gaburedins
containing n-butylamine or methyl 4-aminobutyrate via reaction with intermediate 109 (bottom panel)
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Similarly, if the carbamoyl derivative of methyl 4-aminobutyrate can be tolerated by
GbnB as a substrate, it could form the carbamoyl adenylate 161, which would be
attacked by amino acids to furnish a series of methylated gaburedins 162. Methyl 4-
aminobutyrate could also attack intermediate 161 to give the new gaburedin 163
(Scheme 3.7). It is also possible that neither n-butylamine nor methyl 4-aminobutyrate
would be activated by GbnB; they could both react with intermediate 109 to furnish
new gaburedins 156 and 164 (Scheme 3.7).
Upon LC-MS analysis of the culture extract from the experiments with n-butylamine
and methyl 4-aminobutyrate, it was found that no series of gaburedin analogues 135 or
162 were present (one would expect the [M+H]+ ions corresponding to n-butylamine-
derived analogues of gaburedins 135 to have m/z = 263.0, 249.0, 217.0, 231.0 and
265.0; the methylated gaburedin analogues 162 would have m/z = 307.0, 293.0, 247.0,
261.0 and 309.0). Furthermore, no peak with m/z = 173 was observed for compound
136 or peaks of m/z = 261.0 corresponding to species 163 which would arise from
methyl 4-aminobutyrate attacking intermediate 161.
As shown in Figure 3.17, the only new gaburedin analogue observed in the culture
extract from SMMS enriched with n-butylamine had m/z = 202.9, as would have been
expected for n-butylamine attacking the GABA-carbamoyl-AMP ester intermediate
109 to yield gaburedin 156. Therefore, n-butylamine would appear to act only as a
nucleophile attacking the intermediate 109 formed by GbnB, as opposed to acting as
substrate for GbnB itself (Scheme 3.7). The fragment ion present at m/z = 104.0 is
consistent with neutral loss of the amine and ureido moieties, leaving protonated
GABA rather than neutral loss of the GABA moiety as was observed for all other
gaburedins reported thus far.
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Interestingly, when the gbnR::apra strain was grown on SMMS supplemented with
methyl 4-aminobutyrate, a new gaburedin 164 with the expected m/z of 247.0 for a
gaburedin containing methyl 4-aminobutyrate was observed (Figure 3.17) and UHR-
LC-MS analysis confirmed the molecular formulae to be C10H19N2O5 for the [M+H]+
ion (calculated m/z = 247.1288, found 247.1290) and C10H18N2O5Na for the [M+Na]+
ion (calculated m/z = 269.1108, found 269.1110) however there was no observable
peak at 118.1 as would be expected for the protonated GABA-O-methyl ester
remaining after losing the conserved C5H7NO fragment.
It should be noted that the molecular formulae generated for the [M+H]+ ion and
[M+Na]+ ions of this new compound 164 are identical to those generated for the
molecular ions of gaburedin D 83 containing L-valine, however this new gaburedin 164
Figure 3.17 – Extracted ion chromatograms for gaburedins 80-85 m/z = 247.0, 261.0, 279.0, 292.9 and
294.9 (blue traces) m/z = 203.0 (black trace) and m/z = 247.0 (pink trace) for new gaburedins 156 and
164 observed in the metabolites extracted from the gbnR mutant after growing on SMMS + 1 mM n-
butylamine and SMMS + 10 mM methyl 4-aminobutyrate for 3 days
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also has a peak in its mass spectrum at m/z = 118.1, however this could correspond to a
methyl 4-aminobutyrate fragment ion. Furthermore, this new gaburedin 164 elutes
sooner (tR = 10.2 min), compared with gaburedin D, (tR = 11.3 min, Figure 3.17).
This compound corresponds to the m/z of the gaburedin that would be expected by
attack of the methyl 4-aminobutyrate attacking the AMP-ester intermediate 109.
Therefore, it would appear that the methyl 4-aminobutyrate cannot act as a substrate for
GbnB, as there would be a series of new methylated gaburedins expected to be
observed if this was the case. This result implies that the carboxylic acid group of
GABA is indeed required for turnover by GbnB.
These results of feeding n-butylamine and methyl 4-aminobutyrate do not change the
proposed route to gaburedins as shown in Scheme 3.2, however. The carboxylic acid
group of GABA may simply be required for substrate binding to GbnB (for example,
favourable electrostatic interactions may arise from GbnB interacting with the
carboxylate group of GABA). Even though it is not this carboxylic acid group which is
being activated, changing the negatively charged carboxylate group of GABA for an
uncharged methyl group of n-butylamine or the methyl ester group of methyl 4-
aminobutyrate could lead to unfavourable interactions with the active site residues of
GbnB that are involved in substrate binding; as a result these molecules are not
activated by GbnB.
One other interpretation of these results could be that GbnA and GbnB operate as a
complex within the cell, and the active site of GbnB is only accessible via the interface
between GbnA and GbnB. This would imply that GbnB may be able to turn over n-
butylamine or methyl 4-aminobutyrate, but the gaburedin analogues resulting from
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activation of these substrates are not observed, because the GbnB substrate must arrive
via GbnA rather than by diffusion into the active site from elsewhere in the cell.
3.5 Summary
From these in vivo experiments, it can be confirmed that GbnA does not catalyse the
decarboxylation of lysine, ornithine or arginine, but instead catalyses the
decarboxylation of glutamate into GABA. GABA (or a derivative of GABA) is then
utilised by GbnB, which is likely involved in activation of 108. This intermediate 109
then reacts with a range of nucleophiles (amino acids or amines) present in either the
cell or extracellular milieu to yield the gaburedin natural products.
If the turnover of L-glutamate into GABA is indeed the reaction catalysed by GbnA, it
would be expected that GABA would accumulate in a mutant lacking gbnB. Therefore,
the gbnB/gbnR double mutant strain was grown on both SMMS and SMMS enriched
with 1 mM, 5 mM and 10 mM L-glutamic acid, metabolites extracted and analysed by
LC-MS. There was no observable accumulation of GABA, however.
The results from the feeding experiments presented thus far indicate that if the
incorporation of amino acids into gaburedins is enzyme-catalysed, then the enzyme(s)
involved must have quite broad substrate specificity (whilst the GABA-derived moiety
is conserved, the amino acid moieties found on the other side of the ureido bridge in
gaburedins A-F are structurally diverse). However, all new compounds identified thus
far share the conserved C5H7NO3 ureidyl-GABA fragment, implying that there is a
much higher level of control of substrate tolerance by the enzymes GbnA and GbnB
which are proposed to be involved in biosynthesis of the conserved GABA moiety,
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compared with the final step of gaburedin biosynthesis which involves attack of the
intermediate compound 109 by aminoacyl or amine nucleophiles. The structural
diversity of different nucleophiles which can be incorporated into gaburedins is
discussed in more detail in Chapter 4.
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4. Exploring diversity of gaburedin aminoacyl moieties
In Chapter 3, feeding experiments with specific gaburedin precursors established that
GbnA decarboxylates L-glutamate. It was hypothesised that GbnB adenylates the
carbamoyl group of the GABA derivative 108 (Scheme 3.2). Nucleophilic attack of the
amine onto the carbamoyl adenylate 109 results in ureido bridge formation and the
gaburedin natural products.
Experiments presented thus far have indicated that the nucleophiles attacking this
intermediate carbamoyl adenylate 109 do not require a carboxylic acid group to be
incorporated into gaburedins (as illustrated by the observation that n-butylamine and
methyl 4-aminobutyrate can attack intermediate 109 to form gaburedins 156 and 164,
respectively, Scheme 3.6). Furthermore – as noted in Chapter 2 – the side chains of
amino acids that form gaburedins A-F are very diverse. Given the diversity of
nucleophiles that can be incorporated into gaburedins, it was proposed that this step in
gaburedin biosynthesis is not enzyme-catalysed. Incorporation experiments with a
variety of other nucleophiles could therefore be performed to investigate the formation
of other gaburedin analogues with even more diverse R and C-terminal groups (red and
green in Figure 4.1).
Figure 4.1 – General structure of gaburedins identified thus far. Chapter 4 will focus on the diversity of
substrates with different amino acid side chains (red) and different groups in place of the aminoacyl
carboxylic acid group (green) which can be incorporated into gaburedins
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4.1 In vivo investigations of aminoacyl moiety tolerance
4.1.1 Incorporation experiments with small amino acid side chains
As the incorporation of amino acids into the aminoacyl moiety of gaburedins does not
appear to be enzyme-catalysed, the level of incorporation of each of the non-polar
amino acids phenylalanine, leucine, isoleucine, valine, methionine and cysteine (or N-
acetylcysteine) may reflect their abundance. Figure 4.2 illustrates the concentration of
amino acids present in the medium used (SMMS). The amino acids phenylalanine,
leucine, isoleucine, valine and cysteine are not the most abundant amino acids in the
media, but are the ones which are incorporated into gaburedins 80-85 in unmodified
culture medium.
As described in Section 2.2.4, specific gaburedins can be overproduced by
supplementing the culture medium with a particular amino acid. To gain further insight
Figure 4.2 – Molar concentrations of proteinogenic amino acids in SMMS162
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into the biosynthesis of gaburedins, SMMS modified to include greater concentrations
of other amino acids was prepared. As described in the previous chapters, the
gbnR::apra strain was grown on these media, the metabolites extracted and analysed by
LC-MS to determine whether any additional gaburedin-like molecules were produced
when additional amino acids were added. As in previous experiments, control plates of
the modified media were prepared but not inoculated with bacteria. All plates were
incubated at 30 °C for 3 days and ethyl acetate extracts performed. The samples were
analysed by LC-MS and the presence of any new gaburedin-like molecules were
confirmed by comparing the chromatograms of these samples with and without
bacteria. These analyses excluded the possibility that the new metabolites observed
were not simply products of media components reacting together during autoclaving or
subsequent incubation at 30 °C.
The amino acids L-phenylalanine, L-leucine, L-isoleucine, L-valine, L-methionine and
N-acetyl-L-cysteine all share similar properties (they all belong to the group of amino
acids with uncharged side chains, whose overall charge is zero at pH 7). Therefore,
growth media supplemented with other amino acids possessing uncharged side chain
groups (namely L-alanine, glycine, L-serine, L-threonine) were prepared in order to
determine whether the gbnR::apra strain could produce gaburedins containing these
amino acids also.
Upon growing the gbnR::apra strain on SMMS supplemented with 20 mM L-alanine,
LC-MS analysis revealed that in addition to the previously reported gaburedins A-F
(80-85), there was also production of another new metabolite 165 with a retention time
of 7.0 min, with peaks in its mass spectrum at m/z = 219.4 and m/z = 241.2, consistent
with protonated and sodiated adducts of the same molecule (Figure 4.3). In addition, a
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m/z = 90.2 fragment ion expected for protonated L-alanine consistent with the
characteristic gaburedin mass loss of 129 Da was observed.
Analogous experiments were performed on SMMS supplemented with L-proline,
glycine, L-serine and L-threonine; LC-MS analyses revealed the presence of new
gaburedin-like species 166-169 in these extracts corresponding to m/z = 244.0, 204.8,
234.8 and 248.9 for the [M+H]+ ions of each new gaburedin containing L-proline,
glycine, L-serine and L-threonine, respectively (Figure 4.4). All these new gaburedins
exhibited the same characteristic gaburedin fragmentation pattern, furnishing ions
corresponding to the protonated amino acids from each gaburedin. The incorporation of
L-proline into gaburedin 166 is particularly interesting, as it is the first example of a
secondary amine being incorporated into gaburedins.
This incorporation experiment was repeated with 1 mM, 5 mM and 10 mM final
concentration of L-cysteine. In the extract of the gbnR::apra strain grown on SMMS
supplemented with 1 mM final concentration of cysteine, there was very little change in
Figure 4.3 – Extracted ion chromatograms for gaburedins A-F (80-85) m/z = 247.0, 261.0, 279.0, 292.9
and 294.9 (blue trace) and new gaburedin 165 m/z = 219.0 (green trace) in metabolites extracted at pH 3
from the Streptomyces venezuelae gbnR strain after being grown on SMMS + 20 mM L-alanine for 3
days. The mass spectrum of new gaburedin 165 is also shown
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the yield of gaburedins, with 5 mM cysteine, there was a slight increase in the yield of
the N-acetyl-cysteine derived gaburedin F (85). However, with 10 mM or 20 mM final
concentration of L-cysteine, there was no production of gaburedins 80-85.
In all cases, there was no new gaburedin 170 with the expected m/z = 251 observed in
the culture extracts (Figure 4.5). There are fewer peaks in the base peak chromatogram
of the culture extract from feeding with 10 mM L-cysteine, implying that generally
there are fewer metabolites produced by the gbnR::apra strain in these conditions. This
could perhaps be a stress response of the cells as a result of the dramatic increase in
free thiols caused by the high concentration of L-cysteine in the media.
Figure 4.4 – Extracted ion chromatograms for gaburedins A-F (80-85) m/z = 247.0, 261.0, 279.0, 292.9
and 294.9 (blue traces) and new gaburedins (green traces) of metabolites extracted at pH 3 from the
Streptomyces venezuelae gbnR strain after being grown on SMMS + 20 mM L-proline, glycine, L-
serine and L-threonine for 3 days
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4.1.2 Incorporation experiments with large amino acid side chains
So far, small polar and non-polar amino acids have been shown to be incorporated into
the aminoacyl moiety of gaburedins. To further explore the range of polar amino acids
which can be tolerated, feeding experiments were performed in which SMMS was
supplemented with 20 mM L-asparagine, L-tyrosine and L-histidine.
In the experiments where SMMS was supplemented with 20 mM L-asparagine, a new
metabolite with m/z = 262.1 was observed as would be expected for the gaburedin
containing L-asparagine. UHR-MS confirmed that this new compound had both the
molecular formulae and fragmentation pattern expected for an L-asparagine-derived
gaburedin: C9H16N3O6 for the [M+H]+ ion (calculated m/z = 262.1034, found
262.1035), C9H15N3O6Na for the [M+Na]+ ion (calculated m/z = 284.0853, found
Figure 4.5 – Extracted ion chromatograms for gaburedins A-F (80-85) m/z = 247.0, 261.0, 279.0, 292.9
and 294.9 (blue traces) and m/z = 251.0 for the expected new gaburedin 170 that would be expected
from incorporation of L-cysteine (green traces) in metabolites extracted at pH 3 from the Streptomyces
venezuelae gbnR strain after being grown on SMMS and SMMS supplemented with L-cysteine
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284.0855), and C4H9N2O3 for the [M+H-C5H7NO3]+ fragment ion (calculated m/z =
133.0608, found 133.0608) corresponding to protonated L-asparagine.
L-asparagine has two nitrogens available to react (the N-terminus of its amino acid
backbone, and the amide NH2 of the side chain), it is conceivable that there might be
two new gaburedins observed in the culture extract, resulting from the amino nitrogen
attacking intermediate 109, to give gaburedin 171, and attack of intermediate 109 by
the side chain amide, forming gaburedin 172 (these two compounds would be expected
to have different retention times on a reverse phase liquid chromatography column).
Figure 4.6 – Extracted ion chromatograms for m/z = 262.0 of gaburedin 171 (green trace) and m/z =
277.0 of the gaburedin 106 from incorporation of L-glutamate (orange trace) in metabolites extracted at
pH 3 from the Streptomyces venezuelae gbnR strain after being grown on SMMS containing 20 mM L-
asparagine and SMMS + 20 mM L-glutamate (top panels), and mass spectra of gaburedins 171 and 106
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However, only one is observed (Figure 4.6), and presumably has the structure of
gaburedin 171, as this would be the product of the more nucleophilic N-terminal
nitrogen attacking intermediate 109; the poor nucleophile amide nitrogen would not be
expected to be nucleophilic enough to attack carbamoyl adenylate 109.
Interestingly, there also appeared to be an L-glutamate derived gaburedin 106 present
in this culture extract with molecular formulae of C10H17N2O7 for the [M+H]+ ion
(calculated m/z = 277.1030, found 277.1030), C10H16N2O7Na for the [M+Na]+ ion
(calculated m/z = 299.0850, found 299.0858), and C5H10NO4 for the [M+H-C5H7NO3]+
fragment ion (calculated m/z = 148.0604, found 148.0602) which were confirmed by
UHR-LC-MS. The presence of a gaburedin containing glutamate may be due to adding
such high concentrations of L-asparagine to the media resulting in the bacteria
producing more L-glutamate via primary metabolism. Indeed, L-asparagine is readily
converted into L-aspartate, which enters the Kreb’s cycle as oxaloacetate, leading to
production of 2-oxoglutarate, which is converted into L-glutamate.176
Upon feeding the gbnR::apra strain with 20 mM L-tyrosine, a new gaburedin 173 was
identified in culture extracts of this sample. As expected for a more polar, less
hydrophobic aminoacyl moiety (tyrosine in place of phenylalanine) gaburedin 173 has
a tR = 11.2 min, which is earlier than gaburedin A 80 (which contains phenylalanine
and elutes at tR = 12.6 min), and 173 has the same characteristic gaburedin
fragmentation pattern (Figure 4.7).
As L-tyrosine has a free hydroxyl group in its side chain, it is possible it might attack
the carbamoyl adenylate 109. However – at physiological pH, the side chain hydroxyl
group would not be deprotonated, therefore would not be as available to act as a good
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nucleophile. Therefore, the only gaburedin expected to be observed is the gaburedin
173 that would arise from attack of the carbamoyl adenylate 109 by the amino NH2
group.
UHR-LC-MS analysis confirmed the molecular formulae of the gaburedin containing
L-tyrosine to be C14H19N2O6 for the [M+H]+ ion (calculated m/z = 311.1238, found
311.1235), C14H18N2O6Na for the [M+Na]+ ion (calculated m/z = 333.1057, found
333.1043), and C9H12NO3 for the [M+H-C5H7NO3]+ fragment ion (calculated m/z =
182.0812, found 182.0806) corresponding to protonated L-tyrosine. (Figure 4.7).
A similar incorporation experiment was also performed using L-histidine at final
concentrations of 1 mM and 10 mM. Analysis of the culture extract revealed that there
was no new gaburedin analogue 174 with the m/z = 285.1 expected for incorporation of
L-histidine, however, the gaburedins 80-85 were still produced. These results are
consistent with the results of feeding experiments with other positively charged amino
acids L-lysine and L-arginine reported in Section 3.4.1.
Figure 4.7 – Extracted ion chromatograms for gaburedins A-F (80-85) m/z = 247.0, 261.0, 279.0, 292.9
and 294.9 (blue traces) and new gaburedin 173 with m/z = 311.0 (red trace) expected for incorporation
of L-tyrosine, and UHR mass spectrum of this new gaburedin 173
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4.2 Incorporation experiments with amino acid analogues
4.2.1 Incorporation of amines
In Section 3.4.2, it was reported that feeding with n-butylamine led to production of a
new gaburedin 156 (shown in Figure 4.8). This observation implies that amines can be
incorporated into gaburedins in place of amino acids, suggesting that the carboxylic
acid group of amino acids is not required for incorporation into the aminoacyl moiety
of gaburedins. This hypothesis was tested further by preparation of SMMS enriched
with the valine analogue isobutylamine and leucine analogue isopentylamine at 1 mM
final concentrations. The gbnR::apra strain was grown on these modified media and
the metabolites were extracted. New compounds with m/z of 202.9/224.9 and
216.9/238.9 were observed, as would be anticipated for [M+H]+ and [M+Na]+ adducts
of gaburedins 175 and 176 containing isobutylamine and isopentylamine. The mass
Figure 4.8 – Mass spectra new gaburedins 156, 175, 176 and 103 containing n-butylamine,
isobutylamine, isopentylamine and cyclohexylamine displaying fragments ions at m/z = 104.0 –
corresponding to GABA – that are common to all four amine-derived gaburedins
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spectra of both these new gaburedins both exhibited fragment ions corresponding to
protonated GABA at m/z = 104.0 (Figure 4.8).
The above observations demonstrate that amines can be incorporated into gaburedins.
This is very interesting as GbnB may have the potential to be used as a bio-catalyst to
quickly create libraries of such molecules if supplemented with a range of suitable
precursor nucleophiles. Therefore, it was hypothesised that a gaburedin analogue 103,
with the same structure as the human epoxide hydrolase inhibitor shown in Figure 2.17
may be produced by the gbnR::apra strain grown on media supplemented with
cyclohexylamine.167
Upon growing the gbnR::apra strain on SMMS enriched with 1 mM cyclohexylamine,
it was observed that the ethyl acetate extract of this culture contained a new compound
103, with m/z = 229.1 and 251.1, consistent with those expected for the [M+H]+ and
[M+Na]+ ions of 4-(3-cyclohexylureido)butanoic acid (Figure 4.8). Molecular formulae
were generated for these ions and confirmed to be C11H21N2O3 for the [M+H]+ ion
(calculated m/z = 229.1547, found 229.1547) and C11H20N2O3Na for the [M+Na]+ ion
(calculated m/z = 251.1366, found 251.1368). As with the gaburedins derived from
amines n-butylamine, isobutylamine and isopentylamine, a fragment ion was observed
at m/z = 104.0, corresponding to protonated GABA (Figure 4.8). The intensity of this
peak was too low for molecular formula to be generated in UHR-MS analysis.
When metabolites extracted from the gbnR::apra cultures grown on media containing
isobutylamine, isopentylamine and cyclohexylamine were resuspended in methanol
instead of acetonitrile, it was also observed that there were new gaburedin-like species
present in the base peak chromatograms corresponding to m/z 217.0 for an
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isobutylamine derivative 177, m/z = 231.0 for an isopentylamine derivative 178 and m/z
= 243.0 for a cyclohexylamine derivative 179, respectively (Figure 4.9). These
metabolites correspond to methylated gaburedins 175, 176 and 103, respectively. As
these compounds were only observed upon resuspension with acidic methanol, it was
concluded that they are artefacts created as a result of using methanol to redissolve
metabolites and acidic methanol as the eluent in LC-MS. These molecules are therefore
not produced during the biosynthesis of gaburedins. They likely arise due to attack of
the carboxylic acid terminus of the GABA moiety by methanol under acidic conditions.
Figure 4.9 – Mass spectra of new gaburedins containing isobutylamine, isopentylamine and
cyclohexylamine (panels a, c and e) and the species corresponding to [M+14]+ ions for additional
metabolites present in the extracts upon feeding with these precursor molecules (panels b, d and f)
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4.2.2 Incorporation experiments with aminoalcohols and aminoacyl esters
To further investigate the diversity of amine derivatives which can be incorporated as
amine/aminoacyl moieties in gaburedin biosynthesis (green in Figure 4.1), the
gbnR::apra strain was grown on SMMS supplemented with aminoalcohols L-
phenylalaninol 180, L-valinol 181 and the aminoacyl ester L-phenylalanine-O-methyl
ester 182 (Figure 4.10). Upon growing the gbnR::apra strain on SMMS supplemented
with 1 mM L-phenylalaninol and L-valinol, new gaburedins 183 and 184 were
Figure 4.10 – Structures of amino acid analogues fed to the gbnR::apra mutant to probe diversity of
aminoacyl compounds with different C-terminal groups which can be incorporated into gaburedins
Figure 4.11 – Extracted ion chromatograms for m/z = 281.0 (upper panel) and 233.0 (lower panel) and
mass spectra of the new gaburedins 183 and 184 that are produced by the gbnR mutant when grown on
SMMS + 1 mM L-phenylalaninol (upper panel) and 1 mM L-valinol (lower panel)
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observed, which have the m/z values expected for [M+H]+ ions of 281.1 and 232.9 as
would be expected for incorporation of L-phenylalaninol and L-valinol, respectively.
Also present were the fragment ions m/z = 151.9 and 104.1 that would be expected for
protonated L-phenylalaninol and L-valinol (Figure 4.11).
When the gbnR::apra strain was grown on SMMS supplemented with L-
phenylalanine-O-methyl ester.HCl (10 mM final concentration), two new gaburedin-
like molecules 185 and 186 were observed (Figure 4.12). Compound 185 has m/z of
309.1 for its [M+H]+ ion, with a mass spectrum containing the expected mass loss of
129 Da to leave a fragment at m/z = 180.1, as would be anticipated for a gaburedin
containing protonated L-phenylalanine-O-methyl ester. A second molecule 186 with
m/z of 309.1 was also observed, however the mass spectrum of this peak featured a
Figure 4.12 – Extracted ion chromatograms for gaburedin A m/z = 294.9 (red trace) and m/z = 309.0
(black trace) expected for incorporation of L-phenylalanine-O-Me ester in the metabolites extracted
after growing the gbnR mutant on SMMS + 10 mM L-phenylalanine-O-methyl ester. Mass spectra of
gaburedins 80, 185 and 186 are also shown
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fragment ion at m/z = 166.1, corresponding to protonated phenylalanine, implying that
the methyl group lost is part of the ureidyl-GABA fragment.
Therefore this experiment was repeated with acetonitrile, there were no metabolites
with m/z = 309.0 present in this culture extract, suggesting that the methyl group of L-
phenylalanine-O-methyl ester is not preserved throughout the biosynthesis of
gaburedins. This result implies that both gaburedins 185 and 186 shown in Figure 4.12
are artefacts of the extraction/analysis process. This would result also account for
overproduction of gaburedin A 80, as there may be an increased intracellular
concentration of L-phenylalanine due to hydrolysis of the L-phenylalanine-O-methyl
ester.178
Figure 4.13 – Extracted ion chromatograms gaburedins A-F (80-85) m/z = 247.0, 261.0, 279.0, 292.9
and 294.9 (blue traces) and m/z = 289.8 (red traces) for L-ala-ala incorporation into a new gaburedin
187 and m/z = 218.8 (black traces) for gaburedin 165 arising from incorporation of L-alanine. Mass
spectra of 165 and 187 also shown, with the molecular and fragment ions for 187 highlighted in red
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4.2.3 Incorporation of a dipeptide
After having established that a variety of amino acids amines can be incorporated into
gaburedins, SMMS enriched with the dipeptide L-ala-ala was prepared. LC-MS
analysis of culture extracts from the gbnR::apra strain grown on 10 mM L-ala-ala
revealed the presence of a new gaburedin-like compound 187 with the expected m/z =
289.9 and a fragment ion at 160.9, consistent with the expected m/z values for
protonated L-ala-ala and also having a mass difference corresponding to the conserved
C5H7NO3 ureidyl-GABA fragment (Figure 4.13). The gaburedin 165 containing an
aminoacyl L-alanine moiety was also observed in this culture extract, implying that
some L-ala-ala was hydrolysed either during autoclaving or by the bacteria.
4.3 Discussion of gaburedin biosynthesis
4.3.1 Effect of altering SMMS composition on production of gaburedins A-F
Thus far, there has been discussion of the new gaburedin-like compounds produced by
the gbnR::apra strain when grown on supplemented SMMS, however details of the
effect of the relative amounts of gaburedins A-F (80-85) produced under these growth
conditions has not been addressed in every case. When the gbnR::apra mutant is grown
on media supplemented with amino acids L-glutamic acid, L-alanine, glycine, L-serine,
L-threonine, L-tyrosine, L-proline, L-asparagine, L-tyrosine, L-ornithine there were
new gaburedins produced in addition to 80-85 produced on unmodified SMMS, with
each of these amino acids being incorporated into the aminoacyl moiety of gaburedins.
New gaburedins produced are summarised in Table 4.1 and Figure 4.14. In other
growth conditions (on SMMS supplemented with 1 mM L-lysine, L-arginine, L-
histidine, L-aspartic acid and L-glutamine), there was no dramatic reduction in the
yields of 80-85, however there were no new gaburedins produced corresponding to
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these amino acids being incorporated. However, it was noted that at 20 mM final
concentration of L-lysine, production of gaburedins 80-85 was dramatically reduced.
In the incorporation experiments with isobutylamine, isopentylamine and
cyclohexylamine, there was reduced production of gaburedins 80-85, even at 1 mM
final concentration of each of these amines. This may be because these amines are more
Table 4.1 – Gaburedins identified and overproduced throughout this study
aminoacyl precursor compound(s)
overproduced
m/z
[M+H]+
m/z
[M+Na]+
m/z [fragment
ion]+
L-phenylalanine 80 295.1298 317.1114 166.0872
D-phenylalanine 95 295.0 317.0 166.1
L-leucine 81 261.1141 283.1260 132.1019
d10-L-leucine d10-81 271.1 293.1 142.0
L-isoleucine 82 261.1440 283.1260 132.1018
d10-L-isoleucine d10-82 271.1 293.1 142.0
L-valine 83 247.1295 269.1114 118.0874
d8-DL-valine d8-DL-83 255.1802 277.1617 126.1372
D-valine 95 247.0 269.0 117.9
L-methionine 84 279.1015 301.0834 150.0591
N-acetyl-L-cysteine 85 293.0809 315.0622 164.0382,
122.0281
L-glutamic acid 106, 107 277.1030 299.0858 148.0602
GABA 107 233.1134 255.0949 104.0714
L-ornithine 130 244.1309 266.1116 115.0873
L-lysine none - - -
L-glutamine none - - -
L-aspartic acid none - - -
L-norvaline 138
n-butylamine 156 202.9 224.9 104.1
methyl 4-aminobutyrate 164 246.9 269.9 117.9
L-alanine 165 219.4 241.2 90.2
L-proline 166 244.9 266.9 -
glycine 167 204.8 226.8 76.2
L-serine 168 235.0928 257.0747 106.0506
L-threonine 169 249.1072 271.0890 120.0651
L-cysteine 85 - - -
L-asparagine 171 262.1030 284.0852 133.0607
L-histidine none - - -
L-tyrosine 173 311.1235 333.1043 182.0806
isobutylamine 175 203.1385 225.1205 104.0
isopentylamine 176 217.1564 239.1387 104.0
cyclohexylamine 103 229.1539 250.9 104.0
L-phenylalaninol 183 281.1 303.1 151.9
L-valinol 184 232.9 255.0 104.1
L-phenylalanine-O-methyl ester 80 - - -
L-ala-ala 187, 165 289.8 311.8 160.9
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nucleophilic than amino acids and will attack carbamoyl adenylate 109 at a faster rate
than the amino acids that attack this intermediate to furnish gaburedins A-F 80-85.
Figure 4.14 – Library of gaburedins produced during this study
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Therefore gaburedins are still being biosynthesised, the native aminoacyl moieties of
gaburedins 80-85 are simply substituted for the amines added to the growth media.
As discussed in Section 2.2.5, these feeding experiments appear to suggest that the
incorporation of phenylalanine, leucine, isoleucine, valine and methionine into the
natural gaburedins 80-84 is perhaps mostly due to the intracellular availability of these
amino acids at the time when the carbamoyl adenylate 109 is produced. Therefore,
upon addition of a large excess of other nucleophiles into the growth media, there is
incorporation of these nucleophiles into gaburedin biosynthesis (assuming that these
nucleophiles are taken up by the cell and the nucleophilic attack of carbamoyl
adenylate 109 occurs intracellularly).
In the cases of L-cysteine, L-phenylalaninol and L-valinol, it would appear that
gaburedin production is in fact abolished as the concentrations of these compounds in
the media are increased to 10 mM. However, addition of 1 mM L-cysteine does not
yield new gaburedins, whereas L-phenyalaninol and L-valinol are both incorporated at
concentrations of 1 mM. Therefore, the observation that production is abolished at high
concentrations could be due to addition of reactive species such as cysteine and
aminoalcohols exerting stress on the cells, resulting in gaburedin biosynthesis being
down-regulated (so none of the amines, aminoalcohols or potential derivatives can be
incorporated into gaburedin production). This hypothesis could be tested by RT-PCR to
monitor gene expression of gbnB in these different growth conditions.
The production of such a diverse range of gaburedins (the six gaburedins produced by
the gbnR::apra mutant on unmodified SMMS, and the nineteen additional ones
produced on SMMS supplemented with different amino acids and amines) provide
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more evidence for the hypothesis that the incorporation of the aminoacyl/amine moiety
of gaburedins is not enzyme-catalysed, as this would require unprecedented substrate
specificity. The presence of such a reactive intermediate (carbamoyl adenylate 109)
could account for the diverse range of nucleophiles being able to be incorporated into
gaburedin biosynthesis, as the O-AMP of 109 is a very good leaving group. Figure 4.15
illustrates a summary of the feeding experiments discussed throughout Chapters 3 and
4 with respect to the substrates that can react with intermediate 109 to furnish the
gaburedin natural products.
4.3.2 The acetylation observation
In the presence of amines isobutylamine, isopentylamine, cyclohexylamine and
aminoalcohols L-phenylalaninol and L-valinol, acetylation of the precursor molecules
fed to the gbnR::apra mutant was observed. This is a well documented phenomenon in
bacteria177 however in this case, the observation that acetylation of amine at
concentrations >10 mM appears to be preferential to the incorporation of these amines
into gaburedins. Conversely, the presence of acetylated phenylalanine is observed in
culture extracts of S. venezuelae in which no gaburedin A (80) is observed (this
Figure 4.15 – Schematic to illustrate the substrate tolerance of GbnAB leading to conserved GABA
moiety (blue) and diversity of different amino acids and amino acid analogues that can be incorporated
into gaburedins in vivo (orange, red and green)
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compound with m/z = 208.0 is observed in wild-type culture extracts in addition to
gbnR::apra culture extracts in which gaburedin production has been abolished, such as
when feeding high concentrations of cysteine or aminoalcohols).
The incorporation of N-acetylcysteine into gaburedins to overproduce gaburedin F (85)
would appear to indicate that N-acetylated amino acids can be incorporated into
gaburedins. However, it is unlikely that the amide nitrogen in N-acetylcysteine would
be nucleophilic enough to attack intermediate 109 to give 85. Alternatively, it is
unlikely that a gaburedin containing cysteine would be acetylated, as this would require
acetylation of a very poorly nucleophilic ureido nitrogen atom (Figure 4.16). One could
therefore argue that the gaburedin 85 requires further analysis in order to confirm its
structure. Indeed, attempts to purify 85 by HPLC have proved unsuccessful so far.
Once purified, a sample of gaburedin F could be treated with Ellman’s reagent which
would react with free thiols, staining yellow.179 If no reaction occurs, this would
indicate that the cysteine in gaburedin 85 is in fact S-acetylated.
Figure 4.16 – Schematic to show incorporation of N-acetyl-L-cysteine into the proposed structure for
gaburedin F (85) either directly or via the cysteine derived gaburedin 170. Both routes would require very
poor nucleophiles attacking either the intermediate 109, or acetylation occurring at the poorly
nucleophilic ureido nitrogen of 170. The possible structure of gaburedin F if derived from S-
acetylcysteine is highlighted
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5. Reconstitution of gbnAB system from Streptomyces
venezuelae
The in vivo feeding experiments discussed in Chapter 3 and 4 only permits an indirect
observation of the biosynthetic pathway to gaburedins in the native host S. venezuelae.
In addition, specific (putative) precursors added to the extracellular medium might not
enter the cell, or might have unexpected effects on global metabolism.
By contrast, in vitro assays studies of the proposed biosynthetic enzymes GbnA and
GbnB would allow more refined structure-activity relationships to be established. In
particular, addition of GABA or GABA derivatives to GbnB could be used to probe
whether N-activated GABA is the true substrate for this enzyme. Such assays would
also allow the diversity of gaburedin analogues to be extended to substrates which
could be toxic to – or metabolised by – the native S. venezuelae host strain.
Furthermore, expression of gbnABC in a heterologous host would allow further insight
into whether gbnABC alone are required for gaburedin biosynthesis. As demonstrated
in Section 3.2.2, gbnB is essential for gaburedin biosynthesis. However, whether or not
gbnA and gbnC are also essential for gaburedin biosynthesis remains to be
demonstrated. By comparison of the metabolites produced by strains carrying gbnA and
gbnB, or gbnA, gbnB and gbnC, the role of gbnC can be deduced. Cloning of individual
– or combinations of – genes into an inducible expression vector in E. coli offers a fast,
convenient method to achieve this, providing that the enzymes are active in this
heterologous host.
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Once it has been determined that heterologous expression of S. venezuelae gbnABC in
E. coli confers the gaburedin-producing chemotype, this approach can be extended to
include some of the other gbnABC systems identified in Section 3.1.1, to determine the
nature of the gaburedin-like natural products produced by these systems. Two of these
gbnABC clusters – one from the Gram-positive Streptococcus mutans GS-5 and one
from the Gram-negative Salmonella enterica – have been selected for this purpose
(Figure 5.1). As a proof-of-concept study, it is important to first reconstitute the
gbnAB(C) system from S. venezuelae to establish if gaburedins can be produced when
gbnAB or gbnABC are overexpressed in E. coli, before extending this approach to
orthologous gbnABC systems.
5.1 Cloning gbnAB (sven_4179 and sven_4180) from S. venezuelae
Initially, primers were designed to amplify the genes gbnA (sven_4179) and gbnB
(sven_4180) separately for cloning into an expression vector, allowing each individual
biosynthetic enzyme to be studied in vitro in order to gain greater insight into the
precise function of each of the putative biosynthetic enzymes GbnA and GbnB.
Figure 5.1 – gbnABC clusters from Streptomyces venezuelae, Salmonella enterica and Streptococcus
mutans GS-5. Only the metabolic products of the gbnABC system in S. venezuelae have been reported
so far
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Different primer pairs were designed in order to amplify the genes gbnA and gbnB for
cloning into pET151, a plasmid in which the inserted gene is under the control of the
T7 promoter, and expression is inducible using IPTG via the lac operon. The T7
promoter in pET151 lies upstream of the lac operator, to which the lac repressor LacI
binds, therefore repressing transcription of the downstream gene(s). The expression of
the downstream gene of interest can be induced by addition of the allolactose analogue
isopropyl β-D-1-thiogalactopyranoside (ITPG), which binds to LacI, causing it to be 
released from its DNA target. This results in expression of the downstream gene of
interest, as the lac operator is no longer being repressed.
Therefore, the gene of interest contained within pET151-derived plasmids can be
overexpressed – leading to overproduction of the desired protein – when the plasmid is
introduced into E. coli BL21star, and IPTG added to the culture broth. E. coli BL21star
is a strain which overproduces the specific T7 polymerase when exposed to IPTG,
Figure 5.2 – Schematic to show the steps in creating pET151-derived plasmids using the gbnA and gbnB
genes from S. venezuelae. Primers were designed to include a 5’-CACC overhang to allow
topoisomerase-directed cloning of gbnA and gbnB into pET151
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therefore allowing overproduction of the T7 polymerase to be coordinated with
derepression of expression of the lac operator in the pET151-derived construct.
The addition of a 5’CACC overhang is required for this cloning, so that the
topoisomerase in the TOPO cloning kit can direct the insertion of the gene into the
correct site in pET151, which has a single stranded overhang corresponding to GTGG-
3’ (Figure 5.2). This sequence is complementary to the 5’–CACC overhang included
upstream of the desired insert, therefore allowing the insert to be incorporated into
pET151 when it is recircularised.
Initial attempts to amplify gbnA using the primers A/A’ and to amplify gbnB using
primers D/D’ (sequences of primers used for TOPO cloning can be found in Section
8.5) were unsuccessful, as no PCR products were formed. The template DNA was
varied (different preparations of SV4 F01 cosmid and a ΔgbnR derivative of SV4 F01
were both used). Some non-specific binding was observed, therefore primer pairs B/B’
and E/E’ were ordered in which the regions overlapping with the 5’ and 3’ ends of each
gene were extended.
The SV4 F01 templates used were therefore re-purified – both by use of a mini-prep kit
and by phenol-chloroform extraction. It was found that efficient recovery of cosmid
could only be achieved if the elution buffer was pre-heated to 60 °C and the DNA pre-
incubated on the centrifuge filter prior to elution. The purified SV4 F01 was then tested
by restriction digest with SacI, and by amplification of the gbnR gene with specific
screening primers F/F’ in Table 8.1.
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More SV4 F01 DNA was prepared, checked by restriction digest for the correct pattern
with SacI, and used as the templates for amplification by PCR using the screening
primers I/I’ for gbnA, and H/H’ for gbnB. Control reactions with the gbnR screening
primers F/F’ were also performed. This time, PCR products were obtained for the
reactions using the F/F’ primer pair for gbnR, and H/H’ pair of gbnB screening primers,
yet no PCR products were obtained for the I/I’ gbnA screening primers.
Shorter gbnA primers were also designed (C/C’) and used for PCRs with the same SV4
F01 template DNA. This time, there were two PCR products (Figure 5.3), one at
approximately 500 bp, and one at approximately 1200 bp. The 1200 bp product was
purified and sent for sequencing with the primers C/C’. The results showed that gbnA
had been amplified, although it would appear that primer C binds approximately 400 bp
downstream of the start codon of gbnA. Attempts were also made to amplify gbnB with
the all combinations of D/D’ and E/E’ primer pairs, with only a weak band at
approximately 1600 bp being amplified. This band was too weak for any DNA to be
recovered after gel extraction.
Figure 5.3 – 1% agarose gel of PCR products obtained for DNA regions amplified using control
screening primers F/F’ specific for gbnR, and TOPO cloning primers C/C’ specific for gbnA. The bands
for the PCR products obtained with primers C/C’ were shorter than expected. Colours have been
inverted for clarity
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5.2 Cloning of synthetic S. venezuelae gbnB gene and orthologues
5.2.1 Synthetic genes for heterologous expression in E. coli
To get optimal chance of gene expression in E. coli, synthetic genes were purchased
from Life Technologies. These genes were based on the native S. venezuelae GbnB, as
well as the GbnB homologues Salmonella enterica SeAg_B2133 and Streptococcus
mutans GS-5 SMUGS5_01685 amino acid sequences. However, these synthetic genes
were codon optimised to reflect E. coli codon usage to improve gene expression and
protein production levels in this heterologous host (sequences of the synthetic genes
can be found in Appendix 3). The genes were synthesised and cloned into the pUC-
derived pMK-RQ vector carrying a kanamycin resistance gene (Figure 5.4).
Specific primers were designed to amplify these E. coli codon optimised versions of S.
venezuelae gbnB (primers J/J’), as well as the gbnB homologues Salmonella enterica
b2133 (primers K/K’) and Streptococcus mutans GS-5 smugs5_01685 (primers L/L’)
from their respective pMK-RQ vectors. As discussed in the previous section, the 5’
CACC overhang required for TOPO cloning were also included in the primers
designed. The PCR products obtained using a high fidelity polymerase were purified
and cloned into pET151. Full experimental details can be found in Section 8.5.
Positive colonies containing the new plasmids pJDS06 (carrying synthetic sven_gbnB),
pJDS02 (carrying synthetic seag_gbnB) and pJDS04 (carrying synthetic smug_gbnB)
after TOPO cloning reaction were identified by selection on ampicillin plates, followed
by restriction digests with NdeI for pJDS06 and pJDS02 and digestion with PstI for
pJDS004 (Figure 5.4). These enzymes were selected as they cut once in the insert and
once in the backbone. Clearly different restriction patterns were therefore expected for
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the empty vector compared that the vectors in which sven_gbnB, seag_gbnB or
smug_gbnB had been inserted. Insertion of the correct DNA sequence into each
plasmid was also checked by PCR amplification of the gene of interest using the primer
pairs J/J’, K/K’ and L/L’ for pJDS06, pJDS02 and pJDS04, respectively.
Plasmids that gave both PCR products of the expected sizes and restriction digest
patterns consistent with the insertion of the genes of interest were sent for sequencing
by GATC Biotech, with amplification using the T7 primer pair (see Section 8.5).
Sequencing data confirmed that pJDS06, pJDS02 and pJDS04 contained the intact
sequences of synthetic sven_gbnB, seag_gbnB and smug_gbnB, respectively.
Figure 5.4 – Diagram to illustrate TOPO cloning of synthetic S. venezuelae gbnB, Salmonella enterica
seag_b2133 and Streptococcus mutans GS-5 smugs5_01685 into pET151. Restriction digests using the
enzymes NdeI and PstI were used to confirm the nature of plasmids pJDS06 and pJDS02 and pJDS04,
respectively. These plasmids were also analysed by PCR using primer pairs J/J’, K/K’ and L/L’ and the
inserted genes were sequenced using the T7 primer pair
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5.2.2 Metabolic profiling of engineered E. coli strains carrying gbnB and orthologues
The effect of introduction of gbnB and gbnB-related genes on the metabolite profiles of
E. coli were investigated. All three E. coli BL21star strains carrying the plasmids
pJDS02, pJDS04 and pJDS06 containing synthetic gbnB gene and orthologues were
grown in 50 mL LB containing 10 mM GABA (the proposed precursor for GbnB) and
gene expression was induced with IPTG. Cells were pelleted and ethyl acetate extracts
of the culture supernatants were prepared.
If the biosynthetic pathway to gaburedins presented in Scheme 3.2 is correct, and if
GbnB is functional in the heterologous host E. coli, it is possible that GbnB could turn
over GABA (or its derivative) and produce gaburedins, yet they may not be exported
because GbnC is not present in E. coli. Therefore, cells were lysed and ethyl acetate
Figure 5.5 – Metabolites extracted from culture supernatants of E. coli/pJDS02, pJDS04 and pJDS06
grown in LB supplemented with 10 mM GABA. Base peak chromatograms (red traces) and extracted ion
chromatograms for gaburedins A-F (80-85) (m/z = 247.0, 261.0, 279.0, 292.9 and 294.9) are also shown
(black traces). The large peak at t = 14.0 min has m/z = 261.0, but is unrelated to gaburedins
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extracts of the cell lysates were also performed.
As shown in Figure 5.5, no new metabolites were produced by E. coli carrying pJDS02,
pJDS04 or pJDS06 upon induction with IPTG, indicating that if GbnB (and
orthologues) are functional, no gaburedins are produced upon feeding E. coli BL21star
carrying plasmids pJDS02, pJDS04 or pJDS06 with GABA. Cell permeability to
GABA may be a problem, also the activation of the amino group of GABA that is
predicted to produce the substrate for GbnB may not be occur without GbnA, or
spontaneous reaction of GABA with CO2 may not occur in E. coli. It is therefore
possible that both GbnA and GbnB are required to form a soluble/functional enzyme
complex.
5.2.3 Overproduction of recombinant enzymes in E. coli BL21star
LB cultures of E. coli BL21star carrying each of the plasmids pJDS002, pJDS04 and
pJDS06 were prepared and gene expression induced with IPTG as described in Section
8.3.13. In parallel, control experiments without IPTG induction were performed with
all three strains.
After growing for 16 h at 15 °C, cells were pelleted and lysed. SDS-PAGE gels were
run of soluble and insoluble protein fractions, suggesting that all three GbnB and
GbnB-like proteins were present in the insoluble fractions. For example, a band was
expected at 60.2 kDa for the protein SeAg_B2133 overproduced by overexpression of
seag_b2133 in pJDS02. Indeed, a band at approximately 60 kDa was observed in the
insoluble fraction, but not in the soluble fraction (Figure 5.6).
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The observation that all three proteins were insoluble therefore reduces the possibility
of developing an in vitro assay to prove their substrate specificity. However, GbnB
being insoluble in E. coli does not necessarily mean that it is not functional in this host.
The lack of gaburedins being produced may be due to the other enzymes GbnA and
GbnC being absent in this host. Indeed, as shown in Section 3.1.1, several of the GbnB
and GbnC orthologues appear to be encoded for by a single gene, suggesting that GbnB
and GbnC may function as a complex in the organisms in which GbnB and GbnC are
encoded by discreet genes. Therefore, future attempts at reconstituting the GbnABC
biosynthetic pathway focussed on construction of expression vectors to try and
incorporate both biosynthetic genes gbnA and gbnB, and on attempts to incorporate all
three genes gbnA, gbnB and gbnC into a single expression system.
Figure 5.6 – 10% SDS-PAGE gels to show comparison of soluble and insoluble proteins extracted from
E. coli/pJDS02 carrying synthetic seag_gbnB. The only lane with an intense band for a protein of the
expected mass of 60.2 kDa is the lane loaded with the insoluble protein fraction
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5.3 Alternative cloning strategies for reconstitution of gbnABC in E. coli
5.3.1 Sub-cloning synthetic gbnA into pJDS06 and synthetic gbnB into pJDS05
As GbnB enzymes from Streptomyces venezuelae, Salmonella enterica and
Streptococcus mutans all appear to be insoluble, attempts were made to create a vector
which could be used for protein overproduction of synthetic S. venezuelae GbnA and
GbnB together. This was attempted with the S. venezuelae system in order to first
verify whether or not overexpression of both GbnA and GbnB together would lead to
the gaburedin-producing chemotype. If this proved to be the case, then this approach
could be expanded to include the GbnAB systems from Salmonella and Streptococcus,
in order to determine the metabolic products of the orthologous GbnAB enzymes in
those organisms.
Initially, a pET151 derived plasmid containing synthetic S. venezuelae gbnA
(sven_4179) was constructed. Primers M/M’ were used to amplify synthetic gbnA from
a pMK-RQ template (as in Section 5.2.1, the sequence of this synthetic gene was based
on the protein sequence of S. venezuelae GbnA but with codons altered to reflect codon
usage in E. coli, see Appendix 3). The plasmid pJDS05 purified from ampicillin
resistant colonies was verified as having the correct gene sequence inserted by
restriction digests with SphI, amplification of the gene of interest by PCR using primers
M/M’ and by sequencing of the DNA region of interest with the T7 primer pair.
After sequence verification, the plasmids pJDS05 and pJDS06 were each digested
using SacI in order to create linearised vectors into which synthetic gbnA synthetic
gbnB could be sub-cloned. Therefore, new primer pairs N/N’ and O/O’ were designed
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in which the synthetic versions of gbnA and gbnB would be flanked by the SacI
restriction site (Figure 5.7).
PCR products were obtained using these primer pairs and purified. Single stranded
overhangs were then produced by digestion with SacI. Digested synthetic gbnA,
synthetic gbnB, pJDS05 and pJDS06 were all purified by gel extraction, and then
attempts were made to ligate synthetic gbnA with digested pJDS06 (carrying synthetic
gbnB) and also to ligate synthetic gbnB with digested pJDS05 (carrying synthetic
gbnA). Table 8.3 illustrates the various ligation conditions attempted.
Transformation of E. coli TOP10 with the ligation mixtures did result in colonies on
ampicillin selection plates. However, upon digestion of the plasmids purified form
Figure 5.7 – Schematic of the strategy used to sub-clone synthetic gbnA into pJDS06 carrying synthetic
gbnB and sub-cloning of synthetic gbnB into pJDS05 carrying synthetic gbnA
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these colonies with NdeI, and analysis of the resulting DNA fragments on an agarose
gel, the pattern of bands observed was consistent with empty pJDS05 and pJDS06
vectors. In other cases, the plasmid appears to have rearranged into a much shorter one,
but retained the ampicillin resistance gene (Figure 5.8).
In two of the purified plasmids for gbnB ligated with pJDS05, there was a band at
approximately 2700 bp upon digestion with NdeI (if gbnB had been successfully
inserted in pJDS05, then digestion with NdeI would be expected to give four bands at
5789 bp, 2699 bp, 295 bp and 270 bp) but only very faint bands around 300 bp.
Therefore, sequencing data for the DNA region of interest was obtained using both the
T7 primer pair, and the primer pair O/O’. However, the resulting data showed that the
primers bound non-specifically to the plasmid, implying the insert was not correct. The
primer pair O/O’ were also used in PCRs with the same plasmids, but no PCR products
were obtained. Together, both these results implied that the insertion of gbnB into
pJDS05 was unsuccessful.
Figure 5.8 – Agarose gel of NdeI restriction digests of plasmids after ligations to introduce gbnB into
pJDS05. Lanes giving examples of the different outcomes of the ligations are annotated
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5.3.2 Cloning with pET-Duet and pACYC-Duet vectors
One alternative set of vectors which could be used for co-expression of gbnA, gbnB and
gbnC are the Duet cloning vectors available from Novagen, for example pET-Duet and
pACYC-Duet, which can each be used to co-express two genes.180 Both pET-Duet and
pACYC-Duet contain two multiple cloning sites (MCSs), one of which can include an
N-terminal polyhistidine tag, and the other which can incorporate an S-tag into the N-
terminus of the other protein of interest (Figure 5.9 and Appendix 4).
These tags allow purification of the overproduced proteins either by nickel affinity
chromatography in the case of the polyhistidine tag, or by recognition with specific
antibodies in the case of the S-tag. Each vector has a different origin of replication
(pBR322 in pET-Duet and P15A in pACYC-Duet) making them compatible; these
plasmids will be maintained in E. coli co-transformed with both of them. The vectors
pET-Duet and pACYC-Duet can therefore be used to co-express up to four target genes
of interest. As with pET151-derived constructs, gene expression in pET-Duet and
pACYC-Duet can be induced upon addition of IPTG.
Figure 5.9 – Vectors pET-Duet and pACYC-Duet used for cloning of synthetic S. venezuelae gbnA, gbnB
and gbnC
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Specific primers P/P’ were designed to include restriction sites BamHI and HindIII for
cloning of synthetic gbnA into MCS 1 of pET-Duet. This primer pair was used to
amplify gbnA by PCR using the pMK-RQ+sven_gbnA plasmid (Figure 5.10). As the
multiple cloning sites lie downstream of the ATG start codon in pET-Duet, extra
nucleotides were added to ensure that the insert was in frame in the destination vector.
The purified gbnA PCR product and pET-Duet were both digested with BamHI and
HindIII, and ligated together using T4 ligase. The ligation products were used to
transform E. coli TOP10. Plasmids were extracted from ampicillin-resistant colonies
and verified as having the correct insert by digestion with PstI and PCR using the
primer pair P/P’. Plasmids that had the correct PCR product size and restriction digest
pattern had their multiple cloning sites sequenced using the primers ‘pETup’/‘T7_rev’
to confirm that pJDS09 had been produced (Figure 5.10 and Section 8.5).
For the subsequent cloning of synthetic gbnB into MCS 2 of pET-Duet, synthetic gbnB
was amplified from pMK-RQ using specific primers Q/Q’ to introduce FseI and KpnI
restriction sites at the 5’ and 3’ ends of synthetic gbnB, respectively. This PCR product
and pJDS09 were both digested with FseI and KpnI prior to ligation, and the ligated
products were used to transform E. coli TOP10.
Plasmids were extracted from positive colonies and verified as having the correct insert
by digestion with HindIII and PCRs were attempted with primers ‘UP2’/‘T7term’. No
PCR products were obtained using this primer pair; however some plasmids did exhibit
the expected DNA fragment band pattern upon digestion with HindIII. These MCS2 of
these plasmids were sequenced using the primer pair ‘UP2’/‘T7term’, confirming that
pJDS10 had been created successfully.
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Synthetic gbnC was amplified from a pMA-T template carrying the E. coli codon
optimised S. venezuelae gbnC (sven_4181) using primers R/R’ to introduce BamHI and
HindIII sites into the PCR product. This product and pACYC-Duet were then digested
using BamHI and HindIII and were ligated together to create pJDS11. Plasmids from
positive colonies were digested with AccI to identify plasmids with the correct insert.
These plasmids were verified by sequencing of the MCSs using primer pair
‘pACYCup’/‘T7_term’.
Figure 5.10 – Cloning strategy used to generate plasmids pJDS09-pJDS11 containing synthetic S.
venezuelae gbnA, gbnB and gbnC. Step (i) – amplification of each gene of interest by PCR; step (ii) –
digestion using specifically selected restriction enzymes to leave appropriate overhangs; step (iii) –
ligation of DNA fragments with complementary overhangs
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5.3.3 Metabolic profiling of E.coli carrying pET/pACYC-Duet derived plasmids
Attempts were made to co-transform E. coli BL21star using pJDS10 (carrying synthetic
S. venezuelae gbnA and gbnB) and pJDS11 (carrying synthetic S. venezuelae gbnC) in
order to create a strain which could overexpress gbnA, gbnB and gbnC. Therefore, in
this strain, all three proteins GbnA, GbnB and GbnC would be overproduced. It was
hypothesised that there may be gaburedin-like metabolites produced by this strain, as
overproduction of GbnC would circumvent the potential problem of gaburedins being
unable to cross the cell membrane without GbnC. However, neither chemical
transformation nor transformation of E. coli BL21star by electroporation using both
plasmids pJDS10 and pJDS11 were successful during the timeframe of this project.
Attempts to transform E. coli BL21star using just pJDS10 were successful, however.
Figure 5.11 – Base peak chromatograms (pink traces) and extracted ion chromatograms for gaburedins
A-F (80-85) m/z = 247.0, 261.0, 279.0, 292.9, 294.9 (blue traces) of metabolites extracted from culture
supernatants of E. coli BL21star/pJDS10 grown without IPTG and with 1 mM IPTG in LB with and
without addition of 1 mM L-glutamic acid
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Plasmid pJDS10 was used to transform E. coli BL21star, and this culture was grown in
LB to an OD600nm of 0.6, at which time protein expression was induced with IPTG. In
parallel, cultures without IPTG added were also grown. Cells were pelleted and ethyl
acetate extracts of the culture supernatants were prepared. As shown in Figure 5.11,
there were some new metabolites produced by E. coli BL21star/pJDS10 induced with
IPTG compared to E. coli BL21star/pJDS10 grown without any induction using IPTG.
However, these compounds exhibit a predominant ion with m/z = 303 in their mass
spectra, corresponding to acetylated derivative of IPTG, which has been previously
reported.181 Indeed, there were no gaburedins or gaburedin-like compounds produced.
Therefore, cells were lysed and ethyl acetate extracts of the cell lysates were also
performed, however there were still no gaburedin-like metabolites observed in the LC-
MS chromatograms of the extracts from the cell lysates.
To account for concentration of L-glutamic acid in the LB media being a limiting factor
in gaburedin biosynthesis (for example, if there was an insufficient quantity available to
be utilised by GbnA), this experiment was repeated. The E. coli BL21star/pJDS10
strain was grown in media enriched with 1 mM L-glutamic acid, as this would increase
the availability of the proposed GbnA substrate L-glutamate. Again, LC-MS analysis of
the extracted metabolites revealed that the only new metabolites produced were IPTG-
derived compounds (Figure 5.11).
It is possible that the lack of gaburedin-like metabolites present in these samples is due
to poor production levels of the GbnA and GbnB proteins. Therefore, protein samples
were run to compare the soluble and insoluble fractions of E. coli BL21star/pJDS10
with and without induction using IPTG. However, there were no obvious differences
between the protein fractions extracted from the E. coli BL21star/pJDS10 which were
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induced with IPTG compared to the metabolites extracted from the sample which was
not induced with IPTG (it would be expected that bands at 60.1 kDa and 58.7 kDa
would be present for recombinant GbnA and GbnB, respectively), indicating that the
protocol for co-expression of gbnA and gbnB requires optimisation.
5.4 – Summary of molecular biology work
Analysis of the SV4 F01 cosmid sequence showed there to be an unusually large
intergenic region of 1024 bp between the gbnA gene (sven_4179) and the adjacent,
divergent gene sven_4178. This could imply that there were mistakes in the sequencing
of this part of the S. venezuelae genome; therefore the primers may have been designed
using incorrect sequences based upon this sequencing data. Indeed, this is true for many
examples of sequencing data being used to order synthetic versions of native genes.
Therefore, it would perhaps be prudent in future to re-sequence the entire SV4 F01
cosmid. However, the remaining genes in the gbn-sgn cluster have all been amplified
by PCR from the SV4 F01 template.
It would appear that – despite development of several distinct molecular biology
strategies for producing vectors which carry multiple synthetic genes from the gbnABC
system – none of the plasmids constructed confer the gaburedin-producing chemotype.
The sequences of all genes inserted into the plasmids pJDS02, pJDS04, pJDS06 and
pJDS09-pJDS11 have been verified; therefore future work should be focussed on
optimisation of co-expression of the genes in the plasmids pJDS10 and pJDS11 in E.
coli BL21star.
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It may be possible that E. coli BL21star can confer the gaburedin-producing chemotype
when transformed using combination of plasmids constructed during this study. For
example, both plasmids pJDS06 (carrying synthetic sven_gbnB) and pJDS11 (carrying
synthetic sven_gbnC) could be used to co-transform the same E. coli BL21star,
allowing gbnB and gbnC to be overexpressed in the same cells. The feeding
experiments with GABA in Section 5.2.2 with E. coli/pJDS06 only could be then
repeated, in order to definitively confirm whether or not gaburedins are produced by
this strain when the export protein GbnC is present. This would allow the role of GbnC
in the export of gaburedins to be ascertained.
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6. Regulation of gaburedin biosynthesis in S. venezuelae
In S. coelicolor, deletion of the transcriptional repressor gene mmyR leads to
overproduction of not only methylenomycin, but AHFCA signalling molecules as
well.100 This led to the hypothesis that identification and subsequent deletion of mmyR
homologues in other bacteria (such as gbnR in S. venezuelae) where the mmfLHP,
mmfR and mmyR set of genes is conserved would turn on the production of both new
natural products (as in the case of gaburedins) and turn on production of the AHFCA
signalling molecules predicted to be produced by the MmfLHP analogues SgnLPH
(Figure 6.1).
An induction assay has already been developed for the methylenomycin system,
whereby specific AHFCA signalling molecules were shown to restore the antibiotic
activity of a strain lacking mmfLHP. An analogous induction assay could potentially be
developed to assess if AHFCAs can induce gaburedin production in S. venezuelae. As
Figure 6.1 – Schematic to demonstrate phenotype of S. coelicolor mmyR deletion mutant and proposed
phenotype of S. venezuelae gbnR deletion mutant. Repressor binding sites (AREs) shown in pink. Sizes
of genes not to scale
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the function of gaburedins has not yet been established, an LC-MS assay rather than an
activity-based assay could be developed.
The key biosynthetic enzyme (the butenolide synthase) involved in AHFCA
biosynthesis in S. coelicolor, MmfL, has homologues not only in homologous gene
clusters that contain mmfP and mmfH, but also in gene clusters involved in the
biosynthesis of GBL signalling molecules (there is a shared intermediate in the
proposed biosynthesis of furan and butyrolactone signalling molecules, Scheme
6.1).79,109
Scheme 6.1– GBL and AHFCA biosynthesis proceed via a shared butenolide phosphate intermediate.
The downstream enzymes (for example MmfH, MmfP) determine the nature of the final signalling
molecules produced
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In Streptomyces venezuelae, there are three homologues of mmfL; sven_4183 (sgnL in
the gaburedin cluster, 33 % identity, 44 % similarity at amino acid level), sven_5093
(29 % identity, 38 % similarity at amino acid level) and sven_5969 (jadW1 in the
jadomycin gene cluster, 30 % identity, 43 % similarity at amino acid level). The jadW1
gene is involved in GBL biosynthesis in the regulation of jadomycin (See Section
1.4).95 Therefore, if sgnL is overexpressed (as expected if the transcriptional repressor
gene gbnR is deleted), it is possible that an accumulation of the intermediate
butenolides produced by SgnL could lead to production of both AHFCAs and GBLs
(Scheme 6.1). Indeed, some crosstalk between pathways including afsA homologues
has been implied in jadomycin biosynthesis (in order to abolish jadomycin production
in a jadW1 mutant, it was necessary to also delete sven_5093, yet deletion of sgnL did
not affect jadomycin production). Therefore, crosstalk between the afsA-like pathways
cannot be excluded.95
GBLs and AHFCAs have both been extensively studied by LC-MS. The base peak in
electrospray MS of GBLs is the [M+Na]+; the base peak for AHFCAs is the [M-
H2O+H]+.140,182 Furthermore, mass spectra of GBLs also exhibit peaks for [M-H2O+H]+
and [M-2H2O+H]+ ions, whereas the next most intense peak for AHFCAs corresponds
Figure 6.2 – UHR-MS data for SCB1 (36, top panel) and AHFCA5 (53, bottom panel) illustrating the
typical mass spectra of 6-hydroxy GBLs and AHFCAs observed in electrospray MS in positive ion
mode
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to the [M+Na]+ ion, only a very small peak for the [M+H]+ ion is observed. Figure 6.2
shows example mass spectra of SCB1 (36) and AHFCA5 (53).
6.1 Identification and characterisation of Streptomyces venezuelae signalling
molecules
6.1.1 Metabolic profiling of S. venezuelae mutants
It was noted during initial LC-MS analysis of the culture extracts of the S. venezuelae
wild type, sgnL::apra, gbnR::apra and gbnB::apra,gbnR::scar mutants, that there was
another series of compounds produced by the gbnR::apra mutant strains that were not
produced by the wild type and sgnL::apra strains (Figure 2.1). These metabolites have
[M+Na]+ ions in their mass spectra with m/z = 253.0, 267.0 and 281.0.
Extracted ion chromatograms were produced for the [M+Na]+ species expected for the
known GBLs of both the 6-keto and 6-hydroxy types for the metabolites produced by
the gbnR mutant strain. These analyses revealed that five molecules 188-192 share a
similar fragmentation pattern to that observed for 6-hydroxy type GBLs.183 The mass
spectra of each of these molecules consists of a series of peaks corresponding to the
[M+Na]+ and [M+H]+ molecular ions, accompanied by [M-H2O+H]+ and [M-
2H2O+H]+ fragment ions (Figure 6.3). The molecular formulae of these ions were
confirmed by UHR-MS analyses, confirming there to be one GBL-like molecule 188
with formula C11H20O4, two with formulae of C12H22O4 (189 and 190) one with
formula of C13H24O4 (191) and one with formula C14H26O4 (192, Figure 6.3).
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6.1.2 Comparison of putative signalling molecules with Streptomyces M1152
In order to characterise S. venezuelae signalling molecules, the LC-MS chromatograms
of the gbnB/R strain were compared with culture extract from Streptomyces M1152.
Streptomyces M1152 is a ‘super-host’ which has been engineered to have the
actinorhodin (act), prodiginine (red), calcium-dependent antibiotic (cda) and
coelimycin (cpk) gene clusters removed.81 This results in a very clean base-peak
chromatogram upon LC-MS analysis culture extracts, due to there being far fewer
secondary metabolite compounds in the chromatogram background.
The gene scbR2 (sco_6286) – encoding for a transcriptional regulator which is thought
to regulate SCB biosynthesis – is not present in the M1152 host, whereas the
Figure 6.3 – Extracted ion chromatograms for [M+Na]+ ions of 6-hydroxy type GBLs m/z = 239.0,
253.0, 267.0 and 281.0 observed in metabolites extracted from S. venezuelae gbnR mutants. Mass
spectra of these GBL-like molecules are also shown with the molecular formulae generated for the
[M+Na]+, [M+H]+ and [M-H2O+H]+ ions
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biosynthetic genes involved in SCB biosynthesis scbA (sco_6266), scbB (sco_6267)
and sco_6264 remain.81 This was expected to lead to overproduction of SCBs in
M1152, as an scbR2 deletion mutant of the parent strain S. coelicolor M145 was
previously shown to overexpress scbA, and to overproduce SCB1 (36).149
Hence, extracted ion chromatograms were generated for m/z = 239.0, 253.0, 267.0, and
281.0, corresponding to [M+Na]+ ions for SCB-like GBLs in Streptomyces coelicolor
M1152 culture extract, and metabolites 193-200 were identified (Figure 6.4). As
expected, several of these metabolites 197-200 elute at the approximate retention times
and have fragmentation patterns that would be consistent with SCBs 1-3. The
butenolide synthase scbA is the only afsA homologue in M1152 and is presumably
responsible for the assembly of the GBL-like molecules 193-200 observed in M1152.
As M1152 also has intact scbB and sco_6264 genes (which are proposed to catalyse the
downstream steps to furnish SCBs from the butenolide phosphate intermediate, see
Figure 1.18), therefore the stereochemistry of these GBLs is presumably the same as
the stereochemistry of the SCBs 1-3 (2R, 3R, 6S).81,132,138 However, the stereochemistry
could be confirmed by purification of the compounds and subsequent analysis by CD
and NMR spectroscopy.95,183 Alternatively, chiral HPLC of the culture extract could be
performed, with co-injection of an authentic standard of SCBs.137
Comparison of culture extracts of the S. venezuelae gbnB/R strain and Streptomyces
M1152 strains revealed that several of the compounds 193-200 were also present at the
same retention times in the culture extract of the S. venezuelae gbnB/R strain;
compounds 188 and 193 elute at the same time (19.9 min), 189 and 195 both elute at
21.8 min, 190 and 196 elute at 22.2 min, 191 and 197 elute at 23.7 min and compounds
192 and 199 both elute at 25.0 min (Figure 6.4). If the stereochemistry of the GBLs
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produced by S. venezuelae was different to that of the GBLs extracted from S.
coelicolor M1152, one would expect the GBLs derived from the same precursor
molecules to have different retention times in an achiral column – if the
stereochemistry was different at one or two out of the three stereocentres then the
compounds would be diastereoisomers and would elute at different retention times.137
6.1.3 Characterisation of novel SCBs in S. coelicolor M1152
After initial identification of the eight GBL-like molecules in Streptomyces M1152,
experiments were devised in order to solve their structures. GBLs comprise a conserved
butyrolactone moiety with varying length and branching in the alkyl chain (see Section
1.5). As these are derived from fatty acid biosynthesis, there are specific precursor
molecules (amino acids and carboxylic acids) which are used as starter units in fatty
acid biosynthesis, which are subsequently incorporated into the butenolide
intermediates and ultimately found in SCBs. Scheme 6.2 illustrates ten possible
Figure 6.4 – Top: genetic organisation of the scb-cpk gene cluster as modified in S. coelicolor M1152.
The gene encoding for the transcriptional repressor protein scbR2 has been removed. Bottom: Extracted
ion chromatograms for [M+Na]+ ions m/z = 239.0, 253.0, 267.0 and 281.0 of 6-hydroxy type
butyrolactones in the metabolites extracted from S. coelicolor M1152 and S. venezuelae gbnB/R.
Compound denoted by * has m/z = 267.0 but is not related to GBLs
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structures of SCBs that would derive from five different starter units in fatty acid
metabolism and would give rise to the [M+Na]+ ions with m/z = 239, 252, 267 and 281
shown in Figure 6.4.
As discussed in Section 1.5, the amino acids valine, leucine and isoleucine lose their α-
hydrogens as they are converted into their cognate α-keto acids, which are then 
transformed into starter units isobutyryl-CoA, 3-methylbutyryl-CoA and 2-
methylbutyryl-CoA for fatty acid biosynthesis (Scheme 1.4).135,136 Therefore, it is
Scheme 6.2 – Biosynthetic route to SCBs which would give rise to [M+Na]+ ions with m/z = 239.0,
253.0, 267.0 and 281.0. The number of chain extensions in fatty acid biosynthesis is also shown
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expected that any SCBs derived from these amino acids would retain 7 deuterium
labels for those derived from d8-valine, and 9 deuterium labels from d10-leucine or d10-
isoleucine. SCBs that were derived from propionic and butyric acid would be expected
to retain 5 and 7 deuterium labels, respectively. As the deuterium labels added form
part of the alkyl chain of the SCBs, it was expected that labelling would be observed in
the [M-H2O+H]+ and [M-2H2O+H]+ fragment ions as well as the [M+H]+ and [M+Na]+
molecular ions for each labelled SCB.
Therefore, Streptomyces M1152 was grown in AlaMM media supplemented with 1
mM final concentration deuterium-labelled fatty acid precursor molecules d8-DL-
valine, d10-L-leucine, d10-L-isoleucine, d5-propionic acid and d7-butyric acid. This
method was used previously to probe incorporation of specific deuterium-labelled
precursor molecules into the AHFCAs.79,140 The metabolites were extracted and
analysed by UHR-LC-MS. As expected, feeding with each different precursor molecule
altered the mass spectra of specific SCBs.
For instance by feeding with d8-DL-valine, a proportion of the compound 197 (SCB1)
with retention time 16.4 min and [M+Na]+ m/z = 267.2 was specifically labelled with 7
deuterium labels (Figure 6.5), and the m/z for all peaks for the [M+H]+ molecular ion
and [M-H2O+H]+ and [M-2H2O+H]+ fragment ions also increased by 7. This confirms
that this SCB is derived from valine, therefore it was proposed that 197 is SCB1
(compound 36). No labelling was observed for any of the other SCBs in the
Streptomyces M1152 culture extract, implying that SCB1 is the only SCB directly
derived from valine.
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Extracted ion chromatograms were generated for the [M+Na]+ ions expected for the
remaining SCBs identified, and for the m/z of ions that would be expected if any of
these species were labelled with deuterium from each precursor fed. As shown in
Figure 6.5, compound 198 (tR = 16.5 min) incorporated 7 deuterium labels upon
feeding with d7-butyric acid, suggesting that 198 has the same structure as SCB2 (37).
Compound 199 (tR = 17.3 min) was enriched with 9 deuterium labels upon feeding with
d10-isoleucine, consistent with the known structure of SCB3 (38). Molecular formulae
generated from UHR-LC-MS analyses of these labelled and unlabelled compounds
197-199 are shown in Table 6.1.
Figure 6.5 – UHR-MS of 197-199 extracted from S. coelicolor M1152 grown on different AlaMM
media. From top to bottom: 197 without any labelling, 197 labelled upon feeding with d8-DL-valine,
198 without any labelling, 198 labelled upon feeding with d7-butyric acid, 199 without any labelling,
and 199 labelled upon feeding with d10-isoleucine
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Furthermore, feeding with d10-isolecuine resulted in specific labelling of compound 194
(tR = 15.2 min). Metabolites 195 (tR = 15.3 min) and 196 (tR = 15.5 min) were found to
specifically incorporate nine deuterium atoms from d10-leucine and five deuterium
atoms from d5-propionic acid, respectively. Metabolite 200 (tR = 17.5 min) was labelled
specifically upon addition of d5-propionic acid and 193 (tR = 14.3 min) was labelled
specifically upon addition of d7-butyric acid to the media. It was therefore proposed
that compounds 193, 194, 195, 196 and 200 have structures corresponding to the novel
SCBs 8, 4, 5, 6 and 7 respectively (Scheme 6.2). The results of the labelling
experiments are summarised in Figure 6.6 and Table 6.1. By comparison of the
retention times of the GBLs produced by the S. venezuelae gbnB/R strains with those
Table 6.1 – UHR-MS of [M+Na]+ ions of SCBs 1-8 identified in culture extract of S. coelicolor
M1152 grown on AlaMM media supplemented with different stable isotope precursor molecules.
Full UHR-MS characterisation shown in Appendix 5
retention
time /
min
compound precursor fed Molecular
formula
Observed
m/z
Calculated
m/z
14.3 SCB8 (193) none C11H20NaO4 239.1258 239.1254
14.3 d7-SCB8 (193) d7-butyric acid C11H13D7NaO4 246.1705 246.1693
15.2 SCB4 (194) none C12H22NaO4 253.1421 253.1410
15.2 d9-SCB4 (194) d10-L-isoleucine C12H13D9NaO4 262.1991 262.1975
15.3 SCB5 (195) none C12H22NaO4 253.1421 253.1410
15.3 d9-SCB5 (195) d10-L-leucine C12H13D9NaO4 262.1982 262.1975
15.5 SCB6 (196) none C12H22NaO4 253.1418 253.1410
15.5 d5-SCB6 (196) d5-propionic acid C12H17D5NaO4 258.1726 258.1724
16.4 SCB1 (197) none C13H24NaO4 267.1571 267.1567
16.4 d7-SCB1 (197) d8-DL-val C13H17D7NaO4 274.2022 274.2006
16.5 SCB2 (198) none C13H24NaO4 267.1579 267.1567
16.5 d7-SCB2 (198) d7-butyric acid C13H17D7NaO4 274.2021 274.2006
17.3 SCB3 (199) none C14H26NaO4 281.1729 281.1723
17.3 d9-SCB3 (199) d10-L-isoleucine C14H17D9NaO4 290.2298 290.2288
17.5 SCB7 (200) none C14H26NaO 4 281.1731 281.1723
17.5 d5-SCB7 (200) d5-propionic acid C14H21D5NaO4 286.2045 286.2037
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produced by M1152, it was deduced that SCB1 (191), SCB3 (192), SCB5 (189), SCB6
(190) and SCB8 (188) are also produced by S. venezuelae (Figure 6.4 and Scheme 6.2).
Figure 6.6 – UHR-MS of metabolites 193, 194, 195, 196 and 200 extracted from S. coelicolor M1152
grown on different AlaMM media. 193 was labelled with 7 deuteriums from incorporation of d7-butyric
acid; 194 was labelled with 9 deuteriums from incorporation of d10-isoleucine; 195 was labelled with 9
labels from incorporation of d10-leucine; 196 was labelled with 5 labels from incorporation of d5-
propionic acid; and 200 was labelled with 7 deuterium labels from incorporation of d7-butyric acid
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6.1.4 AHFCA signalling molecules in Streptomyces venezuelae
In addition to the observation of SCBs being present in the S. venezuelae gbnR and S.
venezuelae gbnB/R mutant extracts, closer inspection of the LC-MS data for revealed
the presence of new metabolites 201–204, corresponding to the m/z values consistent
with [M-H2O+H]+ ions of AHFCA or AHFCA-like molecules. Mass spectra of each of
these metabolites illustrated that the two most intense peaks correspond to [M+Na]+
and [M-H2O+H]+ ions.
Therefore, extracted ion chromatograms were generated for the m/z values
corresponding to the [M-H2O+H]+ peaks for the previously characterised AHFCA2
(m/z = 167.0), AHFCAs 1 and 4 (m/z = 181.0) and AHFCAs 3 and 5 (m/z = 195.0).79
Extracted ion chromatograms were also generated for ions with m/z = 209.0, 223.0 and
Figure 6.7 – Extracted ion chromatograms for [M-H2O+H]+ ions of AHFCA species present in the
metabolites extracted from the S. venezuelae gbnB/gbnR, gbnR, sgnL and wild type. Chromatograms
correspond to m/z = 195.0 (blue traces), 209.0 (black traces) and 223.0 (red traces). Peaks denoted by *
are unrelated to AHFCA compounds. EICs for m/z = 167.0, 181.0 and 237.0 have been omitted for
clarity
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237.0 that would correspond to [M-H2O+H]+ ions of AHFCAs that contain longer alkyl
chains. As demonstrated by Figure 6.7, there is one metabolite 201 with [M-H2O+H]+
ion with m/z = 195.0 (corresponding to either AHFCA3 or 5), two metabolites 202 and
203 with [M-H2O+H]+ ion with m/z = 209.0, and compound 204 with an [M-H2O+H]+
ion with m/z = 223.0.
AHFCAs are derived from the same precursors as SCBs, and they exhibit a variety of
alkyl chains in the 4-position of the furan ring.79,109,132 Therefore, to solve the structures
of these AHFCA compounds, a similar set of feeding experiments analogous to the
above feeding experiments were devised. The S. venezuelae gbnB/R strain was grown
on SMMS supplemented with 10 mM d8-DL-valine, 10 mM d10-L-leucine, 10 mM d10-
L-isoleucine, 1 mM d5-propionic acid and 1 mM d7-butyric acid in order to determine
the nature of the side chains of each of the AHFCAs identified (d5-propionic acid and
d7-butyric acid were found to inhibit the growth of the S. venezuelae gbnB/R strain at
10 mM concentration). The S. venezuelae gbnB/R strain was selected for these
experiments instead of the gbnR strain as the gbnB/R strain does not produce
gaburedins, therefore has a cleaner background for LC-MS analyses.
Figure 6.8 illustrates that the m/z of AHFCA-like compound 201 observed at tR = 24.9
min (m/z = 195.0 for its [M-H2O+H]+ ion) does indeed increase by 7 upon feeding with
d7-butyric acid, confirming that this is the same structure as that of AHFCA5 (53)
previously isolated from Streptomyces coelicolor.79 Furthermore, the AHFCA-like
metabolites 202 (tR = 25.9 min) and 203 (tR = 26.1 min) were shown to be specifically
labelled upon supplementing the growth media with d10-leucine and d5-propionic acid,
respectively. These new metabolites 202 and 203 were named AHFCA6 and AHFCA7,
respectively.
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The compound 204 with tR = 27.0 min was named AHFCA8 and shown to be
specifically labelled by d8-valine (Figure 6.8). Molecular formulae for the deuterated
species were all confirmed by UHR-MS analyses (Table 6.2 and Appendix 6), as
exemplified by AHFCA8 in Figure 6.9. All four AHFCAs have an absorption
maximum at 254 nm, as previously reported for AHFCAs.79
Figure 6.8 – Mass spectra of the AHFCAs 5-8 (201-204) identified in the S. venezuelae gbnR deletion
mutants when grown on modified SMMS. AHFCA5 is labelled with 7 deuteriums from d7-butyric acid;
AHFCA6 is labelled with 9 deuteriums from d10-leucine; AHFCA7 is labelled with 5 labels from d5-
propionic acid; and AHFCA8 is labelled with 7 deuteriums from d8-valine. [M+Na]+ ions are
highlighted in red
Chapter Six | Regulation of gaburedin biosynthesis
178
Upon feeding with 10 mM d10-isoleucine and d10-leucine, respectively, there were two
new AHFCA-like metabolites 205 and 206, with ions corresponding of m/z = 246.0 and
286.0 in their mass spectra, as would be expected for incorporation of nine deuterium
Figure 6.9 – AHFCAs produced by S. venezuelae gbnR deletion mutants as demonstrated by
incorporation of the specific precursor molecules shown, and UHR-MS spectra of AHFCA8 (204)
unlabelled (top panel) and AHFCA8 labelled with 7 deuteriums from incorporation of d8-valine (bottom
panel) and molecular formulae generated for the [M-H2O+H]+ and [M+Na]+ and ions are shown
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labels from d10-isoleucine and d10-leucine, respectively (Figure 6.10). These AHFCAs
were named AHFCA9 (isoleucine-derived) and AHFCA10 (leucine-derived).
Table 6.2 – UHR-MS of [M+Na]+ ions of AHFCAs 5-10 identified in culture extract of S. venezuelae
gbnB/gbnR grown on SMMS supplemented with different stable isotope precursor molecules
retention
time / min
compound precursor
molecule fed
Molecular
formula
Observed
m/z
Calculated
m/z
19.4 AHFCA5 (201) none C11H16NaO4 235.0936 235.0941
19.4 d7-AHFCA5 (201) d7-butyric acid C11H9D7NaO4 242.1377 242.1386
19.7 AHFCA6 (202) none C12H18NaO4 249.1089 249.1087
19.7 d9-AHFCA6 (202) d10-L-leucine C12H9D9NaO4 258.1651 258.1668
19.8 AHFCA7 (203) none C12H18NaO4 249.1089 249.1087
19.8 d5-AHFCA7 (203) d5-propionic acid C12H13D5NaO4 254.0* 254.1417
20.1 AHFCA8 (204) none C13H20NaO4 263.1242 263.1254
20.1 d7-AHFCA8 (204) d8-DL-valine C13H13D7NaO4 270.1688 270.1699
20.5 d9-AHFCA9 (205) d10-L-isoleucine C14H13D9NaO4 286.1969 286.1981
20.5 d9-AHFCA10 (206) d10-L-leucine C14H13D9NaO4 286.1* 286.1981
* intensity of peak in UHR-MS too low to generate molecular formula
Figure 6.10 – Mass spectra and proposed structures of 205 produced upon feeding the gbnB/R strain
with d10-isoleucine (top panel) and 206 produced upon feeding the gbnB/R strain with d10-leucine
(bottom panel)
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In order to further verify the structures of 201-203 as corresponding to AHFCAs 5-7
identified in the culture extract of the S. venezuelae gbnB/R strain, LC-MS data were
obtained in which the metabolites extracted from this strain were co-injected with
authentic standards of AHFCAs 5, 6 and 7 (synthesised by N. Malet and S. Zhou in
Prof. G. L. Challis group, Warwick).100 As shown by Figure 6.11, compounds 201, 202
and 203 co-elute with AHFCAs 5, 6 and 7 respectively.
The discovery that AHFCAs are produced by S. venezuelae represents the first example
of AHFCAs being produced by species different from S. coelicolor. Interestingly, one
of these AHFCAs – AHFCA5 has an identical structure to one of the AHFCAs initially
isolated from S. coelicolor, but the other AHFCAs produced by S. venezuelae have
longer alkyl chains. The AHFCAs 6-10 are novel natural products, although AHFCA7
Figure 6.11 – Extracted ion chromatograms for [M-H2O+H]+ ions of AHFCA species present in the
metabolites extracted from the S. venezuelae gbnB/gbnR with no AHFCA added and with AHFCAs 5, 6
and 7 co-injected. Chromatograms correspond to m/z = 195.0 (blue traces), 209.0 (black traces) and
223.0 (red traces)
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has been previously synthesised when the ligand tolerance of MmfR was investigated
(see Section 7.2).100
6.1.5 Deductions about SCB/AHFCA biosynthesis in S. venezuelae
Interestingly, the GBLs and AHFCAs shown to be produced by the S. venezuelae gbnR
deletion mutants are both derived from the same precursor molecules (Scheme 6.3).
Indeed, upon feeding with the deuterium labelled precursors d7-butyric acid, d10-
leucine, d5-propionic acid, d8-valine and d10-leucine, there was overproduction of
compounds 188, 189, 190, 191 and 192 respectively in the S. venezuelae gbnB/R
mutant, consistent with the structures proposed for these molecules in Section 6.1.3.
This result is consistent with the previously reported hypothesis that scbA, mmfL and
their homologues produce butenolide phosphate intermediates, and the downstream
enzymatic steps determine the final structure of GBL and AHFCA signalling molecules
(Scheme 6.2). The observation that exactly the same precursors appear to be utilised for
GBL and AHFCA biosynthesis in S. venezuelae gbnR deletion mutant might suggest
that SgnL is the shared enzyme in the biosynthesis of these specific signalling
molecules.
It is possible that the deletion of gbnR – and therefore de-repression of transcription of
sgnL – leads to overproduction of the butenolide intermediates to such an extent that
the intracellular concentration is too great for the downstream enzymes SgnP and SgnH
to turn over, leading to production of gamma-butyrolactones as a series of shunt
metabolites. Indeed, the potential for cross-talk between the sgnL and jadW1 pathways
cannot be excluded, as SCB3 was recently reported as being produced a S. venezuelae
mutant in which jadW1 had been deleted. Upon deletion of jadW1 and sgnL, there was
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still some SCB3 produced. However, upon construction of a jadW1, sven_5093 double
deletion mutant, SCB3 production was abolished.95 This observation implies that sgnL
Scheme 6.3 – Proposed structures of the GBLs and AHFCAs produced by S. venezuelae gbnR deletion
mutants. The same series of butenolide phosphate intermediates 207-211 are proposed to be utilized in
GBL and AHFCA biosynthesis
Chapter Six | Regulation of gaburedin biosynthesis
183
is not responsible for SCB biosynthesis in S. venezuelae, therefore the presence of
SCBs in S. venezuelae gbnR mutant extracts may be due to other afsA homologues.
Furthermore, the observation that the SCBs and AHFCAs observed in the S. venezuelae
gbnR mutants are derived from the same precursor molecules, may simply reflect the
availability of β-ketothioesters with different alkyl substituents which are available in 
the cell to be scavenged from fatty acid biosynthesis by SgnL, or by JadW1 or
Sven_5093. Alternatively, if the AREs in the sgn and jad clusters are very similar, it is
possible that the GbnR repressor binds to both. Therefore upon deletion of gbnR there
may be some derepression of transcription of jadW1, leading also to SCB biosynthesis.
The observation that S. venezuelae gbnR mutants produce AHFCA as well as GBL
signalling molecules raises the question of whether SCBs or AHFCAs control the
biosynthesis of gaburedins, or whether the presence of both AHFCAs and SCBs in the
gbnR deletion mutants is the result of crosstalk between different signalling pathways.
In order to determine the nature of the signalling molecules (GBLs or AHFCAs)
produced by SgnL, the butenolide synthase gene sgnL was heterologously expressed in
E. coli to determine what profile of different AHFCAs and/or GBLs are produced by an
E. coli strain overexpressing sgnL.
6.2 Production of S. venezuelae signalling molecules in E. coli
6.2.1 Overexpression of sgnL in E. coli
When the AHFCAs produced by S. coelicolor were first characterised, it was shown
that heterologous expression of mmfL alone was sufficient to lead to production of
AHFCAs in E. coli.79 Therefore it was hypothesised that the heterologous expression of
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the mmfL homologue from S. venezuelae, sgnL, would also lead to production of
AHFCAs. However, if GBLs were produced as well, this would account for the above
observation that both AHFCAs and GBLs are produced by S. venezuelae when gbnR is
deleted.
The biosynthetic gene sgnL was amplified by PCR from the SV4 F01 cosmid
containing the whole gbn-sgn gene cluster. Specific primers S/S’ were designed to
amplify the whole sgnL gene and add a 5’-CACC tag required for cloning into the
pET151 expression vector (TOPO cloning is discussed in Section 5.1). Successful
colonies were identified by selection with ampicillin, followed by preparation of
overnight cultures, purification of their plasmids and subsequent digestion with PstI.
Upon verifying the sequence of the sgnL gene insert, the construct pJDS08 was used to
transform E. coli BL21star and protein expression induced using IPTG. In parallel, this
E. coli BL21star/pJDS08 strain was grown without the addition of IPTG to the growth
medium. Metabolites produced by this strain were compared by LC-MS, leading to the
identification of several metabolites 212-214 overproduced in the E. coli
BL21star/pJDS08 induced with IPTG (Figure 6.12).
Molecules 212 and 213 with the m/z values and fragmentation patterns expected for the
AHFCAs 2 and 5 ([M-H2O+H]+ ions with m/z = 167.0 and 195.0, respectively) were
identified. Comparison of these metabolites with an authentic standard of AHFCA2
confirmed the retention times and fragmentation of AHFCA2 authentic standard and
212 extracted from E. coli BL21star/pJDS8 to be the same, implying that 212 is
AHFCA2 (compound 32).
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Furthermore, an additional peak with m/z = 262.8 and the same characteristic AHFCA
fragmentation pattern was also observed (Figure 6.12). UHR-MS analysis confirmed
this new AHFCA-like compound 214 to have the same molecular formulae that would
be predicted for an AHFCA of this size: C13H20NaO4 for the [M+Na]+ ion (calculated
m/z = 263.1254, observed 263.1245), C13H21O4 for the [M+H]+ ion (calculated m/z =
241.1434, observed 241.1419) and C13H19O3 for the [M+H-H2O]+ ion (calculated m/z =
223.1329, observed 223.1321). The retention time at which this metabolite elutes is
also consistent with the retention time that one would expect for a larger molecule
Figure 6.12 – Extracted ion chromatograms m/z = 167.0, 195.0 and 223.0 for [M-H2O+H]+ ions of 212-
214 present in the metabolites extracted from the E. coli BL21star/pJDS8 strain and E. coli
BL21star/pJDS8 strain induced with IPTG. A synthetic standard of AHFCA2 (32) was run in parallel.
Mass spectra of AHFCA 212-214 are also shown
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belonging to this same series (AHFCAs with longer alkyl chains would be expected to
be retained on the column for longer).
It can be deduced that this new AHFCA 214 is distinct from the AHFCA8 produced by
S. venezuelae, as AHFCA8 is derived from valine. However, E. coli is known to only
produce unbranched fatty acids (the predominant starter unit in fatty acid biosynthesis
in E. coli is acetyl-CoA), therefore the AHFCAs produced would be expected to have
no branching in their alkyl chains, either.79,136 Hence this new compound 214 was
named AHFCA8E, the E to signify it is only produced by SgnL when overproduced in
the heterologous host E. coli.
The observation that E. coli carrying sgnL is able to produce AHFCA2 is also of
interest, as no AHFCA2 has been observed to be produced by the native host S.
venezuelae gbnR. This difference in the AHFCA profiles of E. coli BL21star/pJDS08
compared with the S. venezuelae gbnR mutants would imply that the substrate
specificity of SgnL is sufficiently broad that shorter β-ketothioester intermediates than 
can be tolerated by SgnL, to produce smaller butenolides than those shown in Scheme
6.3. Incorporation of the shorter β-ketothioester to allow AHFCA2 be produced by E.
coli compared to S. venezuelae may simply reflect the intracellular availability of
different β-ketothioesters in E. coli and S. venezuelae.
6.2.2 Implications for AHFCA/GBL biosynthesis
The observation that only sgnL is required for AHFCA biosynthesis in E. coli
complements the previously published work in which expression of mmfL alone
resulted in AHFCA production.79 Interestingly, no GBLs (neither of the 6-keto or 6-
hydroxy types) were observed in the culture extract of E. coli BL21star/pJDS08.
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However, as the heterologous host E. coli contains an MmfH homologue (acyl-CoA
dehydrogenase, NCBI accession no. WP_032718200.1 with 26% identity and 41%
similarity to MmfH at the amino acid level), this could be the reason for the production
of AHFCAs instead of GBLs. If the presence of an mmfH homologue in E. coli was the
only reason for production of AHFCAs, then one would expect that expression of other
afsA homologues in E. coli might also lead to AHFCA (rather than GBL) production.
However, upon heterologous expression of afsA from S. griseus in E. coli, Kato and co-
workers noted that 6-keto GBL analogues of A-factor 71 and 72 were produced (Figure
1.17). If the MmfH homologue acyl-CoA dehydrogenase acts on the butenolide
phosphate formed (as suggested in the case of heterologous expression of mmfL in E.
coli) then one would expect AHFCAs to be produced by E. coli carrying other afsA.
The observation that afsA alone in E. coli is sufficient to produce A-factor implies that
the downstream enzyme required (BprA or a homologue) is present in E. coli. Indeed, a
BLAST search of BprA homologues in E. coli revealed that BprA has significant
homology to quinine reductase 2 (NCBI accession no. WP_016159986.1, which has
30% identity, 46% similarity with BprA at the amino acid level).
As there are homologues of both BprA and MmfH in E. coli, when expressing afsA
homologues (therefore producing butenolide intermediates) then one might expect both
AHFCAs and GBLs to be produced in E. coli. However, if the BprA or MmfH
homologues are specific for substrates with different length alkyl chains, this may
account for the different signalling molecules observed when expressing sgnL,
compared with expressing afsA in E. coli. On the other hand, the result that only
AHFCA signalling molecules are produced by E. coli overexpressing sgnL could imply
that sgnL catalyses a different reaction to other afsA homologues. Hence, the signalling
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molecule (GBLs or AHFCAs) resulting from the reaction of the afsA homologue may
be determined at least in part by the AfsA homologue itself (rather than the
downstream reactions proposed to be catalysed by MmfH/P and BprA to yield
AHFCAs or GBLs, respectively).
The result that only sgnL is required for AHFCA biosynthesis lends support to the
hypothesis that AHFCAs are produced by the SgnLPH system in S. venezuelae, yet the
ligands which actually induce gaburedin biosynthesis had not yet been confirmed.
Therefore, bioinformatic analyses to compare the AHFCA binding site in MmfR to the
putative binding site in SgnR were performed, as a high degree of similarity of the
MmfR and SgnR binding pockets would provide evidence for SgnR being an AHFCA-
responsive protein.
6.3 Comparison of SgnR and MmfR ligand binding sites
The ligand binding tolerances of ArpA and homologues BarA and FarA been studied.
Generally, these studies have focused on previously characterised signalling molecules
(to determine whether a GBL receptor responds to 6-keto or 6-hydroxy GBLs with
different stereochemistry at carbon 6).112,142,126 Of the MmfR sub-family of ArpA-like
transcriptional repressors identified, only MmfR has been studied extensively in vitro
and in vivo. More recently, the crystal structure of MmfR has been solved, both in its
apo form and its ligand-bound holo form with the ligand AHFCA2 (32) bound.100 Up
until this point, MmfR is the only ArpA-like repressor known to respond to AHFCA-
like signalling molecules.
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In order to provide in silico evidence for SgnR also being able to bind to the same
AHFCA-type ligands (rather than GBLs), sequence alignments of MmfR and SgnR
were produced using Clustal Omega (Figure 6.13) and the active site residues were
compared. The tyrosines 85 and 144 are conserved throughout the SgnR homologues
identified, yet there is some variation in the amino acid residues interacting with the
alkyl side chain of the AHFCA ligand (Figure 6.13). Amino acid residues of MmfR
SgnR (SVEN_4182) CLUSTAL O(1.2.1) multiple sequence alignment
Streptomyces sp. Alignment
NRRLF5135 ---MNGS---NGRVAFPASQTTPAHRQGRGPELQQERAVRTRMQILDAAAELFAAQGFPSTSVKDVADRVGMTKGAVYFH
roseochromogenes ---------MTSKI--TIPGWTGSPTEDRLPDLRQERAVQTRAQVLRAAAEEFAEKGFKSTSIQDVAKRVGMTKGAVYFH
sp351MFTsu5 ---MRHTRPATAGQPVEPGGKPRKSPVVRGPDPRQDRAVRTRAHILRCAAEIFAVRGYPYTSITDVAQQVGMTKGAVYFH
coelicolor MmfR ---------MTSA-QQPTPFAVR-SNVPRGPHPQQERSIKTRAQILEAASEIFASRGYRGASVKDVAERVGMTKGAVYFH
spNRRLS31 ---------MTSV-QPPTAFAAR-RNVPRGPHPQQERSIRTRAQILGAASEIFAARGYRGASVKDVAERVGMTKGAVYFH
roseoverticillatus-----------------MTTKQRKASVRATAELKQDRAVRTRAQTLHVAAQLFAQQGFRATSMQHIADRLGMTKGAVYFH
purpeofuscus --------------EPPGPFRVRPIATRRGPDPKQDRAARTRLLVLTAAAELFTARGFRHTSVQEVADRVGMTKGAVYFH
olindensis ---------MPEPQPAIAAFASRKFVTRRGPDPKQERSARTRLLVLRAASELFAQHGFRHTSVKDVADRMEMTKGAVYFH
NRRLWC3641 ---------MPEPQPAIAAFASRKFVTRRGPDPKQERSARTRLLVLRAASELFAQHGFRHTSVKDVADRMEMTKGAVYFH
iakyrus ---------MSEPQPAIAAFAPRKFVTRRGPDPKQERSARTRLLVLTAASELFAEQGFRHTSVKDVADRMKMTKGAVYFH
flavovariabilis ---------MSEPQPAIAAFAPRKFVTRRGPDPKQERSARTRSLVLIAASELFAEQGFRHTSVKDVADRMKMTKGAVYFH
spHGB0020 MDAMAVERSAP-----RSRPARDTAPRHRDTGLKQERAVRTRGQVLDAAAKAFATKGFPAVTVQDVAELAGVTKGAVYFH
amel2xE9 -----------------------MTTTGKRSEPKQERARRTRAQILRVAAELFAERGYATVTLQDVAERASMTKGAVYFH
venezuelae SgnR -------------------------MATPRSQPKQERARRTKVHILQSAAELFAERGYATVTLQDVAERAEMTKGAVYFH
globisporus ------------------------------------------MHILQSAAELFAERGYATVTLQDVAERAEMTKGAVYFH
sclerotialus ---------------------------------KQERARQTKRLVLRTAAEAFKEHGYPAVTLQAVAERASMTKGAVYFH
exfoliatus -------------------------------QPKQERSRRTKAQILTAAAEVFAEQGYPAVTLQDVADRVGMTKGAVYFH
* *:: * :*: .:: :*. :*********
NRRLF5135 YPTKEALTVAVVEAHYARWPGLLEAVQAKGLGPMDTLLELLDRTAAAFQDDPVVQAGARLQMEQPLPIDTMPEPYVGWID
roseochromogenes FPNKEILAIAVVEAHYSRWPELLEGILAEGHPPLDTVVRVLDGAAKAFATDIVVQAGARLQLERSLIDAQLPQPYVGWTQ
sp351MFTsu5 FPNKESLAVAVVEELYSRWPLTLEEVRAKGLSPLDTAIEMFNQATEAFQSDPIIQAGTRLQNERAFIDADLPAPYLDWTN
coelicolor MmfR FPSKESLAIAVVEEHYARWPAAMEEIRIQGFTPLETVEEMLHRAAQAFRDDPVMQAGARLQSERAFIDAELPLPYVDWTH
spNRRLS31 FPSKESLAIAVVEEHYARWPATMEEIRAQGFTPLETVEEMLHRAAQGFRDDPVMQAGARLQSERAFIDAELPLPYVDWTH
roseoverticillatusFPTKETLAVAIVEEHYGRWPKVVKEVQAEGLSPVESAEEILKRAAVAFRDDPVMQAGARLQLERPHIDAELPTPYVDWTQ
purpeofuscus YPTKEALAVAVVEHHYARWPLLLAGVTAEGHGPLETAERLLAGAALAFREDVVVQAGTRLQVERPQIDAELPTPYVDWTE
olindensis YPSKEALAVAVVEEHYARWPALLEEVLAEGFGPLETAEQLLARTAVAFRDDIVVQAGARLQIERPHIDAELPTPYVDWTD
NRRLWC3641 YPSKEALAVAVVEEHYARWPALLEEVLAEGFGPLETAEQLLARTAVAFRDDIVVQAGARLQIERPHIDAELPTPYVDWTD
iakyrus YPSKEALAVAVVEEHYARWPALLEEVLTEGYGPLETAEQMLARAAVSFRDDIVVQAGARLQIERPHIDAELPTPYVDWTE
flavovariabilis YPSKEALAVAVVEEHYARWPALLEEVMAEGFGPLETAERMLARTAVSFRDDIVVQAGARLQIERPHIDAELPTPYVDWTE
spHGB0020 FANKEALAQAVAEEFYHVLGVIGQEVEEAGLPPLQAVSELLERTAVAFRDDTMVQAGARLQIERSLIGAEMPMPYLGYTE
amel2xE9 YKNKEELAVAVVQEHYARWPAILEEVTVRRLPPYETLVTVLDRVTRAFRDDIVVQAGARLQVERSLINGDLPKPYVGWED
venezuelae SgnR YTNKEALAVAVVQEHYARWPEILKGAEGDHAEPFDMLTAVLDTVTRAFARDIVVQAGARLQIERALIDAELPEPYVGWED
globisporus YTNKEALAVAVVQEHYARWPEILKGAEGDHEEPFDTLVAVLDAVTRAFARDIVVQAGARLQIERALIDAELPEPYVGWED
sclerotialus YANKEALAVAVIMEHYARWEPLVSEVRSRGLPPLETLLAVLEGAAEAFRDDVMVQAGARLQIERSLIKADLPVPYVGWQE
exfoliatus YANKHVLAVAVVEEHYRRWPELVERVRASEGTPLDILLAVLDGTAEAFRGDSVVQAGARLQIERSLIGADLPKPYEWWRE
: .*. *: *: * * : :: .: .* * ::***:*** *: :* ** : .
NRRLF5135 LLEQLLAEAEEAGELRAGVSPAVAARVLVATFFGTQHIAARLDHRAETTKRWSEARDLLAFALRA-----
roseochromogenes LLAHLLTSAKEAGELRAGVDPEAAARALVSGFFGVQHVSDTLTGRADLLDRWPEFRDLVMTSLRA-----
sp351MFTsu5 LISSLLREAQVMGQLRDGVDPDEAARVTVAAFFGMQHISDNLYLRADIRERWREVRDLLFPALRARPDQR
coelicolor MmfR LLEVPLQDAREAGQLRAGVDPAAAARSLVAAFFGMQHVSDNLHQRADIMERWQELRELMFFALRA-----
spNRRLS31 LLEVLLQDAREVGQLRPGVDPAAAARSLVAAFFGMQHISDNLYQRADIMERWQELRDLMFFALRA-----
roseoverticillatusLLQSLLVTAKYSGELREGVDPEAAARTLVSSFFGVQHISDVLSHRKDIAERWEETRKLLFYSLRA-----
purpeofuscus LLAELLARAEALGELRAGVRPRAAARSLVAAFFGAQHISDVLSERADIVERWAETSELLFRAIRAE----
olindensis LLASLLVAARDQGLLREGVAPDAAARSLVSAFFGAQHISDVLQGRADVVERWAETSELLFHAIRAH----
NRRLWC3641 LLASLLVAAREQGLLREGVAPDAAARALVSAFFGAQHISDVLQGRADVVERWAETSELLFHAIRAH----
iakyrus LLASLLVAARDGGQVREGVSPEAAARSLVSAFFGAQHISDVLRGRADVVERWTETSELLFHAIRAR----
flavovariabilis LLASLLVAARDEGQVREGVSPEAAARSLVSAFFGAQHISDVLRGRADVVER-------------------
spHGB0020 SLTTWLRQARTEGHLAAGTSPEATARVLVSAFFGAQHISWVLNDRADIADRVQEILTAVVPLAAA-----
amel2xE9 YLTGLVEAIDEAGELRPGITPRGAARVLVAAFFGMQHISDVLARRADLTERYGELRHVVLEGLRA-----
venezuelae SgnR YLTRLIAEARDAGQLRDGVEPRAAARVLVSAFFGMQHISDVLSGRSDLTERYEELRTVLLEGLRR-----
globisporus YLSRLIAEARDAGQLRAGVEPRAAARVLVSAFFGMQHISDVLSRRQDLTERHEELRTVLLEGLRG-----
sclerotialus LLTSLITEARDAGQLRADVDPAALARVVVAAFFGSQHISDVLNGRADLMQRHGELIEAVFRGAMP-----
exfoliatus MLAALIADARDAGQLRADTDPKALARVVVSAFFGVQHISDVLTERADMMERYLEMRDAVFKGFIVD----
: : * : * ** *: *** **:: * * : .*
Figure 6.13 – Clustal Omega alignments of SgnR (SVEN_4182), MmfR and homologues in other
Streptomyces species. The amino acid residues identified as interacting with the AHFCA ligand are
highlighted in yellow. The key tyrosine residues identified are highlighted in cyan
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identified to be interacting with AHFCA ligand were compared with the amino acid
residue in the same positions in SgnR. Interestingly, the relative positions of the amino
acids interacting with AHFCA2 in the ligand binding pocket are 100% conserved
between the MmfR and SgnR sequences. This provides evidence for AHFCAs – rather
than GBLs – as being the ligands interacting with SgnR in the S. venezuelae gbn-sgn
system.
To provide more evidence for the potential for AHFCAs to bind in the same active site
in SgnR as in MmfR, a simulated crystal structure for SgnR was generated using
Phyre2 and the solved MmfR-AHFCA2 structure as a template.184 As shown in Figure
6.14, the amino acids in the active site of the structure generated for SgnR align almost
Figure 6.14 – a) Active site residues of MmfR interacting with AHFCA2 from solved crystal
structure100 b) Active site residues of SgnR proposed to interact with AHFCA2 from SgnR structure
generated using Phyre2 c) overlaid active sites residues of MmfR (orange) and SgnR (cyan) showing
that the active site residues are predicted to be conserved between MmfR and SgnR. Images generated
using PyMOL with views restricted to 6Å around the AHFCA2 ligand
a) b)
c)
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perfectly with those amino acids of MmfR shown to interact with AHFCA2, providing
evidence that SgnR is likely to be furan-responsive. However, experimental evidence to
verify these in silico analyses has not been presented thus far.
6.4 Biological role of S. venezuelae AHFCA signalling molecules
6.4.1 AHFCAs induce gaburedin production in an S. venezuelae sgnL-P mutant
To establish if particular AHFCA or GBL signalling molecules could induce gaburedin
biosynthesis, an induction assay was devised in which the sgnL-P::apra mutant (unable
to produce AHFCAs) was fed with a series of culture extracts containing
AHFCAs/GBLs, in order to establish whether gaburedin biosynthesis could be induced
in the sgnL-P::apra strain. This chemical complementation approach could be an
effective way to determine structure-activity relationships, and has been used to assay
induction of methylenomycin biosynthesis in S. coelicolor W81, a strain which lacks
mmfLHP, but the rest of the methylenomycin cluster is intact.79,100 In contrast to the
activity-based methylenomycin induction assay previously reported, gaburedin
production was analysed by LC-MS.
Initial assays were carried out in which culture supernatant of the S. venezuelae gbnB/R
double mutant (which produces AHFCAs and GBLs) was added to the S. venezuelae
sgnL-P mutant, however no inductive effect was observed. SMMS enriched with pure
authentic standards AHFCAs 6 and 7 were also prepared in which AHFCAs were
dissolved in DMSO to a concentration of 10 mM and then added to 5 mL re-melted
SMMS to give final concentrations of 100 μM, 10 μM and 1 μM. It was noted however 
that DMSO appeared to restrict the growth of the S. venezuelae sgnL-P::apra, therefore
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a much more concentrated solution of each AHFCA was made to minimise the quantity
of DMSO which was required to be added to each plate.
Therefore, stock solutions of AHFCAs 5, 6 and 7 were prepared, and then diluted with
DMSO so that 2 μL of each diluted solution was added to each 5 mL SMMS to give 
final AHFCA concentrations of 400 μM, 100 µM, and 10 µM. LC-MS analysis of 
culture extracts of the S. venezuelae sgnL-P::apra mutant grown on these media for 3
days revealed that gaburedin biosynthesis was induced at all concentrations (Figure
6.15). These experiments demonstrate that the inducing molecules in gaburedin
biosynthesis are indeed AHFCAs, and provide the first example after the
methylenomycin system in which AHFCAs have been shown to control biosynthesis of
a natural product.
Figure 6.15 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for gaburedins A-F
(80-85) in metabolites extracted from S. venezuelae sgnL-P::apra strain upon addition of 10 μM, 100 
μM and 400 μM AHFCA5 
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It was also noted during these experiments that SCBs 1, 3, 5, 6 and 8 were still
produced by the gbnR strain, but no SCBs were produced in the sgnL-P::apra strain
induced with AHFCAs (Figure 6.16). Therefore, it can be deduced that gaburedins can
be produced in the absence of SCBs. This result appears to confirm that AHFCAs – not
SCBs – are the true inducer molecules in the gbnABC-sgnLHP system.
6.4.2 Effect of AHFCAs on S. venezuelae gbnR mutant and wild-type strains
Interestingly, the yields of gaburedins produced by the sgnL-P::apra strain upon
addition of AHFCA 6 and 7 were similar for all three concentrations of AHFCAs 6 and
7 used. However, at a higher concentration of AHFCA5 (400 µM) there was actually
less of an inductive effect than at 100 µM concentration, suggesting an upper limit on
concentration of AHFCA required for inducing gaburedin biosynthesis. In control
experiments in which the gbnR mutant (which contains the AHFCA biosynthetic genes
Figure 6.16 – Extracted ion chromatograms m/z = 239.0, 253.0, 267.0, 281.0 for SCBs in metabolites
extracted from S. venezuelae sgnL-P::apra strain upon addition of 10 μM, 100 μM and 400 μM 
AHFCA5, with a positive control experiment adding 400 μM AHFCA5 to the gbnR mutant. The
compound denoted by the * has m/z = 267 and is unrelated to SCBs
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sgnL and sgnP, and overproduces gaburedins) was fed with 400 µM AHFCAs 5, 6 and
7, there were reduced yields of gaburedins compared with the yield of gaburedins
induced in the sgnL-P::apra strain (Figure 6.15 illustrates this effect with AHFCA5),
also implying that high concentrations of AHFCA may have an inhibitory effect on
gaburedin biosynthesis.
Induction assays with AHFCAs were repeated with the S. venezuelae sgnL-P, gbnR and
wild-type strains each grown on SMMS containing different concentrations of
Figure 6.17 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for gaburedins A-F
(80-85) in metabolites extracted from S. venezuelae gbnR::apra strain upon addition of different
AHFCAs to the growth media
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AHFCAs 5, 6 and 7. As shown in Figure 6.17, 10 µM AHFCAs 5-7 increased the yield
of gaburedins produced by the gbnR mutant, compared to no AHFCA being added at
all. AHFCA concentrations of 100 µM added gave yields similar to when no AHFCAs
were added, and 400 µM concentrations of AHFCA5 lowered the yield of gaburedins
produced by the gbnR strain, relative to the level of production without addition of
AHFCAs.
Figure 6.18 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for gaburedins A-F
(80-85) in metabolites extracted from S. venezuelae sgnL-P::apra strain upon addition of different
AHFCAs to the growth media
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In the sgnL-P strain, it was confirmed that addition of 10 µM and 100 µM of all three
AHFCAs 5, 6 and 7 to growth media induced gaburedin production, with the yield of
gaburedins being greatly reduced in the sample which had 400 µM AHFCA5 added
(Figure 6.18). Additional control experiments in which the S. venezuelae wild-type was
grown on SMMS containing the same AHFCA concentrations showed that in all
conditions, gaburedin biosynthesis was completely abolished (Figure 6.19).
Figure 6.19 – Extracted ion chromatograms m/z = 292.9, 279.0, 247.0, 261.0, 249.9 for gaburedins A-F
(80-85) in metabolites extracted from S. venezuelae wild-type strain upon addition of different
AHFCAs to the growth media
Chapter Six | Regulation of gaburedin biosynthesis
197
Taken together, these results suggest that there is a narrow range of concentrations at
which AHFCAs can induce gaburedin biosynthesis (concentrations <10 μM are 
sufficient to abolish production in the wild-type, concentrations between 100 and 400
μM decrease production in the gbnR mutant, and concentrations of 400 μM decrease 
production in the sgnL-P mutant). Therefore, the wild-type strain would appear to be
more sensitive to exogenous AHFCAs than the sgnL-P or gbnR mutants.
Based upon the hypothesis for the regulation of methylenomycin biosynthesis
discussed in Section 1.6, an analogous hypothesis was made for the regulation of
gaburedin biosynthesis (Section 2.1 and Figure 6.20). There is a basal level of sgnL
transcription, leading to AHFCA biosynthesis. At a critical concentration, there is
sufficient AHFCA present to be able to cause SgnR to dissociate from its’ cognate
AREs, leading to expression of gbnA, sgnL and gbnR. Therefore, gaburedin
biosynthesis is activated. This is accompanied by a sharp increase in the intracellular
concentration of AHFCAs due to expression of sgnL. Due to the increased expression
Figure 6.20 – Proposed signalling cascade involved in gaburedin biosynthesis. AREs are shown in
pink. Inhibitory events are denoted by circular arrowheads
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of gbnR, eventually the intracellular concentration of GbnR protein is sufficient to bind
to the AREs in the gbnA, sgnR-sgnL and gbnR-sgnH promoters. This leads to gbnABC
being silenced, even if there are high levels of AHFCAs present (as GbnR is proposed
to be unresponsive to AHFCAs). At this time, even if there is a high intracellular
concentration of SgnR (which may also silence gbnABC) is it possible that the
intracellular concentration of AHFCAs is high enough to cause total dissociation of
SgnR from its target ARE sequences.
In the gbnR deletion mutant, this final step (repression of gbnABC transcription) does
not occur, therefore gbnABC continue to be transcribed, leading to constitutive – rather
than transient – gaburedin biosynthesis (Figure 6.1). Because GbnR is not present, the
only protein able to switch off gaburedin production in the gbnR mutant is SgnR, by
binding to the ARE in the gbnA promoter. However, if the intracellular concentration of
AHFCAs is high enough to cause complete dissociation of SgnR from the ARE
sequences, then gbnABC transcription will continue.
However, when AHFCAs are added to the media (to between 100 μM and 400 μM 
concentration) it would appear that gaburedin production is decreased in the gbnR
mutant. This implies that the extracellular AHFCA concentration plays a role in
switching off gaburedin biosynthesis, as well as inducing gaburedin biosynthesis in the
first place. If AHFCAs are produced in high enough quantities, they may induce
expression of sgnR so much that the concentration of SgnR is great enough to then
silence transcription of gbnABC again.
As SgnL is required for AHFCA biosynthesis, in the sgnL-P mutant no AHFCAs will
be produced. Therefore, SgnR will not be dissociated from its ARE sequence in the
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gbnA operater and gaburedin biosynthesis will not occur. However, upon addition of
exogenous AHFCA to the growth media, SgnR will dissociate from the AREs,
therefore gbnABC transcription (and subsequent gaburedin biosynthesis) will occur, as
will overproduction of SgnR protein. Therefore, there will be a high concentration of
intracellular SgnR protein available to bind to the ARE in the gbnR promoter. This may
lead to repression of gbnR transcription, therefore there may be time lag in the
increased intracellular concentration of GbnR protein. Therefore, addition of AHFCAs
to the sgnL-P mutant can lead to gaburedin production (as shown in Figure 6.18).
Eventually, a point is reached where the concentration of AHFCAs is high enough to
cause so much de-repression of SgnR, that gbnR is transcribed (and enough GbnR
protein is produced) to cause repression of transcription of gbnABC.
In the wild-type, it would appear that a much lower concentration of AHFCAs is
required to repress gaburedin biosynthesis compared to the sgnL-P strain. This may be
explained by the AHFCA concentration being high from the time of inoculation,
therefore there could be early overexpression of sgnR, leading to overproduction of
SgnR. Therefore, addition of AHFCAs to the wild-type could have abolished gaburedin
biosynthesis, due to the high intracellular concentration of SgnR having silenced
gbnABC transcription. This would be consistent with the hypothesis that sgnL mRNA
cannot be translated until later in the developmental cycle (sgnL contains a TTA codon,
as does mmfL). If SgnR is overproduced initially, this may have the effect of delaying
onset of gaburedin biosynthesis in the wild type, therefore it would be interesting to
repeat this feeding experiment to monitor production of gaburedins in wild-type upon
addition of exogenous AHFCAs over a longer period than the three days reported here.
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To summarise, without addition of AHFCAs to the strains, there is only transient
AHFCA production in the cells (eventually the intracellular concentration of
SgnR/GbnR is great enough compared to the intracellular concentration of AHFCAs to
result in transcription of sgnL being totally repressed). The intracellular molar ratio of
SgnR:GbnR:AHFCAs is vital for understanding this regulatory cascade. Transcription
of sgnL, sgnR, gbnR and gbnA could be monitored by real-time PCR in the wild-type
and mutant strains, allowing some insight into the effect of GbnR and SgnL on sgnR
transcription. Indeed, time at which transcription of gbnA, sgnL, sgnR and gbnR occurs
is distorted in the AHFCA feeding experiments presented here; therefore the results
obtained cannot fully explain this complicated signalling cascade.
Moreover, the relative binding affinities of SgnR and GbnR for each of the AREs in the
gbnA, sgnR-sgnL and gbnR-sgnH promoters are important to understand this regulatory
mechanism, and work in our group is currently being undertaken to probe this (K.
Styles). The relative binding affinities of SgnR and GbnR for each of the AREs could
also be probed in vitro by EMSAs, and investigations are ongoing (S. Zhou, Prof. G. L.
Challis group). Preliminary data has demonstrated the ability of AHFCA6 to dissociate
SgnR from the gbnA, sgnR-sgnL and gbnR-sgnH promoters (Figure 6.21).
Figure 6.21 – Gel shift assay with SgnR protein (200 nM) and 28-bp sequence which includes the gbnA
ARE sequence. Concentrations of AHFCA6 added to each sample shown above each lane. Similar
experiments with the sgnR-sgnL and gbnR-sgnH promoters have also been performed (S. Zhou)
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7. Summary and future work
7.1 Conclusions
7.1.1 Deletion of S. venezuelae gbnR leads to overproduction of novel natural products
As demonstrated in Chapter 2, deletion of the arpA-like repressor gbnR in S.
venezuelae leads to overproduction of a series of novel natural products – the
gaburedins. The approach used in the present study demonstrates the first genome-
mining approach to discover a new series of metabolites in Streptomyces by this
rational approach of de-repressing a cryptic biosynthetic pathway by identification and
subsequent deletion of a transcriptional repressor gene.152
Deletion of gbnR leads to overexpression of gbnABC, therefore to gaburedin
biosynthesis. Presumably, this is due to the mechanism by which gbnABC transcription
is ‘switched off’ in S. venezuelae being disrupted by the removal of the gbnR gene.
This is proposed to be analogous to the mechanism by which methylenomycin
biosynthesis is controlled in S. coelicolor.85
7.1.2 Gaburedin biosynthesis proceeds via an intermediate derived from glutamic acid
Analysis of the metabolites produced by a S. venezuelae gbnB/gbnR deletion mutant
demonstrated that gaburedins (which are overproduced in the gbnR deletion mutant) are
not produced when gbnB is also deleted – therefore gbnB is essential for gaburedin
biosynthesis. Bioinformatic analysis of the GbnA and GbnB proteins suggested that
GbnA catalyses a decarboxylation, and that GbnB catalyses formation of an AMP-
ester. This hypothesis was tested with a range of potential substrate analogues of the
GbnA and GbnB enzymes, leading to the suggestion that GbnA is a glutamate
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decarboxylase; this was inferred from the observation that four labels from [U-13C]-L-
glutamic acid are retained throughout the biosynthetic route to gaburedins. The
substrate for GbnB is therefore proposed to be a derivative of GABA, although the in
vivo experiments presented do not explicitly confirm this. The biosynthetic origin of the
ureidyl carbon present in gaburedins also remains ambiguous.
A library of over 25 gaburedin analogues was produced by feeding experiments with a
variety of nucleophiles (amino acids, amines and aminoalcohols). The observation such
a variety of nucleophiles can be incorporated into gaburedins implies a conserved,
reactive intermediate in gaburedin biosynthesis. It is proposed that this reactive
intermediate is the carbamoyl ester 109 as proposed in the biosynthetic route proposed
in Chapter 3.
7.1.3 GbnABC systems exist across a range of species
Genes encoding for gbnABC orthologues in fifteen other bacterial strains have been
identified; these organisms belong to a diverse range of genera, and include Gram
positive and Gram negative organisms. It would appear that GbnB and GbnC exist as a
fusion protein in some of these bacteria. Of the strains identified which contain
gbnABC orthologues, the regulatory cassette of sgnR-sgnLPH-gbnR is only conserved
among some Streptomyces, suggesting that the mechanism by which gaburedin
biosynthesis is regulated in Streptomyces is distinct to the regulatory mechanisms
controlling expression of gbnABC systems in the other organisms.
7.1.4 Heterologous expression of gbnB in E. coli is not sufficient to produce gaburedins
Overexpression of GbnB in E. coli did not lead to production of any gaburedin-like
molecules, even when fed with the putative precursor GABA. It was noted however
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that overexpression of synthetic versions of gbnB, and the homologues seag_B2133
and smugs5_01685 from Salmonella enterica and Streptococcus mutans led to
production of insoluble proteins in E. coli, which may account for their inactivity.
Alternatively, this observation may also suggest that either GbnA or GbnC is required
for gaburedin biosynthesis. In order to address this, a vector has been constructed in
which synthetic S. venezuelae gbnA and gbnB should both be overexpressed in E. coli.
A compatible vector carrying synthetic gbnC has also been constructed allowing for the
whole GbnABC system to be reconstituted in E. coli, and for any metabolites produced
to be compared. This will also help to deduce the role of GbnC in gaburedin
biosynthesis and export.
7.1.5 Gaburedin biosynthesis is controlled by AHFCA signalling molecules
Comparative metabolic profiling of S. venezuelae strains revealed there to be nine
signalling molecules overproduced by a gbnR deletion strain, compared with the wild-
type and sgnL-P deletion strains. Five of these belong to the γ-butyrolactone family, 
and are likely to have the same stereochemistry as SCBs produced by S. coelicolor
M1152. Of the four AHFCAs produced by S. venezuelae gbnR mutants, AHFCAs 6-8
represent new metabolites produced by a Streptomyces strain and are the first example
of AHFCA signalling molecules to be produced by a strain other than S. coelicolor
from which AHFCAs were first purified.
Herein, it has been shown that addition of AHFCAs to the S. venezuelae sgnL-P strain
(unable to produce AHFCAs) can induce gaburedin biosynthesis in this strain.
Therefore, AHFCA signalling in Streptomyces is not unique to the methylenomycin
system. Addition of AHFCAs to the S. venezuelae wild-type strain did not have the
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same effect of inducing gaburedin biosynthesis in this strain, suggesting a complex
mechanism for AHFCA-mediated signalling in S. venezuelae.
7.2 Outlook
7.2.1 Deletion of arpA-like repressors is a valuable tool for natural product discovery
The present work demonstrates how identification of gene clusters encoding for
signalling molecule biosynthesis and transcriptional repressors can be exploited for
natural product discovery. As the signalling molecule/transcriptional repressor gene
clusters are widely distributed across Streptomyces species, this offers a new approach
to natural product discovery. This contrasts more traditional approaches, whereby the
effect of deletion of transcriptional repressors has generally been used to overproduce
already characterised natural products, rather than deletion of the repressor being used
as a method of overproducing cryptic metabolites. This work sets a precedent for
natural product discovery by this novel genome mining approach.
7.2.2 GbnB-type enzymes may have potential for producing drug-like molecules
The example presented in which 4-(3-cyclohexylureido)butanoic acid 103 was
produced demonstrates the capability of GbnA and GbnB to introduce the ureidyl-
GABA moiety into nucleophiles in order to create drug-like molecules in vivo. The
structural similarity of gaburedins to other drug-like molecules such as the
carboxypeptidase inhibitor 102 and the first-generation diabetes drug tolbutamide 105
demonstrate that gaburedins, or derivatives of gaburedins, could find use in a
pharmaceutical setting. More work is needed to demonstrate the ability of GbnA/GbnB
to introduce ureidyl-GABA moieties into other drug-like molecules in vitro.
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7.2.3 Some signalling molecules produced by S. venezuelae gbnR mutants are also
produced by other Streptomyces
The AHFCA signalling molecules discovered during this study demonstrate that S.
coelicolor is not the only organism capable of biosynthesising AHFCAs, and this work
provides a second example of natural product biosynthesis being induced by AHFCAs.
One of the AHFCA molecules – AHFCA5 – is produced by both S. coelicolor and S.
venezuelae and also has been shown to induce methylenomycin and gaburedin
biosynthesis in both these organisms.79,100 This could indicate a possible role for
AHFCAs in interspecies signalling, and also indicates the possibility that AHFCAs
could be used to induce natural product biosynthesis of cryptic metabolites in other
species that contain mmfR-mmfLHP-mmyR-like gene clusters. Indeed, AHFCA5 and
AHFCA7 (201 and 203) have been shown to induce methylenomycin production in
vivo in S. coelicolor W81 and gaburedin production in S. venezuelae sgnL-P:apra.
Several of the SCB signalling molecules produced by S. coelicolor M1152 and S.
venezuelae gbnR mutants have the same structures as SCBs which have previously
been shown to interact with ScbR. For example, synthetic SCB6, SCB7 and SCB8 were
used in the kanamycin resistance reporter assay to dissociate ScbR from its DNA target
(though it must be noted that 480 times more SCB8, and 10 times more SCB6 or SCB7
were required to induce kanamycin resistance compared to SCB1).132
7.2.4 MmfR-MmfLHP-MmyR-like systems exist in a range of Streptomyces
To identify potential AHFCA-responsive systems in other species, a series of protein
BLAST searches were performed, using both SgnR (SVEN_4182) and SgnR-SgnL
(SVEN_4182-SVEN_4183) as the protein query. For the organisms containing SgnR
protein analogues identified in Section 6.3, the genes surrounding the sgnR-sgnL
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homologues were annotated. In addition to the mmfR-mmfLHP-mmyR regulatory
cluster adjacent to the gaburedin clusters S. globisporus and Streptomyces sp. Amel
2Xe9 identified in Section 3.1, these results revealed the presence of eight new mmfR-
mmfLHP-mmyR regulatory systems that had not been previously identified. These gene
clusters from S. exfoliatus NRRL B-2924, S. olindensis, Streptomyces sp. WC-3641, S.
iakyrus, S. flavovariabilis, Streptomyces sp. F-5135, Streptomyces sp. 351MFTsu5.1
and S. roseoverticillatus are shown in Figure 7.1. The other gene clusters shown in
Figure 7.1 were identified by C. Corre, V. Poon and G. L. Challis during the present
study.
For these systems, the autoregulatory response elements (AREs) were also identified
using the MEME suite to first identify the consensus in the promoters of the mmfL,
mmfR and mmyR homologues. This was followed by FIMO analysis of the nucleotide
sequences that contain the mmfR-mmfLHP-mmyR-like gene clusters to reveal whether
any other AREs located in the adjacent gene clusters. The results of these analyses are
shown in Figure 7.1.
Interestingly, the mmfR-mmfLHP-mmyR-like gene clusters identified mostly appear
adjacent to natural product biosynthetic gene clusters which probably encode for
previously unknown natural products. AntiSMASH searches of these gene clusters
revealed no analogous gene clusters. The exception is the Streptomyces S-31 gene
cluster, which contains homologues of the entire methylenomycin gene cluster from the
S. coelicolor SCP1 plasmid. Furthermore, the S. iakyrus and S. flavovariabilis gene
clusters are highly homologous to one another (each protein sequence has a homologue
in the other gene cluster with >80% identity at the amino acid level), as are the S.
olindensis and Streptomyces sp. WC-3641 gene clusters identified.
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7.3 Future work
7.3.1 Biological role of gaburedins
It will be important to establish the biological activity of gaburedins and to establish
whether or not the S. venezuelae gbnABC system can be reconstituted in E. coli using
the Duet vectors pJDS10 and pJDS11 constructed herein. If the co-expression of all
three proteins can be optimised, the culture extracts can be screened for production of
gaburedins or gaburedin-like natural products.
Figure 7.1 – mmfR-mmfLHP-mmyR gene clusters in other Streptomyces species shown with 10 kb
upstream/downstream of the regulatory mini-cluster. AREs identified are shown, as are transcriptional
activators identified in the adjacent clusters
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If gaburedins are produced by E. coli carrying pJDS10 and pJDS11, this could be
followed by heterologous expression of the gbnABC genes from other bacteria in E.
coli. Characterising the metabolites produced by E. coli carrying the gbnA, gbnB and
gbnC genes of these other organisms will hopefully lead to discovery of further new
natural products. This is interesting as there are currently very few examples of natural
products produced by many of these other organisms in which gbnABC gene clusters
have been identified.
7.3.2 Characterisation of SCB signalling molecules in S. venezuelae
Whilst the observation that the same SCBs can be produced by different species may
suggest the potential for interspecies signalling,95 further testing of the capability of the
SCBs identified here to induce natural product biosynthesis in other strains in vivo will
be required. Before this can be determined, however, it will be important to
characterise the SCBs produced by S. coelicolor M1152 and S. venezuelae gbnR
mutants, to confirm that their stereochemistry is actually (2R, 3R, 6R), as proposed.
7.3.3 AHFCA signalling in S. venezuelae
It would be of particular interest to perform further EMSAs with S. venezuelae SgnR
and AHFCAs in order to determine whether or not addition of other AHFCAs would
attenuate the ability of SgnR to bind to the AREs in the gaburedin cluster in vitro.
Indeed, addition of other AHFCAs to the S. venezuelae sgnL-P mutant would also
allow in vivo structure-activity relationships regarding ligands for SgnR to be
established. These structure-activity relationships would complement the previous work
already performed on the MmfR-AHFCA interactions in vitro and in vivo in order to
determine whether the AFHCAs discovered in the extracts of the gbnR deletion
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mutants are the AHFCAs which are most effective at disassembling the SgnR-ARE
complex, as is the case for MmfR and the AHFCAs produced by S. coelicolor.79,100
This would contribute to understanding of AHFCA regulatory mechanisms and would
provide further evidence as to whether or not AHFCA-mediated interspecies signalling
could be possible in nature. Moreover, if the concentration of AHFCA required to
induce gaburedin biosynthesis in the S. venezuelae wild-type strain can be determined,
this will set a precedent for activation of cryptic gene clusters identified in other
organisms containing mmfR-mmfLHP-mmyR-like clusters, without the need for genetic
manipulation.
7.3.4 Deletion of mmyR-like repressors in other Streptomyces species
All of the gene clusters discussed in Section 7.2.4 contain homologues of both mmfR
and mmyR. If the hypothesis of MmyR homologues being responsible for the switching
off of biosynthetic pathways proves to be true – as suggested by this work with the
gaburedin system – then deletion of the mmyR-like genes in these other Streptomyces
species will offer a powerful method of natural product discovery by de-repression of
other cryptic biosynthetic pathways.
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8. Experimental
8.1 Analytical Chemistry
8.1.1 Mass spectrometry and NMR spectroscopy
Mass spectra were obtained using a Bruker Esquire 2000, Agilent 6130 Quadrupole
mass spectrometer or Bruker High Capacity Trap (HCT) + ion trap mass spectrometer
with an electrospray source and 1H, 13C DEPT, COSY, HSQC and HMBC NMR
spectra were obtained using a Bruker Avance DPX-400, DRX-500, or AV-700
spectrometers. Samples prepared for NMR in d6-DMSO were dissolved in 750 μL 
DMSO from glass ampoules and samples run in d4-MeOD or CDCl3 were dissolved in
d4-MeOD or CDCl3 that had been stored under argon.
8.1.2 Extraction protocol
Unless otherwise stated, bacterial cultures were stored at 4 °C until the time of
extraction, then ethyl acetate was added (in equal volume to the volume of culture
media used) and acidified to pH 3 with 37% HCl (HCl was not added to extracts of S.
venezuelae gbnB::apra, gbnR::scar and S. coelicolor M1152 strains used for
comparative analysis of signalling molecules). The ethyl acetate layer was removed,
evaporated under reduced pressure and the remaining residue was redissolved in 500
μL 50:50 HPLC grade methanol/water. For extracts from liquid cultures, the cells were 
pelleted (5000 rpm, 20 minutes) and the above extraction performed on the supernatant.
8.1.3 Liquid-chromatography-mass spectrometry (LC-MS)
20 μL of prepared extracts were injected through a reverse phase column (Zorbax C18,
size 46 x 150 mm, particle size 5 μm) connected to an Agilent 1100 HPLC. The 
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outflow was routed to a Bruker High Capacity Trap (HCT) + ion trap mass
spectrometer with an electrospray source, operating in positive ion mode. A 5 min
isocratic elution (95:5 solventA/solvent B) was followed by gradient elution to 0:100
solvent A/solvent B over 25 min. m/z = 50 to 1500 scan range was used.
The same method was used for samples analysed using the Bruker AmaZon mass
spectrometer. 15 μL injections of microbial culture extracts diluted by a factor of five 
were used and the same liquid chromatography method with acetonitrile in place of
methanol.
The high-resolution data were obtained by performing UPLC-MS through a reverse
phase column (Zorbax Eclipse Plus C18, size 2.1 x 100 mm, particle size 1.8 μm) 
connected to a Dionex 3000RS UHPLC coupled to Bruker Ultra High Resolution
(UHR) Q-TOF MS MaXis mass spectrometer with an electrospray source. Sodium
formate (10mM) was used for internal calibration and m/z = 50 to 1500 scan range was
used. A 0.4 min isocratic elution (95:5 solvent A/solvent B) was followed by a gradient
elution from 95:5 solvent A/solvent B to 0:100 solvent A/solvent B over 12.8 minutes.
Solvents A and B were water (0.1 % HCOOH) and acetonitrile (0.1 % HCOOH). Some
UHR-LC-MS analyses were performed with following method: a 5 min isocratic
elution (95:5 solventA/solvent B) was followed by gradient elution to 0:100 solvent
A/solvent B over 15.3 min. Solvents A and B were water (0.1 % HCOOH) and
acetonitrile (0.1 % HCOOH), respectively.
Other high-resolution analyses were performed using the following gradient: a 5 min
isocratic elution (95:5 solvent A/solvent B) was followed by a gradient elution from
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95:5 solvent A/solvent B to 0:100 solvent A/solvent B over 25 minutes. Solvents A and
B were water (0.1 % HCOOH) and methanol (0.1 % HCOOH).
8.1.4 Reverse phase HPLC
Reverse-phase HPLC was performed using a Zorbax XBD-C18 column (212 x 150 mm,
particle size 5 μm) connected to an Agilent 1200 HPLC equipped with a binary pump 
and DAD detector. Gradient elution was used (solvent A: water with 0.1 % HCOOH,
solvent B: methanol) with a flow rate of 20 mL min-1. Fractions were collected by time
or absorbance at 210 nm. Before each experiment was run, an isocratic equilibration
using the initial solvent profile was performed for 15-20 min.
For purifying gaburedin A 80, The following elution profile was used: 80:20 solvent
A/solvent B for 5 min, then 20:80 solvent A/solvent B over 25 min. Solvent A was
water + 0.1 % formic acid; solvent B was methanol. Fractions were collected (at the
retention time of interest), pooled, methanol removed under vacuum and the metabolite
of interest was re-extracted from the remaining water (2 x 50 mL ethyl acetate). The
ethyl acetate was removed under reduced pressure and the sample re-dissolved in 50:50
methanol/water. This concentrated sample was re-run using the following gradient:
65:35 solvent A/solvent B for 5 min, then 35:65 solvent A/solvent B over 25 min.
Fractions were collected every 0.2 minutes and samples corresponding to the centre of
peak at t = 7.5 min which had the desired m/z = 295 were then combined. This sample
was reconstituted by removal of the organic solvent, re-extracted from the remaining
water and the remaining residue was dried and redissolved in d6-DMSO.
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8.1.5 Chiral HPLC analysis
Samples dissolved in 50:50 methanol/water were injected through an Agilent 1100
equipped with a quaternary pump through a Chiral-PAK IA column coupled to a
Bruker High Capacity Trap (HCT) + ion trap mass spectrometer with an electrospray
source, operating in positive ion mode. A 5 min isocratic elution (75:25 solvent
A/solvent B) was followed by gradient elution to 0:100 solvent A/solvent B over 25
min. Solvents A and B were water (0.1 % TFA) and methanol (0.1 % TFA),
respectively.
8.2 Synthetic Chemistry
Unless stated otherwise, all reactions were performed in oven-dried glassware under an
atmosphere of argon using anhydrous solvents. Pyridine was distilled over CaH2. All
reagents that were commercially available were obtained from Sigma-Aldrich or
Fischer Scientific, with the exceptions of some of the ingredients for the growth media,
and were used as provided without further purification unless otherwise stated.
Reaction temperatures were controlled using an IKA RCT basic hot plate stirrer with an
IKA ETS-D5 temperature controller.
8.2.1 Preparation of methyl (S)-4-(3-(1-methoxy-1-oxo-3-phenylpropan-2-
yl)ureido)butanoate (90)
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To a stirred solution of mono-methyl glutarate (1.2 mL, 9.6 mmol, 1.4 eq) in dry
pyridine (6 mL), diphenylphosphorylazide (1.5 mL, 7 mmol, 1 eq) was added and
stirred at 90 °C for 1 h under argon. After 1 h, L-phenylalanine O-methyl ester
hydrochloride (0.736 g, 3.41 mmol, 0.49 eq) was added and the reaction mixture stirred
at 90 °C for a further 4 h. After being allowed to cool, 30 mL ethyl acetate was added
to the reaction mixture, the mixture washed with 2M HCl (5 x 30 mL), and the ethyl
acetate layer dried (MgSO4) and removed under reduced pressure. The product was
then purified by flash column chromatography (4:1 ethyl acetate: hexane eluent),
yielding 331 mg (1.03 mmol, 30% yield) of protected L-gaburedin-Phe, which was a
white solid. This procedure is modified from the work of Takaya, et al.160
The yield reported here is the overall yield from the two-step, one-pot reaction to yield
the dimethyl ester from mono-methyl glutarate, treating L-phenylalanine O-methyl
ester as the limiting reagent.
δH (400 MHz, CDCl3); 1.77 (2H, s, CH2CH2CH2), 2.33 (2H, t, CH2CH2CO, J = 7.3
Hz), 3.08 (2H, m, CH2Ph, J = 6.1 Hz), 3.14 (2H, t, CH2CH2NH, J = 7.1 Hz), 3.66 (3H,
s, CH2COOCH3), 3.71 (3H, s, CH3COCH), 4.75 (1H, t, CH, J = 6.2 Hz), 7.12-7.27 (5H,
multiplet, ArH)
δC (100 MHz, CDCl3); 25.1 (CH2CH2CH2), 31.0 (CH2CH2CO), 38.4 (CH2ArH), 39.8
(CH2CH2NH), 51.8 (CH2COOCH3), 52.3 (CH3COCH), 54.2 (CH), 127.0 (para ArH),
128.5 (meta ArH), 129.3 (ortho ArH), 136.2 (ipso Ar), 157.7 (NHCONH), 172
(CH3OCOCH), 174.0 (CH2COOCH3)
HRMS (ESI) calc’d for C16H22N2O5Na [M+Na]+ 345.1418, found 345.1421
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8.2.2 Preparation of 4-[(1-benzyl-2-hydroxy-2-oxo-ethyl)carbamoylamino]butanoic
acid (91)
The dimethyl ester protected L-gaburedin-Phe 90 (28.8 mg, 8.94 x 10-5 mol) was
redissolved in 18.5 mL of a stirred 1:1 mixture of methanol/aqueous NaOH to a final
concentration of 2M NaOH and heated to 50 °C. After 24 h, the methanol was removed
and the remaining aqueous solution washed with ethyl acetate (3 x 20 mL), the pH of
the mixture reduced to 1 using 2M HCl, and ethyl acetate extractions (3 x 20 mL)
performed. The ethyl acetate extracts were combined, dried (MgSO4) and the ethyl
acetate removed under reduced pressure. The remaining residue was redissolved in 3
mL of a 1:1 mixture of methanol/water and purified by reverse-phase HPLC using the
same conditions as detailed below, with the gradient as follows: 65:35 solvent
A/solvent B for 5 min, to 35:65 solvent A/solvent B over 25 min. Methanol was
removed under reduced pressure and the water removed by lyophilization using a
VirTis benchtop K freeze-dryer, furnishing 12.6 mg (4.27 x 10-5 mol, 48% yield) of 4-
[(1-benzyl-2-hydroxy-2-oxo-ethyl)carbamoylamino]butanoic acid (gaburedin 91),
which was a white solid. The product was dissolved in d6-DMSO for NMR analysis.
δH (500 MHz, d6-DMSO); 1.54 (2H, m, CH2CH2CH2, J = 8.2 Hz), 2.17 (2H, t,
CH2CO2H, J = 8.5 Hz), 2.84-3.01 (4H, m, CH2Ph and NHCH2CH2, J = 8.3 Hz, 8.2 Hz,
8.3 Hz, 13.6 Hz), 4.29 (1H, m, CH, J = 8.3 Hz, 8.3 Hz), 5.96 (1H, d, CHNHCO, J = 8.8
Hz), 6.17 (1H, t, CH2NHCO, J = 8.3 Hz), 8.16-8.25 (5H, m, ArH)
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δC (125 MHz, d6-DMSO); 28.5 (CH2CH2CH2), 31.1 (CH2CO2H), 38.7 (CH2Ph), 38.5
(NHCH2CH2), 54.1 (CH), 126.2 (ArH, para), 128.0 (ArH, meta), 129.3 (ArH, ortho),
138.8 (Ar, ipso), 158.5 (NHCONH), 174.0, (CO2H), 174.3 (CO2H)
HRMS (ESI) calc’d for C14H19N2O5 [M+H]+ 295.1288, found 295.1283
8.3 Microbiological methods
8.3.1 Bacterial strains
Strains of S. venezuelae wild type and sgnL-P::apra mutant strains and S. coelicolor
M1152 were obtained from the John Innes centre, Norwich, UK (M. Al-Bassam and M.
J. Buttner). The gbnR::apra mutant was constructed in our group, University of
Warwick (C. Corre). The gbnR::scar and gbnB::apra, gbnR::scar mutant strains were
constructed in our group in collaboration with the G. L. Challis group (O. Lazos and
A.-C.Olivan).
8.3.2 Culture media
Mannitol Soya Flour Medium Solid (SFM) was prepared by dissolving Bacto agar (20
g), mannitol (20 g) and soya flour (20 g) in tap water (1 L) and autoclaving before use.
LB medium was prepared using LB Broth, Miller (Fisher) to a final concentration of 25
gL-1. For solid LB, Bacto agar was added (15 gL-1).
Mannitol yeast medium (MYM) was made in batches with the following ingredients
added to the concentrations as follows: maltose (4 gL-1), yeast extract (4 gL-1), malt
extract (10 gL-1) and Bacto agar (18 gL-1).
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Unless otherwise stated, Modified Supplemented Minimal Medium Solid (SMMS) was
made up in batches with the following ingredients added to the concentrations as
follows: Difco casaminoacids (2 gL-1), TES buffer (8.68 gL-1) and Bacto agar (15 gL-1)
were dissolved in distilled water, the pH adjusted to 7.2 using 10 N NaOH and
autoclaved. At the time of use, the media was re-melted and the following ingredients
were added to the stated concentrations: NaH2PO4 + K2HPO4 (50 mM each, 10 mL per
litre of culture), MgSO4.7H2O (1 M, 5 mL per litre of culture), glucose (50% w/v, 18
mL per litre of culture), trace elements solution (2 mL per litre of culture). Trace
elements solution contained 0.1 gL-1 each of ZnSO4.7H2O, FeSO4.7H2O, MnCl2.4H2O,
CaCl2.6H2O and NaCl. The solution was stored at 4°C in a refrigerator.
8.3.3 Modified culture media
Unless otherwise stated, modified Supplemented Minimal Medium Solid (SMMS) was
prepared as above, with the addition of each amino acid to final concentration of 20
mM before adjusting the pH to 7.2. In the cases of the amino acid analogues n-
butylamine, isobutylamine, isopentylamine, cyclohexylamine, L-ala-ala and L-valinol,
a separate stock of the amine was dissolved in sterile water and added to the culture
medium after re-melting, and the amount of water used to dilute the initial ingredients
was altered so that the final concentrations of each ingredient was consistent with those
of the other experiments. The prepared media was poured (15 mL per plate).
8.3.4 Culture media enriched with stable isotope precursors
For the feeding experiments with labelled precursors (L-glutamate-1-13C and L-
glutamate-13C5), 5 mL of media was made to a final concentration of 10 mM, keeping
the final concentration and pH of all other ingredients the same as above. 3 μL bacterial 
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spores were used to inoculate each 5 mL plate. Metabolites were extracted at pH 3 and
the culture extracts were redissolved in 200 μL 50:50 HPLC grade methanol/water. 
For experiments with deuterium labelled precursors (d10-L-leucine, d10-L-isoleucine,
d8-DL-valine), 15 mL SMMS was made to a final concentration of 10 mM precursor
molecule, keeping the final concentration and pH of all other ingredients the same as
above. d5-propionic acid and d7-butyric acids were added after autoclaving to a final
concentration of 1 mM or 10 mM. Metabolites were extracted at pH 6 and the culture
extracts were redissolved in 500 μL 50:50 HPLC grade methanol/water. 
8.3.5 Feeding Streptomyces coelicolor M1152 with stable isotope precursors
AlaMM liquid medium (50 mL) was inoculated with 20 μL spores of Streptomyces
coelicolor M1152 and incubated (30 °C, 180 rpm). After 24 h, a solution of sterile
filtered precursor (d5-propionic acid, d7-butyric acid, d8-DL-valine, d10-L-leucine or
d10-L-isoleucine) was added to give a final concentration of 1 mM. This feeding
procedure was repeated at 12 h intervals until a total incubation time of 5 days, after
which the metabolites were extracted from these cultures and analysed as described in
Sections 8.1.2 and 8.1.3.
8.3.6 Preparation of bacterial spores
Mannitol SFM was used for the production of bacterial spores. Media was remelted and
apramycin added to a final concentration of 50 μg mL-1 for growth of the sgnL-P::apra
and gbnR::apra and gbnB::apra, gbnR::scar mutant strains. No apramycin was added
to the SFM used for growth of the wild type S. venezuelae. Each plate of SFM was
inoculated with 20 μL of bacterial spore stocks. After incubating at 30 °C for 5 days, 
sterile water was added to each plate, the spores resuspended, and filtered. The
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suspensions were centrifuged (3000 rpm, 5 minutes) and the supernatants removed,
leaving approximately 1 mL of suspension. To each suspension, approximately 1 mL of
glycerol (50 %) was added and the spore stocks stored at -20 °C. This a variation of the
method detailed by Hopwood, et al.155
8.3.7 Preparation of S. venezuelae Genomic DNA
Genomic DNA was prepared using the MP Bio FastDNA Spin Kit for Soil extraction
kit and enclosed protocol.
8.3.8 Preparation of SV4 F01 Cosmid DNA
Cosmid DNA was initially prepared using the Fermentas GeneJET Plasmid Miniprep
kit, heating the elution buffer to 70 °C and incubating the samples for 5 min before the
final elution step. For further preparations, the following procedure was performed: 60
μL E. coli MC1061 stock was transformed using 2 μL SV4 F01 cosmid DNA by 
electroporation at 1700 V, 1 mL ice cold liquid LB immediately added and these
cultures incubated at 37 °C for 16 h in liquid LB medium with kanamycin added to a
final concentration of 50 μg mL-1. The cells were centrifuged (5 min at 2000 rpm) and
the pellet resuspended in 50 mM Tris/HCl, pH 8; 10 mM EDTA, (200 μL) and 200 mM 
NaOH, 1% SDS (400 μL).  
The mixture was immediately inverted 10 times and 3 M KOAc, pH 8.5 (300 μL) 
added and the mixture inverted another 5 times. The mixture was centrifuged (5 min at
10,000 rpm) and the supernatant extracted with phenol/chloroform (400 μL), vortexed 
for 2 min and centrifuged (5 min at 10,000 rpm). The phenol/chloroform layer was
removed, isopropanol (600 μL) added and centrifuged (20 min at 10,000 rpm, 4 °C). 
The isopropanol was removed and the pellet washed with 70% ethanol (200 μL), 
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centrifuged (5 min at 10,000 rpm) and left open overnight for the ethanol to evaporate.
The following day, the prepared cosmid DNA was resuspended in 35 μL sterile water. 
This is a variation on the method presented by Gust, et al.82
8.3.9 Chemical transformations
For subsequent transformations, 50 μL chemically competent E. coli DH5α (New 
England Biolabs), E. coli TOP10 (Invitrogen) or E. coli BL21star(DE3) (Invitrogen)
were incubated on ice with 1 μL cosmid for 30 minutes before heat-shock in a 42 ˚C 
water bath (30 s). 250 μL LB (or SOC) media was added and cells incubated (37 ˚C, 
180 rpm, 1 h) after which the cells were added to 25 mL LB plates inoculated with
appropriate resistance marker (50 μg mL-1 kanamycin, 100 μg mL-1 ampicillin, 50 μg 
mL-1 apramycin or 34 μg mL-1 chloramphenicol) and incubated (37 ˚C, 16 h). Single 
colonies were picked and incubated further in 10 mL LB containing appropriate
resistance marker(s) (37 ˚C, 180 rpm, 16 h). 0.7 mL of each culture was taken and 
added to 0.7 mL 50 % glycerol for storage at -80 °C.
For transformations using the E. coli iba TOP10 StarGate cells, the same procedure as
above was used with the following modifications: cells were heat-shocked at 37 ˚C for 
5 minutes, and 900 μL LB was used for the 1 h pre-incubation before spreading the 
cells onto selection plates.
8.5.10 Restriction digests
Unless manufacturer’s guidelines recommended otherwise, 0.5 μL of restriction 
endonuclease enzyme was incubated with 2 μL of the recommended buffer and 15 μL 
of the prepared plasmid DNA for 2 h, after which 7 μL DNA loading dye was added to 
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the reaction mixture and a 1 % agarose gel run of the resulting fragments. Reactions
using FastDigest enzymes were incubated for 30 min.
8.3.11 Polymerase Chain Reaction (PCR) conditions
An Eppendorf Mastercycler gradient and an Eppendorf Mastercycler personal PCR
machine were used for variable annealing temperature and constant annealing
temperature PCR reactions, respectively. Unless otherwise stated, the following
quantities of each reagent were used per reaction: sterile water (36 μL), DMSO (2.5 
μL), dNTPs, 10 mM each (2 μL), Fermentas Taq DNA polymerase, 5 UμL-1 (1 μL), 
(NH4)2SO4 buffer (5 μL), MgCl2 buffer (3 μL) DNA template (0.7 μL). 1 μL of each 
forward and reverse primers were used for each reaction.
Expand High Fidelity polymerase (Roche) was used in PCR reactions with the
following quantities of each reagent per reaction: sterile water (37 μL), DMSO (2.5 
μL), dNTPs, 10 mM each (2 μL), Expand High Fidelity polymerase (Roche), 5 UμL-1
(1 μL), MgCl2 buffer (5 μL) and DNA template (0.5-0.7 μL). 1 μL of each forward and 
reverse primers were used for each PCR reaction.
Primers were obtained from Sigma-Genosys and diluted to 100 μM as per the 
manufacturer’s guidelines before use. The typical program below was used for the
single annealing temperature PCR reactions: Reaction mixture heated to 95 °C (5 min),
30 cycles consisting of denaturation at 95 °C (45 s), annealing at 55 °C (45 s) and
elongation at 72 °C (90 s). This was followed by a further elongation step at 72 °C for
15 min. The reaction(s) were then held at 4 °C until PCR products were used for gel
electrophoresis.
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8.3.12 Agarose Gel Electrophoresis
To 5 μL PCR product, 2 μL loading dye was added, and the samples loaded onto a 1% 
agarose gel, prepared by addition of agarose (1 g) to 100 mL 1x TBE buffer and Gel
Red (5 μL) after allowing the gel mixture time to cool. TBE buffer contained Tris base 
(10.8 gL-1), boric acid (5.5 gL-1), and EDTA (1.17 gL-1).
8.3.13 Protein production in E. coli BL21star
10 μL E. coli BL21star stock carrying the plasmid of interest was in 10 mL LB
containing appropriate resistance marker (concentrations as in Section 8.3.9) and
incubated at 37 °C for 16 h. This culture was used to prepare a 1% v/v culture of LB
and grown until cell density had reached OD600nm = 0.6, when isopropyl β-D-1-
thiogalactopyranoside (ITPG) was added to a final concentration of 0.5 mM. After
addition of IPTG, the cultures were grown for a further 16 h at 15 °C. For initial pilot
expressions, control samples were also prepared, to which no IPTG was added.
8.3.14 Preparation of cell lysates
Cells were pelleted by centrifugation at 5000 rpm for 10 minutes (or 3000 rpm, 30
minutes for smaller volumes), and resuspended in wash buffer containing 100 mM
NaCl, 20 mM Tris-HCl (pH 8.8), and 10% v/v glycerol (6 mL buffer used per 50 mL,
15 mL buffer for 500 mL original cell culture). Phenylmethanesuphonylfluoride
(PMSF) was also added (100 μL per 10 mL resuspended cells). Resuspended cell 
pellets stored at -20 °C until time of use. The resuspended cells were lysed using a
Constant Systems E1061 cell disrupter, and the cell debris pelleted by centrifugation at
18,000 rpm for 30 minutes. The supernatant was removed and stored at 4 °C for later
use as a cell-free extract containing soluble proteins. A pipette tip was used to transfer a
Chapter Eight | Experimental
223
small quantity of the cell debris to 1 ml of the above wash buffer, and the resuspended
cell debris was stored at 4 °C for use later as a sample containing the insoluble proteins.
8.3.15 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE)
Samples were prepared by addition of 3 μL of SDS-dye (Thermo) to 20 μL sample and 
incubated at room temperature for at least 1 h before loading onto the prepared gel.
10% SDS-PAGE gels were prepared as follows – for 5 mL resolving gel: distilled
water (2.025 mL), 30% acrylamide solution (1.67 mL), 1.5 M Tris-HCl, pH 8.8 (1.25
mL), 20% w/v sodium dodecyl sulphate (25 μL), 1% w/v ammonium persulphate (100 
μL) and N,N,N,N-tetramethylethylenediamine (TEMED) (5 μL). Stacking gel was 
prepared as follows: distilled water (705 μL), 30% acrylamide solution (167 μL), 1.5 M 
Tris-HCl, pH 8.8 (127 μL), 20% w/v sodium dodecyl sulphate (5 μL), 1% w/v 
ammonium persulphate (100 μL) and (TEMED) (5 μL). 
After allowing the gel to set for 30 min, gels were pre-run at 200 V for 1 h, and then
run at 120V for 10 min after the samples were loaded, which was increased to 200 V
until the second dye front had reached the base of gel. All samples were run
concurrently with PageRuler Plus prestained protein dye (Thermo).
8.4 Biological assays
8.4.1 Induction assay to screen for gaburedin production by non-producing strain
S. venezuelae gbnB/R was grown on 5 x 25 mL plates of SMMS for 3 days, after which
metabolites were extracted at pH 6 as detailed in Section 8.1.2, and the culture extract
redissovled in 2.4 mL MeOH/H2O, sterile filtered and stored at 4 °C until the time of
use. Culture extract (10 µL) was loaded onto sterile discs and the discs placed in the
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centre of a 25 mL SMMS plate inoculated with 10 µL S. venezuelae sgnL-P::apra
spores after 0, 1 or 2 days of growth.
1 cm x 1 cm agar plugs cut out of a 3-day old plate of S. venezuelae gbnB/R culture
were also added to the centre of a 25 mL SMMS plate inoculated with 10 µL S.
venezuelae sgnL-P::apra spores after 0, 1 or 2 days of growth. Control plates were also
prepared in which MeOH/H2O was loaded onto a sterile disc or sterile agar plug was
added to plates inoculated with sgnL-P spores. Plates inoculated with sgnL-P were all
extracted at pH 3 and screened for gaburedin production by LC-MS as detailed in
Section 8.1.3.
For future experiments, metabolites were extracted from 16 x 3 day old 50 mL SMMS
plates inoculated with S. venezuelae gbnB/R and redissovled in 8 mL MeOH/H2O. 1
mL of this extract was diluted by a factor of 10 in MeOH/H2O. Both culture extracts
were sterile filtered and 1 mL added directly to the sgnL-P strain after 0, 1 or 2 days of
growth. Control plates were also prepared to which MeOH/H2O was added. Plates
inoculated with sgnL-P were all extracted and screened for gaburedin production by
LC-MS as in Section 8.1.3.
8.4.2 Induction assay with purified AHFCA compounds
AHFCAs 6 and 7 were dissolved in DMSO to 10 mM concentrations. These solutions
were then diluted up to 500 µL with sterile dH2O and added to re-melted SMMS (5
mL) to give final concentrations of 100 µM, 10 µM and 1 µM AHFCA. 3 µL S.
venezuelae sgnL-P::apra spores were inoculated into each 5.5 mL plate. These cultures
were incubated at 30 °C for 3 days, the metabolites extracted at pH 3 and analysed by
LC-MS.
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For future experiments using purified AHFCA compounds, stock solutions of AHFCAs
5, 6 and 7 (1 M, 0.25 M and 0.025 M) dissolved in DMSO were prepared. 2 µL of each
of these solutions were added to re-melted SMMS to give final AHFCA concentrations
of 400 µM, 100 µM and 10 µM and each 5 mL plate was inoculated with 3 µL of S.
venezuelae sgnL-P::apra spores. These cultures were incubated at 30 °C for 3 days, the
metabolites extracted at pH 3 and analysed by LC-MS.
8.4.3 Antibiotic assay
Cultures of the target strains of E. coli rosetta kanR, S. coelicolor M1152 and Bacillus
subtilis were grown in LB to a final OD600 of 0.4. 300 µL of these cultures were each
added to 3 mL warmed ‘soft’ LB (0.7% agar) and this mixture added to 25 mL of pre-
prepared LB. S. venezuelae gbnR and gbnB/R was grown on 5 x 50 mL plates of
SMMS for 3 days, after which neutral extractions were performed, and the culture
extracts redissovled in 2.4 mL MeOH, sterile filtered and stored at 4 °C.
7 µL of prepared extract was added to a sterile disc and placed on top of the soft agar
inoculated with the target strains. A control disc was also prepared on each plate,
inoculated with 7 µL ampicillin (5 mg mL-1 final concentration). The plates were
incubated at 30 °C (S. coelicolor) or 37 °C (E. coli and B. subtilis) for 24 hr and
inspected for zones of inhibition.
8.4.4 In vivo assay for gaburedin or gaburedin analogue production by E. coli
BL21star/pJDS02, E. coli BL21star/pJDS04 and E. coli BL21star/pJDS06
As in Sections 8.3.13 and 8.3.14, E. coli BL21star, E. coli BL21star/pJDS02, E. coli
BL21star/pJDS04 and E. coli BL21star/pJDS06 were grown and induced with IPTG,
and GABA was added to a final concentration of 10 mM. The cells were grown and
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pelleted (4000 rpm, 40 min), after which metabolites were extracted from the supernant
(50 mL ethyl acetate, pH 2). The cells were lysed (5 mL buffer) and metabolites
extracted from the cell lysates (10 mL ethyl acetate, pH 2).
8.4.5 In vivo assay for gaburedin or gaburedin analogue production by E. coli
BL21star/pJDS10
As in Section 8.4.4, except cultures were inoculated with 1 mM L-glutamate final
concentration at the same time as addition of IPTG.
8.5 Molecular biology
8.5.1 Construction of plasmids pJDS02, pJDS04, pJDS05, pJDS06 and pJDS08
Each gene of interest was amplified by PCR with High Fidelity Polymerase (Roche) as
described in Section 8.3.11 and appropriately designed primer pairs (Table 8.1). PCR
products were run on a 1 % agarose gel, the bands of interest excised, and purified
using the GeneJet Gel Extraction Kit (Fermentas).
Concentrations of each pure PCR product were determined by use of a Thermo
NanodropLite, and diluted accordingly to fall within the desired range of 1-5 ng μL-1
for cloning into pET151 as directed by the Invitrogen TOPO cloning manual. 1 μL of 
each of the diluted PCR products were mixed with sterile water and the other
components of the kit and incubated for 5 min as directed in the TOPO cloning manual.
E. coli TOP10 cells were transformed (as in Section 8.3.9) using 3 μL of each TOPO 
cloning reaction mixture and poured onto selection plates with 100 μg mL-1 final
concentration of ampicillin.
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Table 8.1– Primers used for cloning gbnA and gbnB from Streptomyces venezuelae into pET151 for
protein overproduction. Restriction sites are highlighted in italics, and 5’-CACC overhangs are
underlined
TOPO cloning primers for cloning native S. venezuelae genes:
Primer Gene to amplify Sequence
A’ gbnA (sven_4179) 5’-CACCATGACCGCATCCACCAGC-3’
A’ gbnA (sven_4179) 5’-GGGAGGTGAGGTGTGGTC-3’
B’ gbnA (sven_4179) 5’-CACCATGACCGCATCCACCAGCTCCAC-3’
B’ gbnA (sven_4179) 5’-GAGCCGGGAGGTGAGGTGTGGTC-3’
C’ gbnA (sven_4179) 5’-CACCATGACCGCATCCACCA-3’
C’ gbnA (sven_4179) 5’-AGCCGGGAGGTGAG-3’
D’ gbnB (sven_4180) 5’-CACCATGATCAAGATCGCGG-3’
D’ gbnB (sven_4180) 5’-GGCGGGGGCGGCCGGGTC-3’
E’ gbnB (sven_4180) 5’-CACCATGATCAAGATCGCGGACATCCG-3’
E’ gbnB (sven_4180) 5’-GGGTCGGCGGGGGCGGCCGGGTC-3’
S’ sgnL (sven_4183) 5’-CACCTCCATCGGTGTGCTGCAG-3’
S’ sgnL (sven_4183) 5’-CCGGCCCTCACGCG-3’
T’ sgnR (sven_4182) 5’-CACCGCGACACCCCGAAGCCAA-3’
T’ sgnR (sven_4182) 5’-TCAGCGGCGCAGGCC-3’
Screening primers:
Primer Gene to amplify Sequence
F’ gbnR (sven_4187) 5’-CCTTGAGTGGTGGTACTG-3’
F’ gbnR (sven_4187) 5’-GACGTCACACTCGTCATC-3’
G’ gbnA (sven_4179) 5’-CTTGCGGCCTTGCGGCCTTG-3’
G’ gbnA (sven_4179) 5’-TCGGGATCGGAGGCGGAGTG-3’
H’ gbnB (sven_4180) 5’-GCCACCAGCTGACCACAC-3’
H’ gbnB (sven_4180) 5’-TCCGGCTGGGAGTTGAGG-3’
I’ gbnA (sven_4179) 5’-CTTGCGGCCTTGCGG-3’
I’ gbnA (sven_4179) 5’-TCGGGATCGGAGGCG-3’
TOPO cloning of synthetic gbnB from sven, seag and smug:
Primer Gene to amplify Sequence
J’ synthetic sven_gbnB 5’-CACCATCAAAATTGCCGATA-3’
J’ synthetic sven_gbnB 5’-AAGGCCCATGAGGC-3’
K’ synthetic seag_gbnB 5’-CACCATGATTACCCTGCGTCG-3’
K’ synthetic seag_gbnB 5’-CCCATGAGGCCCAG-3’
L’ synthetic smugs5_gbnB 5’-CACCATGCTGGCACTGGAAAATC-3’
L’ synthetic smugs5_gbnB 5’-GCCCATGAGGCCCAG-3’
Subcloning synthetic gbnB into pJDS05 and synthetic gbnA into pJDS5:
Primer Gene to amplify Sequence
M’ synthetic sven_gbnA 5’-CACCACCGCAAGCACCAG-3’
M’ synthetic sven_gbnA 5’-CCCATGAGGCCCAG-3’
N’ synthetic sven_gbnA 5’-GAGCTCATGACCGCAAGCACCA-3’
N’ synthetic sven_gbnA 5’-GAGCTCTTAGCTGGTCGCAACTG-3’
O’ synthetic sven_gbnB 5’-GAGCTCATGATCAAAATTGCCGATATC-3’
O’ synthetic sven_gbnB 5’-GAGCTCTTAAACACCAACGGTTTCTG-3’
Sequencing primers:
Primer Gene to amplify Sequence
T7_for T7 promoter forwards 5’-TAATACGACTCACTATAGGG-3’
T7_rev T7 terminator reverse 5’-CTAGTTATTGCTCAGCGG-3’
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Colonies (typically 5 to 10) were picked from these plates, added to 10 mL LB
containing 100 μg mL-1 final concentration of ampicillin and incubated at 37 °C for 16
h. Glycerol stocks were prepared and plasmids purified from these overnight cultures.
The purified plasmids were confirmed as containing the correct gene inserts by PCR
with primers specific for each gene (Tables 8.1 and 8.2) and by restriction digests with
appropriate enzyme(s). Plasmids that gave both the expected sized PCR products and
expected sized DNA fragments resulting from the restriction digests were sent for
sequencing by GATC Biotech, during which the gene of interest was sequenced using
the T7 primer pairs (Table 8.1).
8.5.2 Cloning of SgbnB into pJDS05 and SgbnA into pJDS06
Synthetic S. venezuelae gbnA was amplified from pMK-RQ+sven_gbnA using primers
N/N’ and Synthetic S. venezuelae gbnB was amplified from pMK-RQ+sven_gbnB
using primers O/O’ (Table 8.1). PCR products were gel extracted from 1% agarose gel
and concentrations determined by use of the Thermo NanodropLite. Plasmids pJDS05
and pJDS06 were digested with SacI, followed by treatment with shrimp alkaline
phosphatase (1 µL, 37 °C, 30 min). Digested plasmid was run on a 0.8% agarose gel
and extracted using the gel extraction kit (Fermentas).
Following the product information protocol, the digested pJDS05 was mixed together
with the synthetic gbnB PCR and the digested pJDS06 was mixed with the synthetic
Table 8.2 – pET-151-derived plasmids constructed during this study
pJDS template gene amplified primers
used
enzyme
used
length
/ bp
02 pMK-RQ synthetic seag_gbnB (seag_B2133) K/K’ NdeI 7271
04 pMK-RQ synthetic smug_gbnB (smugs5_01685) L/L’ PstI 7239
05 pMK-RQ synthetic sven_gbnA (sven_4179) M/M’ SphI 7448
06 pMK-RQ synthetic sven_gbnB (sven_4180) J/J’ NdeI 7374
08 SV4 F01 sven_sgnL (sven_4183) S/S’ PstI 6802
Chapter Eight | Experimental
229
gbnA PCR product. These solutions were incubated (25 °C, 2 h) with 0.1 µL (0.1 U) T4
DNA ligase (see Table 8.3 for conditions tested). The ligation product (2 µL) was used
to transform 25 µL E. coli DH5α, and colonies were picked, grown overnight and 
plasmids purified from them. Plasmids were checked for the correct insert by PCR and
restriction digest with NdeI.
8.5.3 Construction of plasmids pJDS09-pJDS11 from Duet vectors
pET-Duet and pACYC-Duet (Novagen) were used to transform E. coli iba StarGate
cells using ampicillin and chloramphenicol to select for positive colonies for pET-Duet
and pACYC-Duet, respectively. Plasmids were purified and verified by restriction
digest with AccI.
Primers P/P’ (Table 8.4) were used to amplify synthetic gbnA from the pMK-RQ
template. Purified PCR product was digested: DNA (30 μL), NEB CutSmart buffer (4 
μL) and BamHI-HF/HindIII-HF (2 μL each) were combined and incubated at 37 °C for 
1 h. pET-Duet (15 μL) was also digested in NEB CutSmart buffer (2 μL) using BamHI-
HF/HindIII-HF (1 μL each) and incubated  at 37 °C for 1 h. Digested PCR product and 
Table 8.3 – Conditions for ligations of SacI digested products and plasmids
for pJDS05 and synthetic gbnB:
digested PCR product
/ fmol
digested plasmid
/ fmol
alkaline
phosphatase used?
Ligation mixtures diluted
prior to transformations?
24.7 8.48 No x1, x10, x100
24.7 8.44 Yes x1, x10
74.1 8.48 Yes x1, x10
for pJDS06 and synthetic gbnA:
digested PCR product
/ fmol
digested plasmid
/ fmol
alkaline
phosphatase used?
Ligation mixtures diluted
prior to transformations?
22.4 6.80 No x1, x10, x100
24.4 8.00 Yes x1, x10
68.2 6.80 Yes x1, x10
73.2 8.10 Yes x1, x10
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pET-Duet were re-purified (gel extraction kit), followed by ligation with T4 ligase
(21.8 fmol digested synthetic gbnA and 8.95 fmol digested pET-Duet were incubated
with 4 μL T4 ligase buffer and 1 μL T4 ligase in total reaction volume of 20 μL at 4 °C 
for 24 h).
The ligation mixture (16 μL) was used to transform E. coli iba StarGate cells, positive
colonies picked from selection plates, grown overnight and plasmid pJDS09 purified
from these overnight cultures. Plasmids were verified as containing the correct insert by
PCR using the specific primers ‘pETup’ and ‘T7_term’ (Table 8.4) used to amplify
synthetic gbnA, and also by restriction digest (15 μL plasmid was incubated with 2 μL 
buffer and 0.5 μL PstI (FastDigest) at 37 °C for 30 min). Plasmids that gave both the
expected sized PCR products and expected sized DNA fragments resulting from the
restriction digests were sent for sequencing (GATC biotech) using primers ‘pETup’
(forwards direction) and ‘pET-RP’ (reverse direction).
Table 8.4 – Primers used for construction and sequencing of plasmids pJDS09-pJDS11. Restriction
site sare shown in italics
Cloning primers:
Primer Gene to amplify Sequence
P’ synthetic gbnA 5’-AATTGGATCCGACCGCAAGCACCAG-3’
P’ synthetic gbnA 5’-ATATAAGCTTTTAGCTGGTCGCAACT-3’
Q’ synthetic gbnB 5’-TATAGGCCGGCCACATCAAAATTGCCGATATC-3’
Q’ synthetic gbnB 5’-ATATGGTACCTTAAACACCAACGGTTTCT-3’
R’ synthetic gbnC 5’-ATTAGGATCCGAATAGCCAGAATACCTATACC-3’
R’ synthetic gbnC 5’-TATAAAGCTTTTAGCTACGGGTGCC-3’
Sequencing primers:
Primer Gene to amplify Sequence
pETup See Appendix 3 5’-ATGCGTCCGGCGTAG-3’
pACYCup See Appendix 3 5’-GGATCTCGACGCTCTCCCT-3’
UP2 See Appendix 3 5’-TGTACACGGCCGCATAATC-3’
DOWN1 See Appendix 3 5’-GATTATGCGGCCGTGTACA-3’
T7_term See Appendix 3 5’-GCTAGTTATTGCTCAGCG-3’
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For the subsequent cloning of synthetic gbnB into MCS 2 of pET-Duet, synthetic gbnB
was amplified from pMK-RQ using specific primers Q/Q’ to introduce FseI and KpnI
restriction sites at the 5’ and 3’ ends of synthetic gbnB, respectively. PCR product and
pJDS09 (25 μL each) were digested with FseI and KpnI (2 μL each, 3 h with 3 μL NEB 
Buffer 1.1) and digestion products re-purified. 113 fmol digested synthetic gbnB and
35.5 fmol digested pJDS09 were incubated with 4 μL T4 ligase buffer and 1 μL T4 
ligase in total reaction volume of 20 μL at 4 °C for 24 h. The ligation mixture (16 μL ) 
was used to transform E. coli iba StarGate cells, positive colonies picked from selection
plates, grown overnight and the plasmid pJDS10 purified from these overnight cultures.
Plasmids were verified as containing the correct insert by digestion with HindIII, and
plasmids that gave the expected band pattern were sent for sequencing (GATC biotech)
using primers ‘UP2’ (forwards direction) and ‘T7_term’ (reverse direction), see Table
8.4.
Primers R/R’ (Table 8.4) were each used to amplify synthetic gbnC by PCR. PCR
product and  pACYC-Duet (25 μL each) were digested with BamHI and HindIII (2 μL 
each, 4 h with 3 μL NEB CutSmart buffer) and digestion products re-purified. 78.9 
fmol digested synthetic gbnC and 21.2 fmol digested pACYC-Duet were incubated
with 4 μL T4 ligase buffer and 1 μL T4 ligase in total reaction volume of 20 μL at 4 °C 
for 24 h.
16 μL of the ligation mixture was used to transform E. coli iba StarGate cells, positive
colonies picked from selection plates, grown overnight and the plasmid pJDS11
purified from these overnight cultures. Plasmids were verified as containing the correct
insert both by digestion with AccI and by double digestion with BamHI/HindIII.
Plasmids that gave the expected band pattern were sent for sequencing (GATC biotech)
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using primers ‘pACYCup’ and ‘T7_term’ (Table 8.4). A summary of the plasmids
pJDS09-pJDS11 constructed from Duet cloning vectors are shown in Table 8.5.
Table 8.5 – Duet-derived co-expression vectors constructed during this study
pJDS parent vector gene inserted primers
used
enzymes used length
/ bp
09 pET-Duet synthetic gbnA (sven_4179) P/P’ BamHI, HindIII 7064
10 pJDS09 synthetic gbnB (sven_4180) Q/Q’ FseI, KpnI 8645
11 pACYC-Duet synthetic gbnC (sven_4181) R/R’ BamHI, HindIII 5040
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Appendix 1 - UV spectrum of gaburedin A (80) obtained during the preliminary
study
Figure T – UV and mass spectrum of compound 80 from preliminary data
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Appendix 2 – Genetic context of gbnABC orthologues in other microorganisms
S. venezuelae
ATCC10712
Salmonella enterica subsp.
enterica serovar Agona str. SL483
Pantoea ananatis LMG 5342
Streptococcus mutans GS-5
Azosporillum brasilense sp245
Vibrio vulnificus MO6_24/O
2000 4000 6000
glyceraldehyde-3-phosphate
dehydrogenase
hypothetical GbnA-like/decarboxylase GbnB orthologues GbnC orthologues fused GbnB/GbnC s
Clostridium papyrosolvens
Enterobacter cloacae
complex
Providencia alcalfaciens Dmel2
Marinomonas sp. ME121
Lactobacillus paraplantarum
Photobacterium
halotolerans
Streptomyces
sp. NRRL B24484
Streptomyces
Amel 2xE9
Streptomyces globisporus
SgnL/H/P and
orthologues
isochromatase
hydrolase
pyruvate
carboxyltransferase
LysR regulator repressor
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Appendix 3 - Sequences of synthetic genes used in this study
Synthetic sven_4179 (S. venezuelae gbnA) native sequence is NCBI Gene ID:
13819337
1 ATG ACC GCA AGC ACC AGC AGC ACA CCG GAA CCG GCA CAT CGT CCG GCA CGT CCG GGT GCA
>>..............................synthetic_gbnA................................>
m t a s t s s t p e p a h r p a r p g a
61 TAT CCG GAT GGT CGT ACA CCG CTG GCA GAT GCA GTT CTG GCA GTT GCA CGT CGT GAT ATT
>...............................synthetic_gbnA................................>
y p d g r t p l a d a v l a v a r r d i
121 GCA ACC TTT CAT GCA CTG CCG CTG AGC CAT GGT CGT AGC ATT CGT GAT AGC CAT ATG CGT
>...............................synthetic_gbnA................................>
a t f h a l p l s h g r s i r d s h m r
181 GAA ACC TAT GAA GCA CTG TTT GGA GCA GCA CAG CTG GCA GCA GAT GTT AGC TAT AGC GGC
>...............................synthetic_gbnA................................>
e t y e a l f g a a q l a a d v s y s g
241 ACC ATG CTG GAT AGC TTT TTT CGT CCG CGT GGT CCG CTG CGT GAA GCA CAG CGT CTG GCA
>...............................synthetic_gbnA................................>
t m l d s f f r p r g p l r e a q r l a
301 GCA CGT AGC TTT GGT GCA GAT GCA ACC TTT TTT CTG AGC GCA GGC ACC AGC ACC GCA AAT
>...............................synthetic_gbnA................................>
a r s f g a d a t f f l s a g t s t a n
361 CGT GTT GCA CTG ACC GCA ATG ACC CGT CCG GGT AGC CGT GTT CTG GCA GAT CGT AGC TGT
>...............................synthetic_gbnA................................>
r v a l t a m t r p g s r v l a d r s c
421 CAT CAG AGC GTT CAT TTT GCA CTG AAT AGC CTG GGT GTT AGC GTT GCA TAT GCA CCG ATG
>...............................synthetic_gbnA................................>
h q s v h f a l n s l g v s v a y a p m
481 CAG CGT TGT TGT GAA GAT TGT CCG CGT ACC TAT GCA GAT CTG CCT CGT CTG CTG GAA ATG
>...............................synthetic_gbnA................................>
q r c c e d c p r t y a d l p r l l e m
541 TTT CGT GCA GCA GCA GTT GAA GGT CGT CCG TAT GAT ACC GTT GTG CTG AGC GCA GTT AGC
>...............................synthetic_gbnA................................>
f r a a a v e g r p y d t v v l s a v s
601 TAT GAT GGT GTT CGT TAT GAT CTG CCG ACC GTT CTG GCA GAA CTG GCA GCA GTT CAT CCG
>...............................synthetic_gbnA................................>
y d g v r y d l p t v l a e l a a v h p
661 GGT GTT GCA GTT CTG GTT GAT GAA GCA TGG GGT GCA GCA CAT CGT TTT CAT CCG CGT CTG
>...............................synthetic_gbnA................................>
g v a v l v d e a w g a a h r f h p r l
721 CGT CCG CTG ACC GCA CTG CAT GCC GTT GAA ACC CTG CGT GCA GCA GAT CCG CGT TTT ACC
>...............................synthetic_gbnA................................>
r p l t a l h a v e t l r a a d p r f t
781 ATG AAT GTT GCA GTT ACC CAT AGC GCA CAT AAA AGC ATG AGC GCA CTG CGT CAG GGT AGC
>...............................synthetic_gbnA................................>
m n v a v t h s a h k s m s a l r q g s
841 TAT CTG CAT CTG ATT GGT GAT GGT GAA GCA CGT GAA CGT ACC GCA CAG GCA CTG TTT CAG
>...............................synthetic_gbnA................................>
y l h l i g d g e a r e r t a q a l f q
901 CAT CAT ACC ACC AGT CCG AGC TGG CCT GTT CTG GCA AGC CTG GAT CTG GCA CGT CTG CAG
>...............................synthetic_gbnA................................>
h h t t s p s w p v l a s l d l a r l q
961 GCA GAA ACC GAA GGT GAA GCA CTG CTG GGT CGT AGT CTG GGG CTG GCA CGT ACC CTG CGT
>...............................synthetic_gbnA................................>
a e t e g e a l l g r s l g l a r t l r
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1021 GTT GAA CTG GCA ACC GAT CCG CGT CTG AGC GCA TAT CGT CCG CTG GGT CCG GAT GGA CAT
>...............................synthetic_gbnA................................>
v e l a t d p r l s a y r p l g p d g h
1081 CTG ACC GAT CCT GCA CAG CTG GTT AGT GAT GAT CCG ACC CGT GTT CTG GTG GAT ATT AGC
>...............................synthetic_gbnA................................>
l t d p a q l v s d d p t r v l v d i s
1141 GCA CTG GGT ATT ACC GCA GCA GAT TTT CGT CGT ATG CTG TTT GAT GAA TAT GCA CTG TAT
>...............................synthetic_gbnA................................>
a l g i t a a d f r r m l f d e y a l y
1201 GTT GCA CGT GAA AGC GGT GAT GCC GTT CTG TTT CAT ATT CAT ATT GGT GTT GAT GAA GCC
>...............................synthetic_gbnA................................>
v a r e s g d a v l f h i h i g v d e a
1261 ACC CTG CTG CGT CTG CTG GAT GCA CTG CGT ACC ATT CAG CGT ACC TAT CGT AGC GCA AGC
>...............................synthetic_gbnA................................>
t l l r l l d a l r t i q r t y r s a s
1321 GAA GCA CTG GCA GCA GGT ACA AGC GAA CAT TTT ATC ATT GCA TAT CCG CCT GGT ATT CCG
>...............................synthetic_gbnA................................>
e a l a a g t s e h f i i a y p p g i p
1381 ATT ACC GTT CCG GGT GAA AAA CTG TGT GAA CGT ACC CTG AGC CAG ATT GAT ACC CTG CGT
>...............................synthetic_gbnA................................>
i t v p g e k l c e r t l s q i d t l r
1441 AGC AGT GGT TGT GAA ATC TAT ACC CTG CGC AAT CCG ACC GTT AGT GCC GGT GCA CTG GCT
>...............................synthetic_gbnA................................>
s s g c e i y t l r n p t v s a g a l a
1501 GCC CAG GCA GCA GCA ACA GGT GCA CTG CCT GTT CCG GCA GGT CAT CTG GCA GCA CCG CCT
>...............................synthetic_gbnA................................>
a q a a a t g a l p v p a g h l a a p p
1561 CCG ACC AGC GAA CGT CTG GCT GGT GCA GCA GCC GCA GTT AGC GCA GCA GGC ACC ACC GCA
>...............................synthetic_gbnA................................>
p t s e r l a g a a a a v s a a g t t a
1621 GCA ACC GTT AGC GCA GCT GCA GCA ACC GCA GTG GCA ACC GCA GTT GCG ACC AGC TAA
>.............................synthetic_gbnA.............................>>
a t v s a a a a t a v a t a v a t s -
Synthetic sven_4180 (S. venezuelae gbnB) native sequence is NCBI Gene ID:
13819338
1 ATG ATC AAA ATT GCC GAT ATC CGT AAA CAT GCA ACC CGT TGG CCT CAG CGT GTT GCA GTT
>>..............................synthetic_gbnB................................>
m i k i a d i r k h a t r w p q r v a v
61 GTT GAT GGT GAA ACC CGT ATG ACC TGG GCA AGC TTT AGC GAT AAA GTT AGC CGT GTT AGC
>...............................synthetic_gbnB................................>
v d g e t r m t w a s f s d k v s r v s
121 TGT GCA ATT CAG GAT CTG CTG CCG GAA ACC CGT CCG GCA CGT GCA GTT TTT CTG GCA GAA
>...............................synthetic_gbnB................................>
c a i q d l l p e t r p a r a v f l a e
181 AAT TCA TGG GAA CTG GTT GTT AGC ATG GCA GCA GTT AGC AGC CTG GGT ATT CCG TGT GTT
>...............................synthetic_gbnB................................>
n s w e l v v s m a a v s s l g i p c v
241 GGT CTG GAT TAT ACC GCA GGT CCG GTT GCA ACC CGT GCA GCA CTG GAT CAG CTG GAA CCG
>...............................synthetic_gbnB................................>
g l d y t a g p v a t r a a l d q l e p
301 ACC GTT GTT ATT ACC AGC CGT GCA CAT CGT GCC CTG CTG GAA GAA TGT GGT TGG CCG AAT
>...............................synthetic_gbnB................................>
t v v i t s r a h r a l l e e c g w p n
361 GGT CGT GAT ATT CTG GAT ATT TTT CTG GAT AGC GAA CCG GTT GGT CTG CCG GAT GGT CAG
>...............................synthetic_gbnB................................>
g r d i l d i f l d s e p v g l p d g q
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421 ACC GTT AGC GTT AGC TTT ACC GAT CTG CTG GTT AGC GCA CCG GGT GAT CCG CAG CCG GTT
>...............................synthetic_gbnB................................>
t v s v s f t d l l v s a p g d p q p v
481 GAA CAG CCG TTT GAA GCA TTT AGC TTT ACC AGC GGC ACC AGC GGT GTT CCG AAA ATG GTT
>...............................synthetic_gbnB................................>
e q p f e a f s f t s g t s g v p k m v
541 GTT CGT CGT ACC AGC TTT GAA GCA CGT CGT TTT GCA GAT CTG GTT GAT CAG TAT GCA TTT
>...............................synthetic_gbnB................................>
v r r t s f e a r r f a d l v d q y a f
601 GAT GAA GAA GAT GTG CAT CTG GTT ACC GTT CCG CTG TAT CAT GCA AGC GGT CCG GGT TGG
>...............................synthetic_gbnB................................>
d e e d v h l v t v p l y h a s g p g w
661 GCA CGT ATT TTT CTG ACC CTG GGT GGC ACC GTT GTT CTG GGT CCG CAT GAT GAT GCC GGT
>...............................synthetic_gbnB................................>
a r i f l t l g g t v v l g p h d d a g
721 GAA CTG ATT CGT ATT ATT CAG GAT GAA GGT GTT AGC ACC ACC CTG ATG GTT CCG CCT GTT
>...............................synthetic_gbnB................................>
e l i r i i q d e g v s t t l m v p p v
781 CTG GCA CGT GTT GTT GCA CAT CCG GAT AGC GAA CAT CTG CAT AAA ACC AGC CGT CTG CAT
>...............................synthetic_gbnB................................>
l a r v v a h p d s e h l h k t s r l h
841 TTT GTT CTG AGC GGT GGT CGT CAT CTG AAT CGT TGG GTT ATT AAC AAT GCA TGG GAT CGT
>...............................synthetic_gbnB................................>
f v l s g g r h l n r w v i n n a w d r
901 CTG GGT CCG GTT CTG CAT CTG TAT TAT GGC ACC ACC GAA ACC GGT GTT AAT GTT ATG ATT
>...............................synthetic_gbnB................................>
l g p v l h l y y g t t e t g v n v m i
961 GGT CCG GAA GAA CTG CAT GTT GCA CCG TGT CGT AGC GGT CGT CCG ATG CCT GGT AAT ACC
>...............................synthetic_gbnB................................>
g p e e l h v a p c r s g r p m p g n t
1021 GTT GTT GTT CTG GAT GCA GAA AAT CGT CCG CTG CCG AAA GGT AGC CGT GGT CGT GTT GCA
>...............................synthetic_gbnB................................>
v v v l d a e n r p l p k g s r g r v a
1081 ATT GCC AGC TAT CAG CTG ATG GAT AGC TAT GCA ACC AGC GAA CCG GAT TTT ATG ACC CTG
>...............................synthetic_gbnB................................>
i a s y q l m d s y a t s e p d f m t l
1141 GAT TAT GGT GGT CGT ACC CAG CGT TTT CTG CTG ACC GGT GAT AGC GGT CTG GTT GAT GAA
>...............................synthetic_gbnB................................>
d y g g r t q r f l l t g d s g l v d e
1201 GCA GGT CGT CTG GAA CTG ACC GGT CGT AAT GAT GGT GTT GCA AAA GCA GAA GCA GGT AAA
>...............................synthetic_gbnB................................>
a g r l e l t g r n d g v a k a e a g k
1261 CCG CTG GAT GTT AAC ATT TTT GGT CTG GAA GCA GAT CTG ATG GAT CTG CCG TGT GTT CGT
>...............................synthetic_gbnB................................>
p l d v n i f g l e a d l m d l p c v r
1321 GAA ACC GCA GTT CTG CGT ACC AGC CTG CCT GGT GCC GGT GAA GTT CTG GTT GTT CCG TTT
>...............................synthetic_gbnB................................>
e t a v l r t s l p g a g e v l v v p f
1381 ACA CCG GTT GCA CCG GAA CGT CAA GAA AGC GGT TAT CGT GCA GTT AGC GCA GCA TGT GCA
>...............................synthetic_gbnB................................>
t p v a p e r q e s g y r a v s a a c a
1441 CGT CGT GTT CCG TGT CTG CCT GCA TAT GTT GTT CCG GTT GAT GCA ATT CCG TAT AGC CCG
>...............................synthetic_gbnB................................>
r r v p c l p a y v v p v d a i p y s p
1501 ACC GGT AAA GTT CGT GCA GCA CAG CTG CTG GAA AGC GTT CTG CCG CTG CTG GAT ATT CGT
>...............................synthetic_gbnB................................>
t g k v r a a q l l e s v l p l l d i r
1561 CCG GCA GAT GAA CGT GAA GCA GAA ACC GTT GGT GTT TAA
>.................synthetic_gbnB.................>>
p a d e r e a e t v g v -
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Synthetic sven_4181 (S. venezuelae gbnC) native sequence is NCBI Gene ID:
13819339
1 ATG AAT AGC CAG AAT ACC TAT ACC CGT GGT GTT CTG CTG TGT CTG CTG GCA ACC GTT AGC
>>..............................synthetic_gbnC................................>
m n s q n t y t r g v l l c l l a t v s
61 TGG GGT GCA ATG TTT CCG CTG ATG GAT AGC ACC CTG CAG CAT ATT GAT CCG TTT ACC TTT
>...............................synthetic_gbnC................................>
w g a m f p l m d s t l q h i d p f t f
121 ACC GTT ATG CGT TAT ACC ATT GCC GGT GCC ATG TTT CTG GTT TTT CTG CGT ATG CGT GAA
>...............................synthetic_gbnC................................>
t v m r y t i a g a m f l v f l r m r e
181 GGT CGC GAA GGT CTG CGT CTG AAA GGT GAA CGT ATT GGT CTG GCA TGG CTG TTT GGT ACA
>...............................synthetic_gbnC................................>
g r e g l r l k g e r i g l a w l f g t
241 GCA GGT TTT GCC GGT TTT CAG TTT CTG GTG TTT TTT GGT CAG GAT CTG ATT GGT GCA CGT
>...............................synthetic_gbnC................................>
a g f a g f q f l v f f g q d l i g a r
301 GGT GCA CTG AAT GCA AGC ATT ATG ATG GCA ACC ATG CCG ATG ATG GGT TTT CTG GTT AAT
>...............................synthetic_gbnC................................>
g a l n a s i m m a t m p m m g f l v n
361 TGG GTG ATG AAA AAA GTT GTG CCT CCG AAA TTT AGC CTG GTG TTT ATT GCA ATG AGC TTT
>...............................synthetic_gbnC................................>
w v m k k v v p p k f s l v f i a m s f
421 GTT GGC ACC ATT CTG GTT GTT AGC AAT GGT GAT ATT GGT AGC CTG ATT GCA AGC CCG AAA
>...............................synthetic_gbnC................................>
v g t i l v v s n g d i g s l i a s p k
481 GAA GCA GGC GCA GAC GCA CTG CTG CTG TTT GCA GCA CTG TGT TGG GTT GTT TAT ACC AGC
>...............................synthetic_gbnC................................>
e a g a d a l l l f a a l c w v v y t s
541 GGT GCA AGC TAT TTT CCG ACC TGG TCA CCG ATC AAA TAT ACC GCA ATT ACC ACC GTT CTG
>...............................synthetic_gbnC................................>
g a s y f p t w s p i k y t a i t t v l
601 GGT CTG GCA AGC GCA ACC GTT ATT ACC GCA GTT ATT CTG GCA GCC GGT GGT GTT CCG GTT
>...............................synthetic_gbnC................................>
g l a s a t v i t a v i l a a g g v p v
661 CCG ACC GCT GGT GCA GTT GGT ACA ATT CTG CCG CAG CTG GCA TAT ATG AGC GTT ATT GCA
>...............................synthetic_gbnC................................>
p t a g a v g t i l p q l a y m s v i a
721 GGT TTT GTT GGT GTT CTG GGT TGG AAT TTT GGT AAT CGT TAT CTG GGT CCG CTG AAT GGT
>...............................synthetic_gbnC................................>
g f v g v l g w n f g n r y l g p l n g
781 GTT CTG TTT ATG GAT GTT GTT CCG GTT ACC GCA TTT GTT ATT AGC GCA CTG ACC GGT GTT
>...............................synthetic_gbnC................................>
v l f m d v v p v t a f v i s a l t g v
841 GTT CCG GCA GGC GTT CAG ATT GTT GGT GCA AGC CTG ACC GCA GCA GCA CTG GTT TTT AAC
>...............................synthetic_gbnC................................>
v p a g v q i v g a s l t a a a l v f n
901 AAT CTG TAT CTG CGT CGT ATT GCA AAA GCA GCA CCG GCA GCA AGT CCG GCA CCG GCA GCT
>...............................synthetic_gbnC................................>
n l y l r r i a k a a p a a s p a p a a
961 AGC GGT CCG AGC GTT GGT AGC AGC AGC GGT ACA AGC AGC GGC ACC GCA AGC GGT AGC GGT
>...............................synthetic_gbnC................................>
s g p s v g s s s g t s s g t a s g s g
1021 AGC GCA AGT GCA CCG GCA CCG GTT GGT AGC GGC ACC CGT AGC TAA
>.....................synthetic_gbnC.....................>>
s a s a p a p v g s g t r s -
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Synthetic seag_b2133 (S. enterica gbnB) native sequence is NCBI Gene ID: 6795111
1 ATG ATT ACC CTG CGT CGT CTG AAT GAA ATT GCA ATT ACC CGT GGT AAC GAT ATC TGC ATC
>>.................................seag_gbnB..................................>
m i t l r r l n e i a i t r g n d i c i
61 ATT GAT AAA GAA CGT CAG TAT ACC TGG TAC GAT ATT ATT CGT CGT ACC GAA AGC CGT ATT
>..................................seag_gbnB..................................>
i d k e r q y t w y d i i r r t e s r i
121 GTT TTT CTG CGT CGT GCA TTT AAT CCG GAA CAG CTG CGT AGC GTT TGT TAT CTG AGC AAA
>..................................seag_gbnB..................................>
v f l r r a f n p e q l r s v c y l s k
181 AAT AGC GTT GAT CTG ATT TGT TGG CTG GCA GCA TTT GCA ACC CTG GGT ATT CCG GCA AAT
>..................................seag_gbnB..................................>
n s v d l i c w l a a f a t l g i p a n
241 GGT CTG GAT TAT AGC CTG CCG ATT GAA ACC CTG CGT GGT CTG CTG ATT AAA ATC AAT CCG
>..................................seag_gbnB..................................>
g l d y s l p i e t l r g l l i k i n p
301 GGT CTG ATG CTG GTT AGC TTT AGC CTG TAT AGT CCG GAT GAA CTG AAT AAA CTG CAT GTT
>..................................seag_gbnB..................................>
g l m l v s f s l y s p d e l n k l h v
361 CGT ACC ATT ACC ATG CTG GCA GTT GAT GCA CCG ACC GAT CCG GTT ATT GGT AGC ATT GGT
>..................................seag_gbnB..................................>
r t i t m l a v d a p t d p v i g s i g
421 GAA TTT CAT CAT CCG GAA CTG GAA AGC CTG CTG GCA ACC CAT ATT CCG GCA CCG TTT CGT
>..................................seag_gbnB..................................>
e f h h p e l e s l l a t h i p a p f r
481 AGC GTT AGC CTG ACC AGC GGC ACC AGC AGC GCA CCG AAA ATT GTT CTG CGT TAT AAT AGC
>..................................seag_gbnB..................................>
s v s l t s g t s s a p k i v l r y n s
541 TTT GAT GCC CGT CGT TTT GAT TGG TTT ACC CAG CGT TTT AAC TTT ACG CAT CAT GAT GGT
>..................................seag_gbnB..................................>
f d a r r f d w f t q r f n f t h h d g
601 TTT CTG CTG ATT CTG CCG CTG TAT CAT GCA GCA GGT AAT GGT TGG GCA CGT ATG TTT ATG
>..................................seag_gbnB..................................>
f l l i l p l y h a a g n g w a r m f m
661 GGT CTG GGT GCA AGC CTG CAT CTG GTT GAT CAG GAT GAT GAA AGC GCA CTG ATT CAG GCA
>..................................seag_gbnB..................................>
g l g a s l h l v d q d d e s a l i q a
721 CTG AGC CTG AAT AGC GTT AAA GCA ACC GTT ATG ACC CCG AAT CTG GTT AGC CGT CTG ACC
>..................................seag_gbnB..................................>
l s l n s v k a t v m t p n l v s r l t
781 AAA CTG GCA AGC GAA ACC GTT CTG CAT CAT TAT CTG CGT TGG GTT CTG GTT GGT GGT AGC
>..................................seag_gbnB..................................>
k l a s e t v l h h y l r w v l v g g s
841 TAT TTT CCG GTT AAA AGC AAA ATT GCA GCC TAT ACC CAT CTG GGC CAT ATC TTT AAT GAA
>..................................seag_gbnB..................................>
y f p v k s k i a a y t h l g h i f n e
901 TAC TAT GGT TGT ACC GAA ACC GGT GTT AAT GTT CTG AGC GAA AGC AGC GAT ATG TTT GAA
>..................................seag_gbnB..................................>
y y g c t e t g v n v l s e s s d m f e
961 TGT CCG GGT AGC GTT GGT CGT GCA TTT GAT GGT AAC AAA ATT CGC ATT CTG GAT GAA GAT
>..................................seag_gbnB..................................>
c p g s v g r a f d g n k i r i l d e d
1021 AAT GTT CCG CTG AAA GCA GGT AAT CGT GGT CGT ATT GCA GTT GCA AGC TAT ATG CTG ATG
>..................................seag_gbnB..................................>
n v p l k a g n r g r i a v a s y m l m
1081 GAT GAA TAT GGT GAT GGT AGC CGT CCG TTT ATT GAA ATT GAT AGC GAA CGC TAT TTT CTG
>..................................seag_gbnB..................................>
d e y g d g s r p f i e i d s e r y f l
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1141 ATG GCC GAT TAT GGT TAT CTG GAT GAT AAT GGT CGT CTG TTT CTG ATG AAT CGC AAC AGC
>..................................seag_gbnB..................................>
m a d y g y l d d n g r l f l m n r n s
1201 GAA ATC AAA TGC GAA CAG GAT ATC TAT CAC ATC GAA GAA CAT CTG CGT GCA CTG CCG TGT
>..................................seag_gbnB..................................>
e i k c e q d i y h i e e h l r a l p c
1261 ATT ACC GAT GTT GCA CTG ATT CCG ATT CGT CAG CAG AAC AAA GAT CAT ATT CGT TGC ATT
>..................................seag_gbnB..................................>
i t d v a l i p i r q q n k d h i r c i
1321 TTC AGC GCC AAA TAC ATC AAC GAA GAT GAT GTG AGC TTT ATT ATG GAT GAA ATC AAA AAC
>..................................seag_gbnB..................................>
f s a k y i n e d d v s f i m d e i k n
1381 AAA ATT AAC CAT ATT GGC GTG ACC GAT TTT ACC GCA CAT ATG GTT GAC AAA ATT CCG TAT
>..................................seag_gbnB..................................>
k i n h i g v t d f t a h m v d k i p y
1441 AGC CCG AGC GGT AAA GTT CGT TTT AGC GAA ATT GTT CAG ACC CTG ACC GCA GCA TAA
>................................seag_gbnB...............................>>
s p s g k v r f s e i v q t l t a a -
Synthetic smugs5_01685 (S. mutans GS-5 gbnB) native sequence is NCBI Gene ID:
13299420
1 ATG CTG GCA CTG GAA AAT CTG ATT CAG ATT CGT AAT CGC AAT CCG GAT AAA CTG ATT CTG
>>.................................smug_gbnB..................................>
m l a l e n l i q i r n r n p d k l i l
61 ATT AGC GAC GAA AAA AGC TTC AGC TGG AAA GAA TAT ACC AAC CTG GTG ATT AAT AAC CTG
>..................................smug_gbnB..................................>
i s d e k s f s w k e y t n l v i n n l
121 CGT AAT ACC ACC CTG CAG AGC GTT CTG AAT AAA ACC GAT CGT GCA ATT ATC ATC AGC GAG
>..................................smug_gbnB..................................>
r n t t l q s v l n k t d r a i i i s e
181 AAT ACC TGG AAA GTG TTC ACC ATT TAT AGC TGT CTG AGC ACC CAG AAA ATT CCG TAT AGC
>..................................smug_gbnB..................................>
n t w k v f t i y s c l s t q k i p y s
241 GGT ATT GAT TAC AGC ATG GAA GAT GAT AAA AAA GTG GCA GCC ATT AAC AAA AGC GGT GCA
>..................................smug_gbnB..................................>
g i d y s m e d d k k v a a i n k s g a
301 AAT ACC GTG TTC TAT AGC AAA GAT CAG AAA CCG AGC CAG AAT CTG CGT AAT AGC CTG AAA
>..................................smug_gbnB..................................>
n t v f y s k d q k p s q n l r n s l k
361 GGT GTT AGC TTT ATT AGC CTG GAT ATC CTG CAT GAT GAT ATT GAA GGT AGC GAT CTG AGC
>..................................smug_gbnB..................................>
g v s f i s l d i l h d d i e g s d l s
421 GAC TTT AAT ATC AAA AAA CAC AGC GAT AGC ATC GTG AGC TTT GGT TTT ACC AGC GGC ACC
>..................................smug_gbnB..................................>
d f n i k k h s d s i v s f g f t s g t
481 ACC GGT CTG CCG AAA TGT ATT TAT CGT GAT TAT AGC TTT GCC ACC GAA CGC ATG AAA GAA
>..................................smug_gbnB..................................>
t g l p k c i y r d y s f a t e r m k e
541 CTG ACC AAA CTG TAT AAC TTT AAC GCG ACC GAT GTT TTT CTG GTT ACC ATG CCG TTT TAT
>..................................smug_gbnB..................................>
l t k l y n f n a t d v f l v t m p f y
601 CAT GTT AGC GTT AAT GGT TGG GTT AAA CTG ACC CTG AAT AAT GGT GGT AGC GTT GTT CTG
>..................................smug_gbnB..................................>
h v s v n g w v k l t l n n g g s v v l
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661 GGT GAT TTT AAC AAT CCG ATT GAT CTG AGC AGC AAA ATC AAA CAG TAT GAC ATT ACC ACC
>..................................smug_gbnB..................................>
g d f n n p i d l s s k i k q y d i t t
721 ATG CTG ATT ACC CCT CCG GTT CTG AAA AGC CTG AAT TTT GTT CTG AAT CAG CAG GGC TTT
>..................................smug_gbnB..................................>
m l i t p p v l k s l n f v l n q q g f
781 ATC AAT AGC ACC GTT CGC TTT ATT ATG GTG GGT GGT AAA AAC TTT CCG CCT AAA CTG AAA
>..................................smug_gbnB..................................>
i n s t v r f i m v g g k n f p p k l k
841 GAA GAA ACC CAG AAC CTG TTT GGT AGC GTT CTG CAT GAA TAT TAT GGT AGC AGC GAA ACC
>..................................smug_gbnB..................................>
e e t q n l f g s v l h e y y g s s e t
901 GGT ATT AAT GTT CTG GCA AAT AGC AGC GAT ATG ATG CTG TAT CCG AGC AGC AGC GGT CGT
>..................................smug_gbnB..................................>
g i n v l a n s s d m m l y p s s s g r
961 GTT ATG AAA GGT AGT GAT GTT ATT ATC GTG GAT AGC GAC AAT CGC AAA ATT CCG AAT AAT
>..................................smug_gbnB..................................>
v m k g s d v i i v d s d n r k i p n n
1021 CAT ATT GGT CGG ATT GCC ATC TAT AGC TAT CAG AAT GCA ACC GGC TAT ATT AAC CAG CCG
>..................................smug_gbnB..................................>
h i g r i a i y s y q n a t g y i n q p
1081 CTG GAA AAA TTC AAT TAC CGC CAG AAA GAA TAC ATC CTG ACC AGC GAT TAT GGC TAT GTG
>..................................smug_gbnB..................................>
l e k f n y r q k e y i l t s d y g y v
1141 AAT AAT GAA GGC TAT ATC TTT GTG GTG CAG CGC ATT CTG AAT CAC GAA AAC AAC AAA ATC
>..................................smug_gbnB..................................>
n n e g y i f v v q r i l n h e n n k i
1201 ATC AAT GTG TTT CAG ATC GAA AAT CGC CTG CGC CTG ATT AAA GAT ATT GAT GAT GTT GCC
>..................................smug_gbnB..................................>
i n v f q i e n r l r l i k d i d d v a
1261 ATC GTG CAG AAA AAT AAC CTG CTG CTG GTT AAC ATT AAA CTG AAA AAA ATC AGC GAA ATG
>..................................smug_gbnB..................................>
i v q k n n l l l v n i k l k k i s e m
1321 AAA CGC AGC CTG GTT AAT GAT CTG GTT TGT TGG ATT CTG GAA AAA ACC AAA ATC CCG TAC
>..................................smug_gbnB..................................>
k r s l v n d l v c w i l e k t k i p y
1381 GAT CTG AAA TAT ACC GAT GAG ATC CAT TAT TCC ATG AGC GGC AAA GTG AAA TAC ACC GAA
>..................................smug_gbnB..................................>
d l k y t d e i h y s m s g k v k y t e
1441 GTG ATT AAT AGC GAA GGT CGT TAA
>..........smug_gbnB.........>>
v i n s e g r -
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Appendix 4 - Maps of pET-Duet and pACYC-Duet multiple cloning sites
pET-Duet:
His-tag is underlined; S-tag highlighted in blue
Primer binding sites for ‘pET up’, ‘UP2’, ‘DOWN1’ and ‘T7_term’ highlighted in red
1 GTGATGTCGG CGATATAGGC GCCAGCAACC GCACCTGTGG CGCCGGTGAT GCCGGCCACG
CACTACAGCC GCTATATCCG CGGTCGTTGG CGTGGACACC GCGGCCACTA CGGCCGGTGC
61 ATGCGTCCGG CGTAGAGGAT CGAGATCGAT CTCGATCCCG CGAAATTAAT ACGACTCACT
TACGCAGGCC GCATCTCCTA GCTCTAGCTA GAGCTAGGGC GCTTTAATTA TGCTGAGTGA
121 ATAGGGGAAT TGTGAGCGGA TAACAATTCC CCTCTAGAAA TAATTTTGTT TAACTTTAAG
TATCCCCTTA ACACTCGCCT ATTGTTAAGG GGAGATCTTT ATTAAAACAA ATTGAAATTC
BamHI
-+-----
181 AAGGAGATAT ACCATGGGCA GCAGCCATCA CCATCATCAC CACAGCCAGG ATCCGAATTC
TTCCTCTATA TGGTACCCGT CGTCGGTAGT GGTAGTAGTG GTGTCGGTCC TAGGCTTAAG
HindIII
-+-----
241 GAGCTCGGCG CGCCTGCAGG TCGACAAGCT TGCGGCCGCA TAATGCTTAA GTCGAACAGA
CTCGAGCCGC GCGGACGTCC AGCTGTTCGA ACGCCGGCGT ATTACGAATT CAGCTTGTCT
301 AAGTAATCGT ATTGTACACG GCCGCATAAT CGAAATTAAT ACGACTCACT ATAGGGGAAT
TTCATTAGCA TAACATGTGC CGGCGTATTA GCTTTAATTA TGCTGAGTGA TATCCCCTTA
361 TGTGAGCGGA TAACAATTCC CCATCTTAGT ATATTAGTTA AGTATAAGAA GGAGATATAC
ACACTCGCCT ATTGTTAAGG GGTAGAATCA TATAATCAAT TCATATTCTT CCTCTATATG
FseI KpnI
-------+- -----+
421 ATATGGCAGA TCTCAATTGG ATATCGGCCG GCCACGCGAT CGCTGACGTC GGTACCCTCG
TATACCGTCT AGAGTTAACC TATAGCCGGC CGGTGCGCTA GCGACTGCAG CCATGGGAGC
481 AGTCTGGTAA AGAAACCGCT GCTGCGAAAT TTGAACGCCA GCACATGGAC TCGTCTACTA
TCAGACCATT TCTTTGGCGA CGACGCTTTA AACTTGCGGT CGTGTACCTG AGCAGATGAT
541 GCGCAGCTTA ATTAACCTAG GCTGCTGCCA CCGCTGAGCA ATAACTAGCA
CGCGTCGAAT TAATTGGATC CGACGACGGT GGCGACTCGT TATTGATCGT
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pACYC-Duet:
His-tag is underlined; S-tag highlighted in blue
Primer binding sites for ‘pACYCup’, ‘UP2’, ‘DOWN1’ and ‘T7_term’ in red
1 GTGATGTCG G GCCATAC CGCGAAAGGT TTTGCGCCAT TCGATGGTGT
CACTACAGCC GCTATATCCG CGGCGGTATG GCGCTTTCCA AAACGCGGTA AGCTACCACA
61 CCGGGATCTC GACGCTCTCC CTTATGCGAC TCCTGCATTA GGAAATTAAT ACGACTCACT
GGCCCTAGAG CTGCGAGAGG GAATACGCTG AGGACGTAAT ACTTTAATTA TGCTGAGTGA
121 ATAGGGGAAT TGTGAGCGGA TAACAATTCC CCTCTAGAAA TAATTTTGTT TAACTTTAAG
TATCCCCTTA ACACTCGCCT ATTGTTAAGG GGAGATCTTT ATTAAAACAA ATTGAAATTC
BamHI
-+-----
181 AAGGAGATAT ACCATGGGCA GCAGCCATCA CCATCATCAC CACAGCCAGG ATCCGAATTC
TTCCTCTATA TGGTACCCGT CGTCGGTAGT GGTAGTAGTG GTGTCGGTCC TAGGCTTAAG
HindIII
-+-----
241 GAGCTCGGCG CGCCTGCAGG TCGACAAGCT TGCGGCCGCA TAATGCTTAA GTCGAACAGA
CTCGAGCCGC GCGGACGTCC AGCTGTTCGA ACGCCGGCGT ATTACGAATT CAGCTTGTCT
301 AAGTAATCGT ATTGTACACG GCCGCATAAT CGAAATTAAT ACGACTCACT ATAGGGGAAT
TTCATTAGCA TAACATGTGC CGGCGTATTA GCTTTAATTA TGCTGAGTGA TATCCCCTTA
361 TGTGAGCGGA TAACAATTCC CCATCTTAGT ATATTAGTTA AGTATAAGAA GGAGATATAC
ACACTCGCCT ATTGTTAAGG GGTAGAATCA TATAATCAAT TCATATTCTT CCTCTATATG
FseI KpnI
-------+- -----+
421 ATATGGCAGA TCTCAATTGG ATATCGGCCG GCCACGCGAT CGCTGACGTC GGTACCCTCG
TATACCGTCT AGAGTTAACC TATAGCCGGC CGGTGCGCTA GCGACTGCAG CCATGGGAGC
481 AGTCTGGTAA AGAAACCGCT GCTGCGAAAT TTGAACGCCA GCACATGGAC TCGTCTACTA
TCAGACCATT TCTTTGGCGA CGACGCTTTA AACTTGCGGT CGTGTACCTG AGCAGATGAT
541 GCGCAGCTTA ATTAACCTAG GCTGCTGCCA CCGCTGAGCA ATAACTAGCA
CGCGTCGAAT TAATTGGATC CGACGACGGT GGCGACTCGT TATTGATCGT
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Appendix 5 - UHR-MS of GBLs identified in S. coelicolor M1152 extract
UHR-MS of SCB 1-8 identified in culture extract of S. coelicolor M1152 grown on AlaMM media
compound Molecularformula
Observed
m/z
Calculated
m/z
Assignment
SCB8 (193)
C11H20NaO4 239.1258 239.1254 [M+Na]+
C11H21O4 217.1444 217.1434 [M+H]+
C11H19O3 199.1335 199.1329 [M-H2O+H]+
C11H17O2 181.1227 181.1223 [M-2H2O+H]+
SCB4 (194)
C12H22NaO4 253.1421 253.1410 [M+Na]+
C12H23O4 231.1594 231.1591 [M+H]+
C12H21O3 213.1487 213.1485 [M-H2O+H]+
C12H19O2 195.1377 195.1380 [M-2H2O+H]+
SCB5 (195)
C12H22NaO4 253.1421 253.1410 [M+Na]+
C12H23O4 231.1600 231.1591 [M+H]+
C12H21O3 213.1495 213.1485 [M-H2O+H]+
C12H19O2 195.1385 195.1380 [M-2H2O+H]+
SCB6 (196)
C12H22NaO4 253.1418 253.1410 [M+Na]+
C12H23O4 231.1593 231.1591 [M+H]+
C12H21O3 213.1496 213.1485 [M-H2O+H]+
C12H19O2 195.1388 195.1380 [M-2H2O+H]+
SCB1 (197)
C13H24NaO4 267.1571 267.1567 [M+Na]+
C13H25O4 245.1753 245.1747 [M+H]+
C13H23O3 227.1644 227.1642 [M-H2O+H]+
C13H21O2 209.1541 209.1536 [M-2H2O+H]+
SCB2 (198)
C13H24NaO4 267.1579 267.1567 [M+Na]+
C13H25O4 245.1749 245.1747 [M+H]+
C13H23O3 227.1643 227.1642 [M-H2O+H]+
C13H21O2 209.1540 209.1536 [M-2H2O+H]+
SCB3 (199)
C14H26NaO4 281.1729 281.1723 [M+Na]+
C14H27O4 259.1912 259.1904 [M+H]+
C14H25O3 241.1801 241.1798 [M-H2O+H]+
C14H23O2 223.1699 223.1693 [M-2H2O+H]+
SCB7 (200)
C14H26NaO 4 281.1731 281.1723 [M+Na]+
C14H27O4 259.1919 259.1904 [M+H]+
C14H25O3 241.1800 241.1798 [M-H2O+H]+
C14H23O2 223.1696 223.1693 [M-2H2O+H]+
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Appendix 6 - UHR-MS of AHFCAs identified in this study
UHR-MS of AHFCAs 5-8 identified in culture extract of S. venezuelae gbnR mutants grown on
SMMS and AHFCA8E identified in the E. coli/pJDS8 culture extract
compound
Molecular
formula
Observed
m/z
Calculated
m/z
Assignment
AHFCA5 (201)
C11H16NaO4 235.0936 235.0941 [M+Na]+
C11H17O4 213.1112 213.1121 [M+H]+
C11H15O3 195.1006 195.1016 [M-H2O+H]+
AHFCA6 (202)
C12H18NaO4 249.1089 249.1087 [M+Na]+
C12H19O4 227.1251 227.1278 [M+H]+
C12H17O3 209.1174 209.1172 [M-H2O+H]+
AHFCA7 (203)
C12H18NaO4 249.1089 249.1087 [M+Na]+
C12H19O4 227.1261 227.1278 [M+H]+
C12H17O3 209.1158 209.1172 [M-H2O+H]+
AHFCA8 (204)
C13H20NaO4 263.1242 263.1254 [M+Na]+
C13H21O4 241.1420 241.1434 [M+H]+
C13H19O3 223.1320 223.1329 [M-H2O+H]+
AHFCA8E (214)
C13H24NaO4 263.1245 263.1254 [M+Na]+
C13H25O4 241.1419 241.1434 [M+H]+
C13H23O3 223.1321 223.1329 [M-H2O+H]+
